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NBR1 (Neighbour of BRCA1) is a ubiquitously expressed scaffold protein that 
mediates intracellular functions through protein-protein interactions.  The C-terminal 
UBA domain of Nbr1 binds mono- and polyubiquitinated chains whilst the N-
terminal PB1 domain interacts with the structurally similar protein p62.  The aims of 
this thesis were to further characterise the biological functions of Nbr1 by identifying 
novel protein interactors.  A yeast-2-hybrid screen revealed a direct interaction 
between Nbr1 and the autophagic effector protein LC3.  This suggested a role for 
Nbr1 in the autophagic degradation of polyubiquitinated proteins.  A further yeast-2-
hybrid screen identified a direct interaction between Nbr1 and the microtubule 
associated protein MAP1B.  It is hypothesised that via its interaction with MAP1B 
and LC3, Nbr1 targets ubiquitinated proteins to the microtubule network where they 
can be transported to sites of autophagosomal formation.  Further putative interactors 
were identified for Nbr1 including the ubiquitin conjugating enzyme, UBE20 and the 
eukaryotic translation elongation factor eEF1A.  These suggested a role for Nbr1 as a 
scaffold to facilitate protein ubiquitination and degradation by the proteasome as 
eEF1A is involved in the cotranslational degradation of polyubiquitinated proteins. 
 
In bone, Nbr1 was previously identified as a key regulator of osteoblast 
differentiation and activity.  The work described in this thesis strengthened these 
observations and highlighted that the interaction between Nbr1 and p62 is also 
important for the maintenance of bone.  Mice with the Nbr1
D50R
 point mutation 
which inhibits the interaction between Nbr1 and p62 displayed an early osteoporotic 
phenotype due to altered osteoblast function and osteoclast size and nucleation that 
was subsequently resolved with age.  Additionally, Nbr1 was demonstrated to 
interact with osteocalcin, a protein secreted by osteoblasts.  Finally, sequence 
analysis of idiopathic high bone mass cases determined that sequence variation in the 
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His  Histidine 
HMERF Hereditary Myopathy with Early Respiratory Failure 
IBMPFD Inclusion body myopathy with Paget‘s disease and frontotemporal 
dementia 
IBSP  Integrin-binding bone sialoprotein 
IGF  Insulin-like growth factor 
Ihh  Indian hedgehog 
IL-1  Interleukin-1 
IM  Isolation membrane 
IPTG  Isopropyl β-D-thiogalactopyranoside 
JNK  Jun N-terminal Kinase 
JPD  Juvenile Paget‘s disease 
kDa  Kilodalton 
Keap1  Kelch-like ECH-associated protein 1 
LAMP2 Lysosomal-associated membrane protein 2 
LC3  Microtubule-associated protein 1 light chain 3 
LD  Linkage disequilibrium 
LIR  LC3 interaction region 
LRP5  low density lipoprotein receptor-related protein 5 
MAP1B Microtubule associated protein 1B 
MAP1B-HC Microtubule associated protein 1B heavy chain 
MAP1B-LC1 Microtubule associated protein 1B light chain 1 
MAPK  Mitogen-activated protein kinase 
MCP-1 Monocyte chemoattractant protein-1 
M-CSF Macrophage colony-stimulating factor 
MEFs  Mouse embryonic fibroblasts 
MicroCT Micro computer tomography 
MMP  Matrix metalloproteinase 
mTOR  Mammalian target of rapamycin kinase  
MURF  Muscle specific RING finger protein 
NBR1  Neighbour of BRCA1 (human) 




NFATc1 Nuclear factor of activated T cells 1 
NF-κB  Nuclear factor-κB 
NGF  Nerve growth factor 
NPC2  Niemann-Pick C2 
OPG  Osteopotegerin 
OPPG  Osteoporosis-pseudoglioma syndrome 
Osx  Osterix 
PAS  Pagophore assembly site 
PB1  Phox and Bem1p 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDB  Paget‘s disease of bone 
PDGF-bb Platelet-derived growth factor bb 
PE  Phosphatidylethanolamine 
PEST  Proline, glutamine, serine, threonine 
PFA  Paraformaldehyde 
PI3K  Phosphatidylinositol 3 kinase 
PI3P  Phosphatidylinositol-3-phosphate 
PIAS  Protein inhibitor of activated STAT 
PTH  Parathyroid hormone 
PTHrP  Parathyroid hormone-related protein 
RANK  Receptor activator of nuclear factor-κB 
RANKL Receptor activator of nuclear factor-κB ligand 
Rnf26  Ring finger protein 26 
ROA  Regulation of autophagy 
ROI  Region of interest 
S1P  Sphingosine 1-phosphate 
S6K  Ribosomal kinase 
SD   Synthetic dropout (yeast media) 
SD  Standard deviation (statistics) 
SDF-1  Stromal cell-derived factor-1 
SDS PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 




SAP  Shrimp Alkaline Phosphatase 
SNP  Single nucleotide polymorphism 
SOST  Sclerostin 
SPRED2 Sprouty related with Ena/VASP homology 1 domain 2 
SQSTM1 Sequestosome 1 
SRF  Serum response factor 
SUMO  Small ubiquitin-like modifier 
Tb.BV/TV Trabecular bone volume/tissue volume 
Tb.N  Trabecular number 
Tb.Sp  Trabecular separation 
Tb.Th  Trabecular thickness 
TENS  Tris, EDTA, NaOH, SDS 
TGFβ  Transforming growth factor β 
Th2  T helper 2 
TK  Thymidine kinase 
TNF  Tumour necrosis factor 
TNFR2 Tumour necrosis factor receptor 2 
TRAF  TNF receptor-associated factor 
TRAP  Tartrate-resistant acid phosphatase 
Trp  Tryptophan 
TXAS  Thromboxane synthase 
UBA Ubiquitin associated 
UBC9  Ubiquitin-like protein SUMO-1 conjugating enzyme 
ULK1  Unc-51-like kinase 1 
UPS  Ubiquitin proteasome system 
USP  Ubiquitin specific protease  
VCP  Valosin-containing protein 
WB  Western blot 
WIPI1  WD repeat domain phosphoinositide interacting 1 
Wnt  Wingless and Int proteins 
WT  Wild type 
YFP  yellow fluorescent protein 
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Chapter 1. Introduction 
1.1. Bone  
The vertebrate skeleton is largely comprised of two distinct tissue types; cartilage 
and bone (Karsenty, 1999).  Bone has many functions including providing 
mechanical support to soft tissues, serving as levers for muscle action, supporting 
haematopoiesis and housing the brain and spinal cord (Harada and Rodan, 2003).  It 
forms a highly ordered structure which enables it to carry out its functions. 
 
1.1.1. Bone structure 
Bone tissue is comprised of an outer layer of cortical (compact) bone which 
surrounds the inner trabecular (spongy) bone.  Both bone types have the same matrix 
composition however cortical bone has a greater mass to volume ratio which 
provides maximum resistance to tension and bending whilst trabecular bone is a 
more loosely organised porous matrix, and has a greater metabolic function (Figure 
1.1).  The cortex constitutes 80% of mature bone and is lined on the outside by the 
periosteum whilst the inner marrow cavity is lined by the endosteum; both of which 
are thin layers of fibrous tissue.  The embryonic skeleton and regions of rapid bone 
turnover in the adult skeleton consist of woven bone that is subsequently resorbed 
and replaced by slower forming lamellar bone.  Woven bone consists of an irregular 
pattern of collagen fibres and hydroxyapatite crystals whilst lamellar bone is more 
uniform in structure composed of collagen fibres arranged in parallel sheets around 
blood vessels to form osteons or Haversian systems (the primary structural unit of 
cortical bone).  (Bilezikian, 2002; Buckwalter, 1995; Ng et al., 1997).  Micro 
Computer Tomography (MicroCT) is a widely used technique for the study of bone 
morphology and microarchitecture and has been instrumental in aiding the bone 
phenotypic analysis of mutant mouse models.  It was first pioneered by Feldkamp et 
al. (Feldkamp et al., 1989) and uses X-ray attenuation data from multiple angles to 
reconstruct a 3D representation of the bone in question (Bouxsein et al., 2010). 
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The bone extracellular matrix (ECM) constitutes 90% of the volume of bone tissue, 
and consists of an organic and an inorganic component.  The organic phase is 
primarily comprised of type I collagen fibres (90%) and noncollagenous proteins 
(10%) such as osteonectin, osteopontin, osteocalcin and glycoproteins.  The 
inorganic phase consists of hydroxyapatite crystals and serves as an ion reservoir.   
Approximately 99% of bodily calcium and 85% of phosphorus are associated with 
bone mineral crystals.  The ECM is rich in growth factors such as fibroblast growth 
factor-2 (FGF2) (Montero et al., 2000), cell adhesion molecules and proteolytic 
enzymes and provides a structural framework for bone cells to adhere to 
(Buckwalter, 1995; Camozzi et al., 2010).  
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 1.1.2. Cell types present in bone 
There are three main cell types that are found within bone; osteoblasts, osteoclasts 
and osteocytes. The osteoblast is derived from mesenchymal stem cells and its 
primary function is to synthesize and release type I collagen and noncollagenous 
bone matrix proteins including osteocalcin and osteonectin.  Osteoblasts 
subsequently regulate the mineralisation of the organic matrix (Buckwalter, 1995; 
Sommerfeldt and Rubin, 2001).  Following the synthesis and mineralisation of the 
bone matrix, osteoblasts can undergo cell death, decrease their activity and form 
bone lining cells that cover the bone surface or they differentiate into osteocytes.  
Osteocytes embed into the bone matrix and regulate bone formation.   
 
Osteoclasts are the third main cell type found in bone.  They originate from the 
hematopoietic stem cell population (Walker, 1975) and develop through the fusion of 
mononuclear myeloid precursors.  Once fully differentiated, osteoclasts function to 
resorb the fully mineralised bone matrix (Edwards and Mundy, 2011).   
 
The formation and maintenance of bone is a tightly coupled process mediated by the 
bone forming activity of osteoblasts and the bone resorbing activity of osteoclasts 
(discussed in section 1.3).  In early human life, osteoblast activity predominates over 
osteoclast activity until peak bone density is reached between the ages of 25-35 
years.  After these initial years, the adult skeleton is maintained by removing and 
replacing tissue.  Throughout this time, bone formation rate is equal to resorption.  
Later in life, resorption starts to accede formation resulting in a net loss of bone 
tissue and reduced bone mass and skeletal strength (Bilezikian, 2002). 
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1.1.3. Bone development  
There are two distinct mechanisms that contribute to the formation of the skeleton; 
intramembranous and endochondral ossification.  During intramembranous 
ossification (Figure 1.2), mesenchymal cells develop directly into osteoblasts giving 
rise to the flat bones of the skull, the clavicle and the pectoral girdle (Franz-
Odendaal, 2011; Hartmann, 2009).  The majority of bones however (including the 
appendicular skeleton, facial bones and vertebrae), are formed by endochondral 
ossification whereby cells at the centre of mesenchymal condensations differentiate 
into chondrocytes creating the template for future bone (Figure 1.3).  The 
transcription factor Sox9, is expressed by chondroprogenitor cells and is essential for 
chondrogenesis (Hargus et al., 2008).  Differentiated chondrocytes undergo 
unidirectional proliferation and form a columnar layer of dividing cells that express 
cartilaginous matrix genes such as type II collagen, aggrecan and chonromodulin-1.  
After proliferation, chondrocytes become prehypertrophic, exit the cell cycle and 
differentiate into post-mitotic hypertrophic chondrocytes. They synthesize type X 
collagen and mineralize their surrounding matrix before undergoing cell death.  
Following this, perichondrial cells surrounding the cartilage begin to differentiate 
into osteoblasts and form the bone collar, which will eventually become the cortical 
bone.  Blood vessel invasion from the bone collar into zones of hypertrophic 
chondrocytes occurs, resulting in the infiltration of osteoblasts and osteoclasts into 
the cartilaginous extracellular matrix (ECM).  The ECM is then degraded and 
replaced with primary spongiosa (the precursor of trabecular bone and bone marrow) 
(de Crombrugghe et al., 2001; Hojo et al., 2010; Karsenty and Wagner, 2002; Provot 
and Schipani, 2005).  The replacement of chondrocytes by osteoblasts leads to the 
development of organised growth plates at each end of the expanding bone which are 
separated by an internal space containing the bone marrow.  At the growth plate, new 
chondrocytes are generated and their proliferation enables longitudinal bone growth 
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1.2. Molecular regulation of bone cell differentiation 
Skeletogenesis occurs during both embryonic development and postnatal life. The 
differentiation and activity of osteoblasts, osteoclasts and osteocytes is tightly 
controlled both spatially and temporally in order to maintain bone integrity. 
 
1.2.1. Osteoblasts 
Osteoblasts are cuboidal in shape and their cytoplasmic processes extend through the 
osteoid matrix and come into contact with osteocytes (Sommerfeldt and Rubin, 
2001). The differentiation of mesenchymal stem cells into osteoblasts requires a 
specific set of transcription factors and growth factors and results in the fully 
functioning bone forming cell (Figure 1.4).   
 
1.2.1.1. Transcription factors 
The earliest and most specific marker of the osteoblast lineage is the transcription 
factor Runx2 (Cbfa1) whose expression is restricted to cells of the mesenchymal 
condensations and precedes osteoblast differentiation (Ducy et al., 1997).  The 
absolute requirement of Runx2 for the differentiation of mesenchymal progenitors 
into osteoblasts was demonstrated with the generation of a Runx2 deficient mouse 
model (Komori et al., 1997).  Affected mice died shortly after birth with a skeleton 
completely lacking in bone.  Osterix (Osx), a zinc finger-containing transcription 
factor is also essential for osteogenesis.  Mice deficient in osterix also died soon after 
birth due to lack of bone formation and the arrest of osteoblast differentiation 
downstream of Runx2 (Nakashima et al., 2002).  Through its interaction with nuclear 
factor of activated T cells c1 (NFATc1), osterix activates the Col1a1 (encoding type 
1 collagen) promoter and controls osteoblastic bone formation. In NFATc1 deficient 
cells, nodule formation assays demonstrated that bone formation was severely 
impaired (Koga et al., 2005).  The actions of both Runx2, osterix and NFATc1 result 
in cells of the early osteoblast lineage expressing the bone specific markers alkaline 
phosphatase (ALP) and type 1 collagen (Candeliere et al., 1999). 
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The transcription factor ATF4 is required for osteoblast terminal differentiation.  
Mice lacking ATF4 exhibit delayed skeletal development, a decrease in bone 
formation and a failure to reach normal bone mass.  This has been attributed to a 
decrease in the synthesis of type I collagen by osteoblasts (Yang et al., 2004).  ATF4 
mRNA expression is not restricted to osteoblasts however there is a selective 
accumulation of the ATF4 protein in these cells resulting in the expression of 
osteoblast specific proteins such as osteocalcin (Yang and Karsenty, 2004). 
 
The activator proteins 1 (AP1) are a group of transcription factors that have a variety 
of functions in different cell types, however a subset are specifically involved in 
bone formation.  Mice overexpressing Fra-1 showed a progressive increase in bone 
mass (manifested by an increase in cortical thickness and trabecular number and 
diameter), first observed at four weeks of age.  This was due to a cell-autonomous 
increase in the number of mature osteoblasts (Jochum et al., 2000).  Mice 
overexpressing another osteoblast specific AP1 family protein ΔFosB have increased 
bone formation throughout the skeleton and a continuous post-developmental 
increase in bone mass (Sabatakos et al., 2000).  
 
1.2.1.2. Indian hedgehog and Wnt Signalling 
Along with transcription factors, a number of signalling pathways and extracellular 
molecules are important for osteoblast differentiation and maturation.  Indian 
hedgehog (Ihh) is essential for osteoblast differentiation.  When the transmembrane 
protein smoothened, which is essential for Ihh signal transduction was knocked out 
specifically from perichondrial cells, mice displayed impaired bone collar formation 
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The Wnt signalling pathway is also important for osteoblast differentiation and a 
number of key proteins in this pathway have been extensively studied.  Genetic 
disruption of β-catenin (a central player in the Wnt signalling pathway) in mice lead 
to a complete absence of intramembranous and endochondral skeleton.  Osteoblast 
development was arrested after Runx2 expression but before the expression of 
osterix, suggesting a key role for Wnt signalling in early bone formation (Hu et al., 
2005).  LRP5 (low density lipoprotein receptor-related protein 5) is also part of the 
Wnt signalling pathway and targeted disruption in mice lead to a decrease in quantity 
of mineralised bone in the primary spongiosa and a lower bone mass throughout life.  
Affected mice also had a decrease in bone formation rate and a decrease in total 
osteoblast number (Kato et al., 2002). Activation of Wnt signalling in cell culture 
models can also induce osteoblast differentiation (Bain et al., 2003).  Altered 
expression of Wnt ligands in mice can also result in a range of skeletal phenotypes 
(Glass Ii and Karsenty, 2006).  For example, overexpression of Wnt10b in 
osteoblasts causes an increase in bone formation, bone mineral density and trabecular 
number (Bennett et al., 2007).  
  
1.2.1.3. Growth factors  
Growth factors present in the bone ECM and systemic circulation can also influence 
bone formation.  A number of fibroblast growth factors (FGFs) are important for 
intramembranous and endochondral ossification and are differentially expressed in 
both bone and cartilage.  Deletion of any one of these ligands or their receptors cause 
a variety of skeletal malformations (Ornitz and Marie, 2002).  Binding of FGFs to 
their receptors leads to activation of a number of downstream signalling pathways 
including mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 
kinase (PI3K) (Miraoui and Marie, 2010).  FGF-2 is expressed in osteoblasts and is 
important for bone formation and the maintenance of bone mass.  Genetic ablation of 
FGF-2 in mice results in reduced trabecular bone volume and number due to a 
decrease in bone formation rate, and osteoblast differentiation and proliferation 
(Montero et al., 2000).  Furthermore, mice lacking the fibroblast growth factor 
receptor 3 (FGFR3) display an array of skeletal abnormalities including kyphosis, 
bowed femurs that were thicker and longer and an expansion of the hypertrophic 
chondrocytes in the growth plate (Deng et al., 1996). 
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Insulin-like growth factor-I and –II (IGF-I and -II) are the most abundant growth 
factors present in skeletal tissue and are important in the paracrine and autocrine 
regulation of bone.  IGF-I utilises the PI3K pathway which induces the activation of 
downstream effectors including Akt, MAPK and ERK1/2 (Qiang et al., 2002; Sakata 
et al., 2004).  IGF-I maintains appropriate levels of bone matrix by upregulating type 
1 collagen transcription and downregulating the expression of collagenase 3.  
However, a decline in IGF-I expression is required for the terminal differentiation of 
osteoblasts (Canalis, 2009).  Systemic IGF-I is important for regulating cortical bone 
as mice exhibiting a 75% decrease in serum IGF-1 levels have a decreased cortical 
bone volume and thickness, bone mineral density and periosteal circumference 
(Yakar et al., 2002).  In contrast, overexpression of skeletal IGF-1 using the 
osteocalcin promoter caused an overall increase in trabecular bone volume and 
thickness but no difference in cortical bone volume (Zhao et al., 2000).  This 
suggests that IGF-I exerts site specific actions on bone formation.  
 
Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor β (TGFβ) super-family and were first identified for their ability to induce 
endochondral bone formation through a Smad dependent signalling pathway (Canalis 
et al., 2003).  In vitro studies have shown that BMP-2 is able to convert myoblastic 
cell lines into the osteoblastic lineage and induce the expression of osteoblast 
specific markers such as ALP, osteocalcin and Runx2 (Katagiri et al., 1994).  
Postnatal osteoblast specific disruption of Bmpr1a (type 1A receptor for BMPs) in 
mice and overexpression of the BMP agonist noggin under the control of the 
osteocalcin promoter demonstrated essential roles for BMP signalling. Both mouse 
models displayed a decrease in bone mass with no change in the number of 
osteoblasts suggesting impaired osteoblast function (Devlin et al., 2003; Mishina et 
al., 2004).  Disruption of Bmpr1a also highlighted the potential of BMP signalling 
molecules to regulate osteoblast function in different ways as aged mice showed an 
increase in bone mass due to reduced bone resorption (Mishina et al., 2004). 
 
1.2.1.4. Crosstalk between signalling pathways in osteoblasts 
The signalling pathways involved in osteoblast differentiation and function are 
interconnected and highly complex.  Runx2 appears to link some of the signalling 
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pathways as BMP signalling increases Runx2 expression (described above) whilst β-
catenin can bind to and activate the transcription of Runx2 (Gaur et al., 2005).  Using 
luciferase assays, it was demonstrated that FGF signalling can antagonise the Wnt 
signalling pathway (Ambrosetti et al., 2008) therefore influencing 
osteoblastogenesis.  Furthermore, BMP-2 treatment can induce the expression of 
Wnt signalling family members in a dose-dependent manner in primary calvarial 
cultures (Chen et al., 2007).  These are just a few examples of how signalling 
pathways may be  interlinked (Lin and Hankenson, 2011) and serve to illustrate the 
complexity of osteoblastogenesis. 
 
1.2.2. Osteocytes 
Following the synthesis and mineralisation of the bone matrix, approximately 10-
30% of osteoblasts differentiate into osteocytes which are the longest lived bone cell 
and form between 90 and 95% of all cells in adult bone (Franz-Odendaal et al., 
2006).  During the transition of osteoblasts into osteocytes, cells embed into the 
mineralised bone matrix, show a reduction in the expression of bone markers such as 
ALP and an upregulation of osteocyte markers including dentin matrix protein 1 
(DMP-1), FGF 23 and sclerostin (Bonewald, 2011).  Sclerostin acts to impair 
osteoblast activity by inhibiting the Wnt signalling pathway (Lin et al., 2009). 
Furthermore, DMP-1 is important for osteocyte differentiation as DMP-1 deficient 
mice display aberrant osteocyte maturation, and hypomineralised bone accompanied 
by an increase in FGF 23 expression.  This also results in a reduction in circulating 
phosphate and an osteomalacia phenotype illustrating that osteocytes have an 
endocrine function (Feng et al., 2006).  
 
Differentiating osteocytes undergo significant morphological changes.  They become 
smaller in size, contain less cell organelles (e.g. ribosomes and endoplasmic 
reticulum), have an increased nucleus to cytoplasmic ratio and form dendritic 
processes.  Osteocyte morphology is controlled by podoplanin (E11/gp38), the 
earliest osteocyte specific protein and knock-down of expression in an osteocyte cell 
line blocked the elongation of dendrites (Zhang et al., 2006).  Morphological changes 
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are also accompanied by redistribution of cytoskeletal proteins such as filamin and 
actin binding proteins (Kamioka et al., 2004). 
 
Osteocytes are able to respond to changes in mechanical loading.  Upon mechanical 
stimulation, they modulate the expression of IGF-I, osteocalcin, and sclerostin which 
can influence the activity of osteoblasts and osteoclasts (Kawata and Mikuni-
Takagaki, 1998; Mikuni-Takagaki et al., 1996; Robling et al., 2008).  The 
importance of osteocytes to the maintenance of bone has been further illustrated by 
the generation of osteocyte deficient mice that display fragile bone, osteoblast 
dysfunction, trabecular bone loss and are resistant to mechanical unloading-induced 
bone loss (Tatsumi et al., 2007).  There is also a high correlation between bone 
remodelling sites and osteocyte apoptosis (Hedgecock et al., 2007).  Furthermore, 
proapoptotic molecules can be found in osteocytes that are close to microcracks, 
these can be transmitted to the bone surface to initiate osteoclast differentiation and 
bone repair (Verborgt et al., 2002).  Collectively, these data suggest that osteocytes 
have important functions in regulating bone mass and maintaining skeletal integrity.  
 
1.2.3. Osteoclasts 
Osteoclasts develop through the fusion of mononuclear myeloid precursors and are 
located on trabeculae and endosteal cortical bone surfaces, usually in a resorption pit.  
Osteoclast differentiation is a multistep process that eventually leads to a fully 
functioning cell that acts to resorb bone matrix proteins (Edwards and Mundy, 2011) 
(Figure 1.5).  
 
1.2.3.1 Transcription factors and signalling molecules  
The molecule known to initially influence the differentiation of the osteoclast from 
its myeloid precursor is the transcription factor PU.1.  Mice deficient in PU.1 died 
within 24-48 hours of birth, showed an osteopetrotic phenotype and completely 
lacked both osteoclasts and macrophages suggesting that PU.1 regulates the initial 
stages of myeloid differentiation (Tondravi et al., 1997).  Transplantation of normal 
bone marrow into PU.1 deficient mice rescued this phenotype which confirmed the 
origins of the osteoclast (Tondravi et al., 1997).  Micro-ophthalmia-associated 
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transcription factor (MITF) is also essential for osteoclast differentiation.  Mutations 
in the Mitf locus result in bone resorption defects and an inactivation of MITF target 
genes such as tartrate-resistant acid phosphatase (TRAP) (Hodgkinson et al., 1993; 
Luchin et al., 2001).  Furthermore, the macrophage colony-stimulating factor (M-
CSF) is important for the maturation and commitment of osteoclast precursor cells.  
Mice lacking functional M-CSF display osteoclast-deficient osteopetrosis (Wiktor-
Jedrzejczak et al., 1982; Yoshida et al., 1990). M-CSF binds directly to its receptor c-
fms on the surface of early osteoclast progenitors and activates downstream 
signalling pathways including ERK 1/2 to promote osteoclast proliferation and 
differentiation (Faccio et al., 2003).  Additionally, the oncoprotein, c-Fos, which is a 
member of the AP-1 transcription factor complex is important for osteoclast-
macrophage lineage determination.  Mice lacking c-Fos develop osteopetrosis, 
display a block in the differentiation of osteoclasts and an increase in the bone 
marrow macrophage numbers (Grigoriadis et al., 1994) (Figure 1.5). 
 
The requirement of marrow stromal cells for the differentiation of osteoclasts in vitro 
led to the discovery of the key osteoclastogenic cytokine, receptor activator of 
nuclear factor-κB ligand (RANKL) (Yasuda et al., 1998).  RANKL is expressed on 
the surface of osteoblasts and signals through the transmembrane signalling receptor 
RANK (a member of the TNF receptor family), present on the osteoclast surface 
(Nakagawa et al., 1998).  Downstream of the RANK receptor, TNF receptor-
associated factor (TRAF) proteins initiate a signalling cascade that results in the 
activation of nuclear factor-κB (NF-κB) and the expression of osteoclastogenic genes 
(Darnay et al., 1998; Jimi et al., 1999a; Lamothe et al., 2008).  Mice lacking subunits 
of the NF-κB complex display an osteopetrotic phenotype due to a reduction in 
osteoclast numbers (Iotsova et al., 1997).  Additionally, the NFATc1 transcription 
factor could be seen as a master regulator of osteoclastogenesis as without it, 
embryonic stem cells fail to differentiate into osteoclasts on stimulation with 
RANKL (Takayanagi et al., 2002).  RANKL is negatively regulated by the decoy 
receptor osteopotegerin (OPG) that is produced by osteoblasts.  There is a careful 
balance between RANKL and OPG levels to ensure the correct differentiation of 
osteoblasts and osteoclasts and to control the rate of bone resorption (Gori et al., 
2000).  The inhibitory action of OPG was confirmed in mice lacking the protein as 
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they displayed an age dependent decrease in bone mass, lack of trabecular bone and 
decreased bone strength due to enhanced osteoclastogenesis (Mizuno et al., 1998). 
 
A number of inflammatory cytokines have also been identified as stimulators of 
osteoclast differentiation.  In the presence of M-CSF, TNFα induces the formation of 
osteoclasts (Azuma et al., 2000).  This is important for the osteoclast formation and 
activation in inflammatory arthritis which is characterised by the eroding of 
periarticular bone by osteoclasts (Kitaura et al., 2005).  Interleukin-1 (IL-1) also 
stimulates the multinucleation and function of osteoclasts (Jimi et al., 1999b).  Upon 
binding to their receptors, these molecules can initiate a cascade of signalling events 
leading to the activation of the NF-κB and Jnk pathways (Katagiri and Takahashi, 
2002). 
 
1.2.3.2 Osteoclast fusion 
Osteoclastogenesis requires the fusion of mononuclear preosteoclasts to form large 
multinucleated mature osteoclasts.  A number of molecules have been implicated in 
this process.  Osteoclast cell fusion was completely abrogated in mice deficient in the 
dendritic cell-specific transmembrane protein (DC-STAMP) however, the expression 
of osteoclast markers such as tartrate-resistant acid phosphatase (TRAP) were 
unaltered suggesting that DC-STAMP is not important for osteoclastogenesis but is 
important for cellular fusion (Yagi et al., 2005). The d2 isoform of vacuolar (H
+
) 
ATPase (v-ATPase) V0 domain (Atp6v0d2) deficient mice also display a reduction in 
osteoclast fusion and an increase in bone mass due to defective osteoclast resorption 
activity (Lee et al., 2006).  NFATc1 induces the expression of both DC-STAMP and 
Atp6v0d2 demonstrating that it is also important in the regulation of osteoclast 
fusion (Kim et al., 2008a). 
 
1.2.3.3. Formation of the osteoclast ruffled border 
Once differentiated, the mature osteoclast must create an isolated microenvironment 
to carry out its function of resorbing the bone matrix. Osteoclasts undergo significant 
cytoskeletal rearrangement to form a distinct actin complex termed the podosome 
and together with adhesion-associated proteins such as integrin αVβ3 this mediates 
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osteoclast attachment to the bone matrix creating the ‗sealing zone‘ (Novack and 
Faccio, 2011; Pfaff and Jurdic, 2001). The highly specialised ruffled border is then 
formed by fusion of secretory vesicles with the plasma membrane within the sealing 
zone and the delivery of H
+
/ATPase and the chloride channel ClC-7 to the cell 
surface.  This enables the acidification of the sealed extracellular space between the 
osteoclast and the bone (Blair et al., 1989; Kornak et al., 2001).  The resulting acidity 
and the secretion of proteases and enzymes such as cathepsin K, matrix 
metalloproteinases (MMPs) and TRAP results in the degradation of the bone matrix.  
The digested components are subsequently transcytosed and secreted at the side of 
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1.3. Bone remodelling 
To maintain stability and integrity, bone undergoes constant renewal.  It is estimated 
that as much as 25% of trabecular and 3% of cortical bone is resorbed and replaced 
each year (Ng et al., 1997).  Bone remodelling occurs in Basic Multicellular Units 
(BMU) (Frost, 1969) where bone lining cells prepare the endosteal membrane by 
exposing the mineralised matrix.  They then form a canopy over the bone to be 
remodelled creating a temporary bone remodelling compartment (BRC) (Hauge et 
al., 2001) (figure 1.6). 
 
The remodelling cycle consists of three main phases; resorption, reversal or 
transition and formation.  Resorption is initiated with the recruitment of osteoclast 
precursors to the remodelling site where they differentiate and attach to the bone 
matrix.  A reversal or transition phase subsequently takes place when mononuclear 
cells are recruited to the site of resorption.  These cells prepare the freshly resorbed 
bone surface for subsequent bone formation by osteoblasts.  The formation phase 
proceeds and osteoblasts deposit bone matrix (osteoid) to replace what has been 
resorbed by osteoclasts.  The resulting matrix is then mineralised and the surface is 
covered with bone lining cells which marks the termination phase. A resting period 
then follows before a new cycle is initiated (Feng and McDonald, 2011; Hadjidakis 
and Androulakis, 2006).  This cycle of removal and formation requires the intricate 
coordination of signals and communication between cells of the osteoblast and 
osteoclast lineages. 
 
Chapter 1                                                                                                     Introduction 
40 
 
Chapter 1                                                                                                     Introduction 
41 
 
1.3.1 Initiation and resorption phases 
Bone remodelling is initiated by a number of stimuli including hormones, 
inflammation, mechanical loading or inactivity and low blood calcium.  Osteocytes 
are thought to be the main sensors of microcracks and mechanical loading.  They 
express RANKL on their dendritic processes which results in osteoclast formation 
and resorption activity (Zhao et al., 2002).  Hormones are important for the systemic 
control of bone remodelling. Parathyroid hormone (PTH) is secreted in response to 
changes in blood calcium and when administered continuously to rats, it increases 
RANKL expression and decreases OPG expression in osteoblasts and results in an 
increase in osteoclast number and resorption and a decrease in bone formation 
related genes (Ma et al., 2001).  In contrast, when administered intermittently, PTH 
can increase bone formation, mineral density and strength (Ejersted et al., 1995).  
Collectively, this suggests that PTH can exert different effects on bone remodelling.  
Oestrogen is also critical for maintaining bone mass as it can promote osteoclast 
apoptosis.  Ablation of the osteoclastic oestrogen receptor in female mice resulted in 
trabecular bone loss and an increase in osteoclast number (Nakamura et al., 2007). 
  
Chemokines or chemotactic cytokines secreted by stromal cells or bone lining cells 
can recruit osteoclast precursors to areas of bone remodelling.  Monocyte 
chemoattractant protein-1 (MCP-1) is a member of the CC chemokine subfamily 
expressed by osteoblasts in the presence of PTH and is thought to recruit osteoclast 
precursors to sites of bone remodelling and promote their fusion (Li et al., 2007).  
Stromal cell-derived factor (SDF-1) is another chemokine produced by marrow 
stromal cells that binds to osteoclast precursors and induces the osteoclast expression 
of matrix metalloproteinase-9 (MMP-9), contributing to their chemotactic migration 
to sites of remodelling (Yu et al., 2003).  
  
1.3.2. Transition phase 
The transition phase of bone remodelling succeeds resorption of the bone matrix and 
requires carefully regulated cross-talk between osteoblasts and osteoclasts.  Bone 
lining cells are thought to clean the resorbed pit and prepare it for bone formation 
(Everts et al., 2002). The recruitment of osteoblasts to the site of bone formation is 
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regulated in part by factors such as IGF-I and –II, FGF, and BMPs that are all 
released from the bone matrix during resorption (Sims and Gooi, 2008).  Factors 
secreted by osteoclasts have been demonstrated to activate the bone formation phase.  
For example, sphingosine 1-phosphate (S1P) enhances the migration and survival of 
osteoblasts (Ryu et al., 2006) whilst the platelet-derived growth factor bb (PDGF-bb) 
is secreted by osteoclasts and acts as a chemotactic factor to which osteoblasts 
respond (Sanchez-Fernandez et al., 2008).  Membrane bound molecules also play a 
critical role in the communication between osteoblasts and osteoclasts during the 
transition phase.  The ephrinB2 transmembrane ligand expressed on osteoclasts can 
interact with the tyrosine kinase receptor EphB4 expressed on osteoblasts.  This 
enhances osteoblast differentiation by reducing RhoA activity and suppresses 
osteoclast function by reducing c-Fos and NFATc1 activities (Zhao et al., 2006).  
Extracellular calcium released as a result of bone resorption also functions in the 
transition phase as it acts as a negative feedback loop and induces osteoclast 
apoptosis and the termination of resorption by osteoclasts (Lorget et al., 2000). 
 
1.3.3 Formation and termination phases 
The end result of the many factors regulating bone remodelling discussed above is 
the formation of new bone matrix by osteoblasts.  Bone matrix deposition is then 
negatively regulated by the secretion of sclerostin by osteocytes.  Sclerostin is 
transported to the bone surface where it inhibits the late stages of bone formation by 
osteoblasts (van Bezooijen et al., 2004). 
 
Bone resorption within a BRC is estimated to take 2-3 weeks and is much faster than 
bone formation as osteoblasts take approximately three months to replace the 
equivalent amount of bone (Harada and Rodan, 2003). In spongy bone, remodelling 
occurs on the surface of the trabeculae.  In cortical bone however, remodelling 
occurs in tunnels where osteoclasts form ‗cutting zones‘, removing bone whilst 
osteoblasts follow and fill in the tunnels in the ‗closing cone‘.  The mechanisms 
controlling bone remodelling in trabecular and cortical bone are largely the same 
(Eriksen, 2010).   
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1.4. Bone disease 
Maintaining the balance between bone formation and resorption is critical for the 
correct functioning of bone tissue.  A deviation from this balance can result in a 
broad spectrum of skeletal pathologies (Janssens and Van Hul, 2002).  These can be 
caused by primary defects in osteoblasts and osteoclasts or can be a consequence of 
immunological or endocrinological abnormalities (Lazner et al., 1999).  Mouse 
models have been instrumental in identifying genes and molecular mechanisms 
involved in skeletal development and remodelling (as described above).  However, 
the identification of genetic mutations in individuals with skeletal disorders is also an 
important step to identifying causes of disease and therapeutic targets.  In addition, 
genome-wide association studies (GWAS) are crucial for identifying genetic loci that 
may be contributing to disease.  Although there are many idiopathic skeletal 
disorders, a large number of genes have been identified as contributing to bone 
disease and a selection of these will be discussed below. 
 
1.4.1. Low bone mass diseases 
When bone resorption exceeds bone formation, this can result in either a generalised 
or localised loss of bone mass.  Osteogenesis imperfecta is characterised by low bone 
mass and although they do not account for all cases, various mutations in one of the 
two chains that encode type I collagen (COL1A1 and COL1A2) have been identified.  
This leads to abnormalities in the structure of the bone matrix and reduced cortical 
and trabecular thickness (Rauch and Glorieux, 2004).  Mutations in the LRP5 gene 
have been identified in individuals with osteoporosis-pseudoglioma syndrome 
(OPPG) (Gong et al., 2001).  LRP5 is part of the Wnt signalling pathway and 
reduced Wnt signalling in osteoblasts can result in decreased bone formation (Kato et 
al., 2002).  Many genes including OPG (Ohmori et al., 2002), and tumour necrosis 
factor receptor2 (TNFR2) (Spotila et al., 2000) have also been identified by 
association studies to be involved in low bone mass phenotypes. 
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1.4.2. High bone mass diseases 
High bone mass (HBM) can be as deleterious to health as low bone mass and results 
in a reduction of the bone marrow cavity (Günther and Schinke, 2000). Van 
Buchem‘s disease, characterised by generalised bone overgrowth, has been attributed 
to a deletion downstream of the SOST gene (encoding sclerostin) that is likely to 
cause the suppression of SOST gene expression and therefore increase osteoblast 
activity (Balemans et al., 2002).  Pycnodysostosis is the result of a mutation in the 
CTSK gene that encodes cathepsin K.  This leads to the ablation of cathepsin K 
collagenase activity and therefore an increase in bone mass (Gelb et al., 1996).  
Mutations in the TBXAS1 gene that encodes thromboxane synthase (TXAS) are 
thought to be responsible for Ghosal syndrome, a disorder of increased bone density.  
TXAS normally acts to regulate RANKL and OPG gene expression by osteoblasts 
and genetic inactivation decreased RANKL expression, and increased OPG 
expression and therefore an overall decrease in osteoclastogenesis was observed 
(Genevieve et al., 2008).  Furthermore, activating mutations in the LRP5 gene have 
been identified in individuals with high bone mass (Boyden et al., 2002).  
Association studies have identified the Osterix locus (Timpson et al., 2009) and the 
IBSP (integrin-binding bone sialoprotein) gene  to be associated with bone mineral 
density in populations where extremes of high and low bone mineral densities were 
compared (Duncan et al., 2011).  In addition to genetic factors, HBM can also be a 
secondary effect of other diseases such as myelofibrosis (Diamond et al., 2002) or 
hepatitis C infection (Manganelli et al., 2005).   
 
1.4.3. Paget’s disease of bone (PDB) and p62 
Paget‘s disease of bone (PDB) is the second most common bone disorder in 
Caucasian populations and affects approximately 3% of individuals over 50 years of 
age (Goode and Layfield, 2010; Helfrich and Hocking, 2008).  PDB can affect just 
one (monostotic) or multiple (polyostotic) bones and symptoms can range from 
asymptomatic to pain, bone deformity, fractures and neurological complications such 
as deafness and spinal cord compression (Falchetti et al., 2010). PDB is characterised 
by focal increases in osteoclastic bone resorption and increased formation of 
disorganised bone that is weak and prone to fracture.  Affected osteoclasts are 
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enlarged, have an increased number of nuclei and also contain intranuclear inclusion 
bodies.  Osteoclast precursors from Pagetic lesions display increased expression and 
responsiveness to RANKL (Menaa et al., 2000).  The familial clustering and ethnic 
differences observed in the prevalence of the disease suggests a genetic 
predisposition however, environmental factors could also be involved as clinical 
severity has altered in areas such as the UK and New Zealand over the past few 
decades (Ralston, 2008).  In addition to classical PDB, other, rarer forms have been 
described that include early onset Paget‘s disease (ePDB), juvenile Paget‘s disease 
(JPD), familial expansile osteolysis (FEO), expansile skeletal hyperphosphatasia and 
inclusion body myopathy with Paget‘s disease and frontotemporal dementia 
(IBMPFD) (Helfrich and Hocking, 2008; Ralston, 2008). 
 
Mutations in the ubiquitously expressed scaffold protein p62/SQSTM1 are thought to 
be the primary cause of approximately 40% of all classical Paget‘s disease cases 
(Helfrich and Hocking, 2008).  Through positional cloning studies, mutations in this 
gene were identified as having likely causal roles in the disease (Hocking et al., 
2002; Laurin et al., 2002).  Subsequently, over 20 mutations in p62 have been 
identified in individuals with PDB, most of these clustering in the ubiquitin-
associated (UBA) domain (Goode and Layfield, 2010).  The deletion of the UBA 
domain of p62 in osteoclast precursors enhances osteoclastogenesis (Yip et al., 
2006).  UBA domains are known to bind mono- and polyubiquitinated chains and 
facilitate protein degradation.  Mutations observed in PDB individuals that cluster in 
the UBA domain of p62 are known to alter p62 ubiquitin binding ability (Cavey et 
al., 2006; Cavey et al., 2005; Garner et al., 2011).  Several studies that have analysed 
transgenic mouse models harboring the common PDB mutation p62
P394L
 have 
observed differing results.  In one study, osteoclast precursors from p62
P394L
 mutant 
mice displayed hyperresponsiveness to RANKL but bones from these mice were 
histologically normal (Hiruma et al., 2008).  A separate study has shown that the 
p62
P394L
 mutation does indeed cause a phenotype remarkably similar to PDB as mice 
displayed an age dependent increase in focal bone lesions with increased bone 
formation and resorption and the accumulation of woven bone (Daroszewska et al., 
2011). 
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Mutations have also been identified in p62 that reside outside of the UBA domain.  
Some exert modest effects on ubiquitin binding (Najat et al., 2009) whilst others 
have no effect (Rea et al., 2009).  One of these mutations is located in the LC3-
binding region (discussed later) of p62 however, its effects on protein function are 
still unclear (Falchetti et al., 2009). Studies within families have shown reduced PDB 
clinical severity in offspring inheriting a p62 mutation (Bolland et al., 2007) which 
suggests that other factors such as common polymorphisms in other genes or 
environmental factors are likely to be involved.  Additionally, it has been suggested 
that viral infection plays a role in the pathogenesis of PDB (Kurihara et al., 2011) 
however data is conflicting as some studies have found no evidence of viral nucleic 
acid sequences in Pagetic bone samples (Helfrich et al., 2000).  While p62 is a 
ubiquitously expressed protein the mutations observed in PDB patients only affect 
the osteoclast.  The mechanisms responsible for this apparent cell specificity are still 
unclear. 
 
Whilst p62 mutations are a major cause of classical PDB, they only account for 40% 
of cases (Helfrich and Hocking, 2008), therefore other factors are likely to be 
involved.  Both linkage and association studies have identified a number of 
susceptibility loci (Albagha, 2011; Albagha et al., 2010; Chung et al., 2010; Hocking 
et al., 2001).  Additionally, mutations in other genes have been identified in 
individuals with the more severe forms of PDB.  For example, complete deletion of 
the OPG gene was identified in patients with JPD (Whyte et al., 2002) whilst 
mutations affecting the signal peptide region of RANK have been found in patients 
with ePDB, FEO and Expansile skeletal hyperphosphatasia (ESH) (Hughes et al., 
2000; Nakatsuka et al., 2003; Whyte and Hughes, 2002). 
 
p62 is known to play an important role in the regulation and maintenance of bone 
tissue. Mice deficient in p62 did not initially display any skeletal phenotype 
suggesting that basal osteoclastogenesis is not affected by loss of p62 (Duran et al., 
2004).  However, on stimulation with parathyroid hormone-related protein (PTHrP), 
mice showed impaired osteoclastogenesis and inhibition of NF-κB activation (Duran 
et al., 2004).  Later, it was revealed that p62 deficient mice have an age dependent 
increase in bone density and mature-onset obesity due to an increase in ERK activity 
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and adipocyte differentiation (Rodriguez et al., 2006).  These mouse studies confirm 
the important role for p62 in NF-κB activation, osteoclastogenesis and the 
maintenance of bone.  There are also multiple binding sites for AP-1 and NF-κB 
transcription factors in the promoter region of p62 suggesting p62 transcription may 
be regulated by these factors (Vadlamudi, 1998). 
 
p62 was initially identified as a phosphotyrosine-independent ligand of the Src 
homology 2 (SH2) domain of p56
lck 
(Joung et al., 1996)
. 
 A number of biochemical 
studies have identified the mechanisms by which p62 modulates NF-κB signalling.  
Upon stimulation with IL-1 or nerve growth factor (NGF), p62 acts as a scaffold 
protein, binding to TRAF6 and ultimately resulting in the activation of NF-κB (Sanz 
et al., 2000; Wooten et al., 2001).  Additionally, in response to TNFα, activation of 
NFκB can be achieved by the formation of a signalling complex that includes p62, 
RIP and aPKC. (Sanz et al., 1999).  RANK is a member of the TNF receptor family 
and through its interaction with TRAF6 is important for NF-κB signalling (Darnay et 
al., 1998).  Deletion of the UBA domain or TRAF6 binding domain of p62 abolishes 
TRAF6 polyubiquitination and NGF induced NF-κB signalling (Wooten et al., 
2005).  Furthermore, the deubiquitinating enzyme cylondromatosis (CYLD) binds to 
the UBA domain of p62 (but not the UBA mutant p62
P392L
) in a ubiquitin-
independent manner and negatively regulates NF-κB signalling (Jin et al., 2008; 
Sundaram, 2011).  Collectively, these data suggest that p62 modulates NF-κB 
signalling through several of its interaction domains. 
 
 1.5. Autophagy 
Autophagy (meaning ‗auto‘ oneself, ‗phagy‘ to eat) refers to the process that 
eukaryotic cells use to deliver long-lived proteins and organelles to the lysosome for 
degradation.  There are three main types of autophagy; macroautophagy, 
microautophagy and chaperone-mediated autophagy, that differ in their physiological 
functions and the mode of cargo delivery to the lysosome (Levine and Kroemer, 
2008; Yoshimori, 2004).  Macroautophagy is the main process for bulk degradation 
of cytosolic proteins and organelles and will be referred to as autophagy from here 
on.  
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Autophagy commences with the formation of the preautophagosome structure or the 
phagophore assembly site (PAS), referred to as the isolation membrane (IM) or 
phagophore in mammals.  This membrane subsequently expands and sequesters 
cytosolic components of the cell and eventually closes to form a double membrane 
bound vesicle termed the autophagosome.  The autophagosome then fuses with the 
lysosome to become an amphisome or degradative autophagosome.  This structure 
matures into an autolysosome and its contents are degraded (Tooze et al., 2010) 
(Figure 1.7). 
 
The PAS has already been identified in the yeast S. cerevisiae, as the perivacuolar 
compartment where proteins required for autophagy are localised (Suzuki et al., 
2001), however, the origin of autophagosomal formation in mammals is still under 
debate.  Live cell imaging has been used to show that the autophagosome could form 
from the endoplasmic reticulum (Axe et al., 2008) or randomly in peripheral regions 
of the cell, a long way from the nucleus (Jahreiss et al., 2008).  Recently, the plasma 
membrane has also been shown to contribute to autophagosomal formation 
(Ravikumar et al., 2010).  Together, these data suggests that the membrane origins of 
the autophagosome may arise from multiple sources. 
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1.5.1. The molecular basis of autophagy  
The initial breakthrough in the identification of the autophagic molecular machinery 
arose from yeast genetic studies.  A total of 35 AuTophaGy-related genes (ATG) 
have now been identified (Mizushima et al., 2011) and many of these have 
mammalian homologues.  The Atg proteins involved in autophagosome formation 
are composed of a number of functional groups; the ULK1 (Atg1) complex, the PI3K 
complex, Atg9, the Atg2-WIPI (Atg18) complex and finally the two ubiquitin 
conjugating systems (Mizushima et al., 2011).  Each one of these complexes has a 
crucial role in the autophagic process (Figure 1.8). 
 
Autophagy can be induced by a variety of stimuli including amino acid starvation, 
growth factor withdrawal and at times of structural remodelling (Levine and 
Kroemer, 2008).  Upon autophagic induction, the number of autophagosomes 
increases by more than 10-fold (Mizushima et al., 2011).  Amino acid and growth 
factor signals converge on the master regulator mammalian target of rapamycin 
(mTOR).  Under starvation conditions, mTOR is inhibited resulting in the activation 
of ULK1 which phosphorylates both Atg13 and FIP200 to initiate autophagosomal 
formation (Hosokawa et al., 2009a).  The transcription factor FoxO3 also induces the 
transcription of multiple autophagy genes and acts in parallel to the mTOR pathway 
(He and Klionsky, 2009; Zhao et al., 2007). 
 
The ULK1 complex consists of ULK1, Atg13, FIP200 and Atg101 and each one of 
these components is essential for autophagosome formation (Hosokawa et al., 2009a; 
Hosokawa et al., 2009b).  Using genetic knock-down studies, it has been 
demonstrated that the ULK1 complex is the most upstream step in autophagosomal 
formation (Itakura and Mizushima, 2010).  The PI3K complex acts downstream of 
the ULK1 complex and consists of vacuolar sorting protein 34 (Vps34), Vps15, 
Beclin1 (Atg6 homolog) and Atg14L.  This complex produces PI3P and is present on 
the IM and elongating membrane (Longatti and Tooze, 2009).  PI3P is required for 
the recruitment of the Atg18-Atg2 complex to the autophagosomal membrane (Obara 
et al., 2008).  The mammalian Atg18 homolog WIPI-1 accumulates in large vesicular 
and cup-shaped structures upon induction of autophagy which are blocked by 
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wortmannin treatment, an inhibitor of autophagy (Proikas-Cezanne et al., 2004).  The 
only known transmembrane Atg protein is Atg9 and although its exact function is 
unclear, it is required for autophagosomal formation (Noda et al., 2000). 
 
The two ubiquitin conjugating systems function at a later stage in autophagosomal 
elongation (Itakura and Mizushima, 2010).  Atg12 conjugation is the first 
ubiquitination-like reaction, Atg12 is activated and transferred to Atg10 (an E2-like 
enzyme) by Atg7 (an E1-like enzyme) (Tanida et al., 2001). Atg10 then conjugates 
Atg12 to Atg5 to form the Atg12-Atg5 complex.  A mutation in Atg10 that is 
essential for Atg12 conjugation severely reduced autophagic activity (Shintani et al., 
1999).  Atg16L interacts with Atg5 forming the Atg12-Atg5-Atg16L complex and 
dissociates from the membrane upon closure of the isolation membrane.  This 
renders Atg16L a reliable marker to distinguish between the forming autophagosome 
and the mature autophagosome (Mizushima et al., 2003).  The Atg12-Atg5-Atg16L 
complex is important for the elongation of the isolation membrane as demonstrated 
in Atg5-deficient embryonic stem cells that exhibited defects in autophagosomal 
formation (Mizushima et al., 2001). 
 
The second ubiquitin-like conjugation system consists of the yeast protein Atg8 and 
functions downstream of the Atg12-Atg5 complex (Itakura and Mizushima, 2010).  
To date, four Atg8 homologues have been identified; microtubule associated protein 
1 light chain 3 (LC3), GABARAP, GATE-16 and Atg8L (Tanida, 2011).  All 
homologues are essential for the autophagic process however, they differ in their N-
terminal structure which is required for tethering and membrane fusion (Shpilka et 
al., 2011).  LC3 is involved in membrane elongation whereas GATE-16 family 
proteins are involved at a later stage, possibly in the sealing of the autophagosome 
(Weidberg et al., 2010).  There are three human homologues of LC3; MAP1LC3A, 
MAP1LC3B and MAP1LC3C all of which are synthesised as proLC3 and 
subsequently cleaved by Atg4 to form LC3-1 (He et al., 2003; Kirisako et al., 2000).  
LC3-1 localises to the cytosol (Kabeya et al., 2000) and is activated by Atg7,  
transferred to Atg3 and conjugated to the phospholipid phosphatidylethanolamine 
(PE) (Tanida et al., 2002; Tanida et al., 2001) resulting in LC3-II which localises to 
the autophagosomal membrane (Kabeya et al., 2000).  LC3-II on the cytosolic 
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surface can be delipidated by Atg4B and recycled for further autophagosome 
formation whereas LC3-II on the inner membrane of the autophagosome is degraded 
(Kabeya et al., 2004).  The LC3 conjugation system is essential for autophagosomal 
formation as mice deficient in Atg3 are defective in elongation and closure of 
isolation membranes (Sou et al., 2008).  The two conjugation systems functionally 
cooperate, as the Atg12-Atg5 complex is required for targeting LC3 to the isolation 
membrane (Mizushima et al., 2001) whilst Atg3 deficient mice display a defect 
Atg12-Atg5 conjugation (Sou et al., 2008).  LC3 is a widely used marker of 
autophagosomes and autophagic activity and can be measured via Western blotting 
for LC3-I and –II levels (Mizushima et al., 2010).   
 
Subsequent to the two ubiquitin-conjugating systems, the autophagosome elongates 
and fuses to form the autophagosome.  During autophagosomal maturation, fusion 
with different endosomal populations occurs (Liou et al., 1997).  Early endosomal 
fusion with autophagosomes is essential for autophagosomal maturation as 
demonstrated by the siRNA depletion of subunits of the coat protein complex I 
(COPI).  Loss of COPI resulted in an accumulation of ubiquitin containing 
aggregates and LC3-II positive vesicles (Razi et al., 2009). Loss of components of 
the endosomal sorting complex required for transport (ESCRT) also leads to the 
accumulation of autophagosomes (Lee et al., 2007a).  Furthermore, inhibition of 
early/late endosomal conversion by overexpression of the early endosomal marker 
Rab5 or knock-down of the late endosomal marker Rab7 inhibited downstream 
mTOR signalling measured by S6K1 phosphorylation (Flinn et al., 2010).  This 
suggests that proteins involved in endosomal maturation are also involved in 
regulation of autophagy.  Following maturation of the autophagosome and fusion 
with endosomes, the mature autophagosome fuses with the lysosome and its contents 
are degraded by hydrolytic enzymes (Lawrence and Brown, 1992).   
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1.5.2. The role of microtubules in autophagy 
Microtubules form a complex, interconnected network within the cell and serve as 
tracks for intracellular movement of proteins and organelles.  This movement is 
powered by the motor proteins kinesin which moves cargo towards the plus end of 
microtubules (the cell periphery) and dynein which moves cargo towards the minus 
end of microtubules (Monastyrska et al., 2009).  It is widely accepted that 
microtubules play an important role in the autophagy process; however, the 
molecular mechanisms involved are still unclear.   
 
The first connection between microtubules and autophagy-related genes was 
established with the identification of LC3 which can bind and stabilise microtubules 
(Faller et al., 2009; Mann and Hammarback, 1994) . Aplin et al. had previously 
demonstrated that disruption of the microtubule network, with drugs such as 
nocodazole, blocks fusion of autophagosomes with lysosomes but has no effect on 
the formation of autophagosomes (Aplin et al., 1992).  However, Reunanen et al. 
found that nocodazole had no effect on autophagosome fusion with lysosomes 
(Reunanen et al., 1988).  Subsequent studies have agreed that microtubules facilitate 
autophagosome formation (Fass et al., 2006; Köchl et al., 2006) but disagreed on 
whether microtubules are required for autophagosomal fusion with lysosomes (Fass 
et al., 2006; Köchl et al., 2006).  Discrepancies could be explained by the different 
cell types used, the concentrations of drugs and the time-points studied.  Additional 
studies have identified acetylated microtubules as being required for fusion of 
autophagosomes with lysosomes (Xie et al., 2010) and that the movement of mature 
autophagosomes towards lysosomes is dependent on the motor protein dynein 
(Jahreiss et al., 2008; Kimura et al., 2008).   
 
Roles for distinct populations of microtubules have been proposed where labile 
microtubules specifically recruit markers of the autophagosome isolation membrane 
such as the Atg12-Atg5 conjugate and WIPI-I, whereas stable microtubules bind 
mature autophagosomes and facilitate their movement towards lysosomes (Geeraert 
et al., 2010).  LC3 and Atg12 also bind the microtubule associated protein MAP1B, 
providing an additional mechanism for the targeting of autophagosomal structures to 
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the microtubule network (Behrends et al., 2010; Wang et al., 2006). Collectively, 
these data demonstrates that microtubules are required for different stages of 
autophagosome formation and maturation and that microtubule binding proteins 
provide a further mechanism for the recruitment of the autophagy machinery. 
 
The tubulin deacetylase HDAC6 binds both polyubiquitinated protein aggregates and 
dynein motors, therefore coupling protein aggregates to the microtubule network 
(Kawaguchi et al., 2003).  When the microtubule network is disrupted using 
nocodazole, colocalisation of LC3 and ubiquitin is abolished.  Furthermore, 
inhibition of HDAC6 deacetylase activity impairs the recruitment of LC3 to sites of 
aggregated proteins (Iwata et al., 2005).  This suggests that HDAC is required for the 
recruitment of autophagic machinery and protein aggregates to sites of 
autophagosomal formation and that this also requires the microtubule network.  
 
 1.5.3. Selective autophagy and p62 
The aggregate forming ability of p62 was first identified by Shin et al. (Shin, 1998).  
Subsequently, p62 has been observed to accumulate in ubiquitin (Ub)-containing 
inclusions in a number of protein aggregation diseases including Parkinson‘s disease, 
Alzheimer‘s disease and tumourigenesis (Mathew et al., 2009; Wooten et al., 2006).  
Accumulation of p62 occurs in autophagy deficient mice and promotes 
tumourigenesis (Mathew et al., 2009).  Additionally, p62 binds both mono- and 
polyubiquitinated chains (Seibenhener et al., 2004; Vadlamudi et al., 1996), and 
together with its ability to polymerize via its PB1 domain, p62 targets large 
ubiquitinated protein aggregates for autophagosomal degradation (Bjørkøy et al., 
2006; Tan et al., 2008).  p62 depletion causes a reduction in ubiquitin-positive 
inclusion bodies (Pankiv et al., 2007a), however the formation of LC3-labelled 
autophagosomes and their delivery to lysosomes is not affected (Shvets et al., 2008).  
Although autophagy had been thought of as a non-selective process, the binding of 
p62 to ubiquitinated proteins provides a mechanism by which specific cargo can be 
selectively degraded.   
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The autophagic marker LC3 localises to p62 containing subcellular structures and 
through its LC3 interaction region (LIR), p62 directly binds to LC3.  This interaction 
is required for the degradation of p62 bodies (Pankiv et al., 2007a).  An 11 amino 
acid motif in p62, which contains conserved acidic and hydrophobic residues, was 
identified as the LC3 recognition sequence (Ichimura et al., 2008).  LC3 belongs to a 
ubiquitin-like protein family and its interaction with p62 is dependent on the N-
terminal ten amino acids located within its ubiquitin core (Shvets et al., 2008). 
Structural studies revealed that the LIR region is highly conserved throughout LC3 
interacting proteins and consists of a WXXL-like sequence (Noda et al., 2010).  The 
LC3 interaction region functions in a number of autophagic receptors including Nix 
(Novak et al., 2010) and Atg32 (Noda et al., 2010) and this interaction is likely to 
serve as a mechanism through which autophagic receptors tether their cargo to the 
autophagic membrane (Noda et al., 2010).  With respect to p62, it becomes possible 
to propose a model whereby misfolded proteins are identified by molecular 
chaperones and labeled with polyubiquitin chains which in turn are recognized by 
p62 and sequestered into larger aggregates.  These aggregates are targeted to the 
forming autophagosome via the interaction between p62 and LC3 (Johansen and 
Lamark, 2011).  p62 is itself degraded by autophagy and is often used as a marker of 
autophagic flux.  Levels of p62 increase upon blockage of the autophagy pathway 
(Mizushima et al., 2010). 
 
The autophagic degradation of invading bacteria has been termed xenophagy and p62 
is recruited to ubiquitinated proteins localized to bacteria and targets them for 
degradation. These structures are also labeled with LC3.  The LIR and UBA domains 
of p62 are required for autophagic degradation of the invading bacteria.  Upon 
knock-down of p62 by siRNA, there was also a 50% reduction in bacteria targeted 
for autophagy, suggesting that p62 facilitates autophagic degradation of invading 
bacteria (Zheng et al., 2009).  The removal of p62 by selective autophagy can also 
impact on intracellular signalling pathways.  Hypoxia induced autophagy enhances 
degradation of p62 which results in increased activation of ERK 1/2 in carcinoma 
cells as p62 normally acts to inhibit ERK signalling (Pursiheimo et al., 2008).  
Additionally, p62 is known to interact with Keap1.  Keap1 facilitates the degradation 
of the transcription factor Nrf2.  Under conditions of impaired autophagy, p62 
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interacts with Keap1 and competitively inhibits its interaction with Nrf2.  Nrf2 is 
therefore stabilised and this results in the abnormal accumulation of a variety of Nrf2 
target proteins which are present in autophagy-deficient livers and may contribute to 
liver abnormality (Komatsu et al., 2010). 
 
The role of p62 in autophagic degradation is largely thought to depend on the 
ubiquitination of target proteins however recently p62 has been identified in the 
clearance of non-ubiquitylated substrates.  The non-ubiquitylated protein 
STAT5A_ΔE18, which is prone to aggregation, forms HDAC6 dependent 
aggresomes which are degraded by autophagy.  This degradation is dependent on 
STAT5A_ΔE18 binding to the PB1 domain of p62 (Watanabe and Tanaka, 2011).  
 
1.5.4. Autophagy and bone 
There has been limited research with respect to autophagy and bone however, recent 
studies have demonstrated that autophagy is likely to be important for bone 
maintenance and cell survival. 
 
Osteocytes reside deep within the mineralised bone matrix, often out of contact with 
the vascular supply, where oxygen levels are low.  Low oxygen levels affect the 
osteogenic activity of pre-osteocyte cells through the transcription factor hypoxia-
inducible factor-1 (HIF-1) (Zahm et al., 2008).  As autophagy is activated under 
hypoxic conditions (Tracy et al., 2007) and is dependent on HIF-1 (Bellot et al., 
2009), it is likely that autophagy may play a role in the differentiation and survival of 
osteocytes.  Osteocytes located in cortical bone display a punctate distribution of 
LC3 as observed in longitudinal sections of rat tibiae.  Furthermore, autophagy is 
upregulated in cultures of an osteocyte cell line under hypoxic and low calcium 
conditions and this was dependent on HIF-1 (Zahm et al., 2011).  Hypoxic conditions 
have also been demonstrated in primary osteoblast cultures to decrease the formation 
of bone nodules and the expression of ALP and osteocalcin therefore suggesting that 
autophagy could be involved in the bone forming and mineralisation activity of 
osteoblasts (Utting et al., 2006). Additionally, an increase in osteoclast formation has 
been noted under hypoxic conditions (Arnett et al., 2003).   




A genome-wide association study (GWAS) identified single nucleotide 
polymorphisms (SNPs) in a number of genes involved in the regulation of autophagy 
(ROA) including Atg12, Atg7 and Atg5.  These SNPs were shown to be associated 
with wrist bone mineral density (Zhang et al., 2010).  Furthermore, misfolded 
collagen accumulates in the ER and can be toxic to cells.  Elimination of collagen is 
mediated by autophagy suggesting that in diseases such as osteogenesis imperfecta 
where misfolded collagen accumulates in cells, autophagy could provide a possible 
therapeutic target (Ishida et al., 2009). 
 
Systemic factors could also influence the autophagic activity and survival of bone 
cells.  Glucocorticoid therapy is known to cause osteoporosis and bone weakness and 
has recently been demonstrated to induce autophagy in osteocytes (Xia et al., 2010).  
Whilst autophagy is largely thought to be a cellular survival mechanism, prolonged 
activation causes the massive accumulation of autophagosomes and results in 
apoptosis (Eisenberg-Lerner et al., 2009). This suggests that long term treatment with 
glucocorticoid could lead to prolonged autophagic induction and ultimately cell 
death resulting in reduced bone strength and osteoporosis (Xia et al., 2010).   
 
The multifunctional scaffold protein p62 is involved in the maintenance of bone 
(section 1.4.3) and is a key autophagic protein (section 1.5.3).  Whilst p62 
accumulates in large inclusions in numerous diseases, its role in autophagy in bone is 
largely unclear.  Recently, p62 was identified as an interacting partner of the 
autophagy-linked FYVE domain-containing protein (ALFY) in osteoclasts.  Upon 
starvation, p62 and ALFY translocate from the nucleus to the cytoplasm and 
colocalise in cytoplasmic aggregates.  This translocation is faster in mature 
osteoclasts compared to osteoclast precursors (Hocking et al., 2010).  The UBA 
domain of p62 is required for the formation of these aggregates (Clausen et al., 
2010), however, their formation is not affected by the PDB-causing mutation P392L 
(Hocking et al., 2010).  The mechanism by which mutated p62 could lead to over-
activation of osteoclasts in PDB but have no affect on other cells could be 
attributable to the differences observed in response to starvation in osteoclasts and 
their precursors (Hocking et al., 2010).  PDB is a late-onset disease and as the 
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efficiency of the autophagy pathway declines with age (Cuervo and Dice, 2000), this 
suggests that autophagy deficiency could be contributing to the PDB phenotype. 
 
Inclusion body myopathy associated with Paget‘s disease of bone and fronto-
temporal dementia (IBMPFD) is a disease that could also link autophagy to the 
regulation and maintenance of bone.  IBMPFD is characterised by muscle myopathy, 
fronto-temporal lobar degeneration in the brain and late-onset PDB and is caused by 
mutations in the valosin-containing protein, p97/VCP (Ju and Weihl, 2010; Watts et 
al., 2004).  p97 is an essential, ubiquitously expressed,  member of the type II AAA 
(ATPase associated with various activities) ATPase family and its knockdown in 
mice is lethal (Müller et al., 2007).  P97 mediates a wide variety of cellular processes 
including protein degradation via the ubiquitin proteasome system (UPS) (Wójcik et 
al., 2004) and the endoplasmic reticulum-associated protein degradation (ERAD) 
pathway (Rabinovich et al., 2002).  One of the main pathological features of 
IBMPFD is the presence of ubiquitinated inclusions probably due to the role of p97 
in autophagosomal protein degradation.  Cells expressing the IBMPFD associated 
mutations in p97 display an increased level of autophagosome markers including 
LC3-II and p62 and an accumulation of non-degradative autophagosomes (Ju et al., 
2009).  Delivery of aggregates to the sites of autophagosome formation is also 
impaired and overexpression of HDAC6 can rescue this and reduce cell death (Ju et 
al., 2008).  IBMPFD therefore demonstrates the importance of autophagy in the 
maintenance of bone.  
 
1.6. The Ubiquitin proteasome system (UPS) 
The ubiquitin proteasome system (UPS) is the major non-lysosomal mechanism 
utilised by the cell to degrade misfolded and damaged proteins.  Proteins are 
ubiquitinated and subsequently targeted for degradation via the proteasome.  Under 
normal conditions, unwanted proteins are removed promptly before any damage can 
be caused to the cell.  However, many diseases such as Alzheimers, Parkinsons and 
myopathies can be caused by the accumulation of proteins that form aggregates due 
to the failure of parts of the UPS (Leroy et al., 1998; van Leeuwen et al., 1998; Zolk 
et al., 2006).  




Proteins are tagged for degradation by the proteasome with chains of ubiquitin, a 
small, highly conserved, ubiquitously expressed, protein (Wilkinson et al., 1980).  
The process by which ubiquitin is added to target proteins is termed ubiquitination 
and is mediated by a cascade of enzymes.  Ubiquitin is initially activated by an E1 
ubiquitin activating enzyme in the presence of ATP, resulting in the formation of a 
thiol ester bond with the carboxyl group of glycine76 on ubiquitin.  The activated 
ubiquitin molecule is subsequently transferred to the active site of an E2 ubiquitin 
conjugating enzyme through another thiol ester bond and attached to a lysine residue 
of the target protein, aided by an E3 ubiquitin ligase enzyme.  The precise 
mechanisms of different E3s vary, however they all promote the transfer of ubiquitin 
either directly or indirectly. The ubiquitin conjugation cascade contains a large 
family of E2s and an even larger family of E3s that confer substrate specificity.  
(Nandi et al., 2006; Passmore and Barford, 2004) (Figure 1.9).  
 
Additional ubiquitin molecules can be added to form polyubiquitin chains.  The 
efficient multiubiquitination of a substrate requires an additional conjugation factor 
(E4) that catalyses the extension of the ubiquitin chain in collaboration with E1, E2 
and E3 enzymes (Koegl et al., 1999).  Ubiquitin can form chains at all seven of its 
lysine residues (K6, K11, K27, K29, K33, K48 and K63) of various lengths and 
therefore can create a range of molecular signals influencing DNA repair, ribosome 
function, the stress response and protein degradation (Wooten et al., 2006).  
Monoubiquitination can also provide signals for cellular functions such as histone 
regulation and endocytosis (Hicke, 2001) whilst the synthesis of mixed ubiquitin 
chains have been reported to prevent protein degradation by the proteasome (Kim et 
al., 2007a).  K48- and K29-linked chains are thought to be the principle signal for 
degradation via the proteasome and a chain of at least four ubiquitin moieties are 
required for substrate recognition (Thrower et al., 2000).  
 
The 26S proteasome is a large cytosolic protease complex that consists of a 20S 
proteolytic core particle and one or two 19S regulatory caps.  The 19S cap has 
several functions including recognition of polyubiquitinated substrates, 
deubiquitination and translocation of substrates to the lumen of the core particle.  
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Protease enzymes are contained within the proteasome core and act to degrade 
targeted proteins (Ferrell et al., 2000).  Many proteins also transiently associate with 
the 26S proteasome (Berke and Paulson, 2003). 
 
1.6.2. Ubiquitin recognition and deubiquitinating enzymes (DUBs) 
Ubiquitin binding domains (UBD) are diverse modules present in many proteins and 
can bind to mono- and polyubiquitinated chains.  Over twenty different UBD 
families have been identified to date (Dikic et al., 2009) that diverge in both structure 
and the type of ubiquitin modification they recognise.  The ubiquitin associated 
domain (UBA) is one such UBD. 
 
The UBA domain was first identified in 1996 and is approximately 45 residues in 
length.  It is structurally similar to ubiquitin itself (Hofmann and Bucher, 1996) and 
contains three -helices and a hydrophobic core (Mueller and Feigon, 2002).  UBA 
domains bind monoubiquitin and a number of different lysine-linked 
polyubiquitinated chains (Raasi et al., 2005).  They also have lysine chain specificity, 
some only bind one polyubiquitinated chain type whereas others bind several 
different types and some do not bind ubiquitin at all (Raasi et al., 2005). Through 
binding to monoubiquitin and specific polyubiquitinated chains, UBA domains can 
modulate a variety of cellular functions.  The UBA domain of p62  binds to the K48-
linked polyubiquitinated chains on tau and thereby facilitates its degradation by the 
proteasome (Babu et al., 2005).  The UBA domain of Rad-23 binds K48-linked 
multi-ubiquitin chains leading to the selective inhibition of chain assembly and 
disassembly, which prevents protein degradation by the proteasome (Raasi and 
Pickart, 2003).  The dimerisation of UBA domains affects their ubiquitin binding 
ability.  This has been illustrated by a study of the p62 UBA domain which was 
demonstrated to dimerise and this dimerisation inhibited its ability to bind ubiquitin 
(Long et al., 2010).  In addition, destabilisation of the p62 UBA domain dimer 
interface affects NFκB signalling (Long et al., 2010).  UBA domains have also been 
implicated in the direct interaction of proteins which do not involve ubiquitin.  This 
has been illustrated by the interaction of the E3 ligase MURF2 with the UBA domain 
of p62 (Lange et al., 2005). 




Ubiquitination is a reversible process and removal of ubiquitin from substrates is 
catalyzed by deubiquitinating enzymes (DUBs).  In order for tagged proteins to be 
degraded, ubiquitin must be removed and recycled before the protein enters the 
proteolytic core (Yao and Cohen, 2002).  DUBs can also rescue poorly ubiquitinated 
or slowly degraded ubiquitin conjugates from proteasomal degradation. UCH37 is a 
subunit of the 19s regulatory particle and achieves this function by disassembling the 
degradation signal from the distal end of Lys48-linked chains thereby releasing the 
protein before it is degraded (Lam et al., 1997). Furthermore, the endosomal 
degradation of membrane receptors is regulated by DUBs.  USP10 acts to 
deubiquitinate the cystic fibrosis transmembrane conductance regulator (CFTR) 
chloride channel and therefore promote its endocytic recycling.  Knock-down of 
USP10 increased the multi-ubiqutination of CFTR and therefore enhanced its 
degradation via the lysosome (Bomberger et al., 2009).  Among their diverse 
functions, DUBs have been implicated in the regulation of osteoclastogenesis.  Mice 
deficient in the DUB CYLD displayed an osteoporotic phenotype due to an increase 
in osteoclast response to RANKL.  CYLD was shown to negatively regulate RANK 
signalling by inhibiting TRAF6 ubiquitination, and activation of downstream 
signalling events (Jin et al., 2008).   
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1.6.3. Autophagy and UPS Crosstalk 
Selective autophagy and the UPS system both require the ubiquitination signal 
therefore, it is likely that they are functionally linked.  Whilst K48-linked ubiquitin 
chains are generally a signal for degradation via the proteasome (Thrower et al., 
2000), K63-linked chains are recognized by components of the autophagosome-
lysosome pathway (Tan et al., 2008).  However, specificity may overlap as proteins 
such as p62 are involved in the degradation of proteins via the proteasome and 
autophagy (Geetha et al., 2008; Pankiv et al., 2007a).  Additionally, inhibition of 
autophagy increases the levels of proteasome substrates such as p53.  This was 
largely found to be due to an increase in p62 levels which inhibits the clearance of 
ubiquitinated proteins by the proteasome (Korolchuk et al., 2009).  Chemical 
inhibition of lysosome function also reduces proteasomal function, again suggesting 
a link between proteasomal and autophagic activity (Qiao and Zhang, 2009).   
 
1.7. NBR1 
Expression cloning with an antibody raised against CA125 (an ovarian tumour 
antigen) identified a novel peptide sequence which lacked the mucin-like membrane 
protein characteristics expected of CA125 (Campbell et al., 1994).  The new gene 
was identified as 1a1.3b which was later renamed NBR1 (Neighbour of BRCA1).  
Analysis of the genomic sequence of NBR1 in breast and ovarian cancer patients did 
not identify any mutations in its coding region.  This suggests that mutations in this 
gene are not involved directly in causing breast or ovarian cancer in these patients 
(Campbell et al., 1994).   
 
This thesis focuses on extending the current knowledge of Nbr1 as a scaffold protein 
involved in multiple protein-protein interactions.  It also further investigates the 
involvement of Nbr1 in bone formation and remodelling. 
 
1.7.1. The NBR1/Nbr1 gene 
NBR1 was mapped to chromosome 17 in humans (Campbell et al., 1994) and 
chromosome 11 in mice (Chambers and Solomon, 1996) and in both species lies in 
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close proximity to the breast cancer susceptibility gene BRCA1 (Chambers and 
Solomon, 1996). Murine Nbr1 has two main transcripts, produced by alternative 
splicing; Nbr1 (1a), the testes predominant form (Dimitrov et al., 2001) and Nbr1 
(1b) which is highly expressed in the neural tube during early embryonic stages 
(Whitehouse et al., 2002) but is widely expressed in all tissues later in development 
(Chambers and Solomon, 1996; Dimitrov et al., 2001).  Expression of the Nbr1 1a 
and 1b transcripts are controlled by two different promoters, α and β respectively.  
Analysis of the 289 base pair region separating Brca1 and Nbr1 in a reporter 
transient transfection assay demonstrated that the α promoter is bidirectional and 
controls the expression of both Nbr1 and Brca1 (Whitehouse et al., 2004).  The ATG 
start sites are located in exon 2 of Nbr1, therefore the protein coding sequence is 
unchanged between transcripts a and b (Chambers and Solomon, 1996). 
 
1.7.2. The NBR1/Nbr1 protein 
Nbr1 is 89% homologous between mouse and human and is highly conserved 
(Chambers and Solomon, 1996) with homologues identified throughout the 
eukaryotic kingdom (Svenning et al., 2011).  Analysis of the structure of Nbr1 has 
shown that it is structurally similar to the scaffold protein p62 and possesses a 
number of common protein domains (Figure 1.10).  The N-terminus contains a Phox 
and Bem1p (PB1) domain (Ito et al., 2001) that is evolutionarily conserved and 
found in many scaffold proteins involved in cellular signal transduction pathways 
(Moscat et al., 2006).  PB1 domains display the topology of ubiquitin-like β-grasp 
folds and either contain an acidic OPCA motif (type I), an invariant lysine residue on 
the first β strand (type II) or both of these motifs (type I/II).  Type I and type II PB1 
domains interact in a front-to-back manner where acidic residues on the OPCA motif 
form salt bridges with the basic residues on the type II PB1 domain (Sumimoto et al., 
2007).  Analysis of the crystal structure of the PB1 domain of Nbr1 has revealed that 
it adopts a ubiquitin-like β-grasp fold containing two α-helices, a mixed β-sheet and 
an OPCA motif making it a type I PB1 domain (Müller et al., 2006).  Two sequential 
folding transitions states in the PB1 domain of Nbr1 have also been identified and 
characterised (Chen et al., 2010). 
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The central region of the NBR1 protein contains a zinc-binding domain and two 
coiled-coil (CC) domains.  The zinc binding domain is similar to that present in 
dystrophin-like proteins and CREB-binding proteins (Whitehouse et al., 2002) while 
CC domains are responsible for protein oligomerization (Beck and Brodsky, 1998).  
Through its first coiled-coiled domain, Nbr1 is able to homodimerise (Whitehouse et 
al., 2002). 
 
The C-terminus of Nbr1 contains a UBA domain.  As described above, UBA 
domains can bind both mono- and poly ubiquitin and using ubiquitin binding assays, 
it was shown that both human and mouse Nbr1 UBA domains can bind 
monoubiquitin and K48- and K63-linked polyubiquitin chains ranging from two to 
seven in length (Waters, 2009). 
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1.7.3. Interacting partners of Nbr1 
At the outset of this project, a number of proteins were known to interact with Nbr1 
(Figure 1.11).  Yeast-2-hybrid analysis showed that amino acids 451-597 of NBR1 
interact with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and 
integrin binding protein (CIB) (Whitehouse et al., 2002).  FEZ1 is highly expressed 
in the developing brain and FEZ1 deficient mice show characteristics of 
schizophrenia and hypersensitivity to psychostimulant drugs (Sakae et al., 2008).  
FEZ1 also interacts with and is phosphorylated by PKCδ, which has been shown to 
stimulate the neuronal differentiation of PC12 cells and suggests a role in axonal 
guidance (Kuroda et al., 1999).  Additionally, FEZ1 interacts with E4B (U-box-type 
ubiquitin-protein isopeptide ligase) which promotes its polyubiquitination however, 
this does not affect its degradation but does provide a signal for neurite extension in 
PC12 cells (Okumura et al., 2004).  FEZ1 also interacts with the microtubule protein 
β-tubulin and facilitates the movement of mitochondria along the microtubule 
network towards extending neurites in PC12 cells (Fujita et al., 2007) and may play a 
role in the remodelling of microtubules through its interaction with PKCδ (Mori et 
al., 2009). FEZ1 and NBR1 colocalise in perinuclear compartments when 
overexpressed in COS-7 cells (Whitehouse et al., 2002).  
 
CIB interacts with polo-like kinase 3 and regulates its activity during cell division.  
Altered expression of CIB results in multinucleated cells due to aberrant centrosomal 
segregation (Naik and Naik, 2011).  Mice deficient in CIB display cardiac 
dysfunction and hypertrophy in response to pressure overload (Heineke et al., 2010).  
As Nbr1 plays a role in muscle function (see below), this could provide a further 
mechanism by which it exerts its function.  Additionally, CIB interacts with the 
apoptosis signal-regulating kinase 1 (ASK1) and negatively regulated stress activated 
MAPK signalling pathways (Yoon et al., 2009).  CIB is normally localised in the 
nucleus, however on coexpression with NBR1 in COS-7 cells it redistributes to 
perinuclear regions that colocalise with NBR1 (Whitehouse et al., 2002). 
 
Yeast-2-hybrid studies also showed direct interactions between the N-terminus of 
Nbr1 and Ubc-9, PIASγ and HIPK2 (unpublished data). HIPK2 is a negative 
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regulator of Wnt signalling and functions to phosphorylate β-catenin, enhancing its 
degradation (Kim et al., 2010). Ubc-9 is an E2 SUMO conjugating enzyme that 
covalently modifies target proteins by the addition of the small ubiquitin-like 
modifier (SUMO) whilst PIASγ is a SUMO E3 ligase (Gareau and Lima, 2010).  
These two proteins link Nbr1 to the sumoylation pathway. 
 
The type I PB1 domain of Nbr1 interacts with the type I/II PB1 domain of p62 
(Lamark et al., 2003).  The D50R mutation in NBR1 (a point mutation in exon three 
causing amino acid 50 to be changed from aspartic acid to arginine) can inhibit 
interaction with p62 whilst a corresponding mutation in p62 (K7A) also abrogates 
this interaction.  This suggests that the PB1 domain of p62 utilises its basic cluster to 
interact with the OPCA motif of the PB1 domain of Nbr1 (Lamark et al., 2003).  p62 
also contains a ZZ domain, and two PEST sequences which are regions of the protein 
that are rich in the amino acids proline (P), glutamic acid (E), serine (S), and 
threonine (T) and act as proteolysis signals (Rechsteiner and Rogers, 1996).  The C-
terminus of p62 contains a UBA domain which binds polyubiquitinated chains, and 
this is important for degradation of proteins via autophagy and the UPS (discussed 
above) (Figure 1.11).  p62 has been far more extensively studied than Nbr1 and as 
discussed is implicated in bone remodelling, obesity, signalling pathways such as 
NF-κB and protein degradation.  Due to similarities with p62, it is likely that Nbr1 is 
involved in these biological processes, some of which have been identified and are 
discussed below. 




Chapter 1                                                                                                     Introduction 
71 
 
1.7.4. The role of Nbr1 in bone 
To elucidate a function for Nbr1, our laboratory generated a mouse model that 
expressed a truncated form of the protein.  Exons 6, 7, and part of 8 were deleted 
causing a frameshift and premature stop codon resulting in mice expressing only 
amino acids 1-135 of the protein (trNbr1) (Whitehouse et al., 2010). The resulting 
protein lacked the UBA, ZZ and both CC domains but retained the PB1 domain.  
This strategy was used due to the close proximity of the Brca1 gene, the 
bidirectionality of the promoter and the known lethality of the Brca1-deficient mice.  
When the trNbr1 mice were generated, there was also very little known about the 
structure of the Nbr1 protein and the PB1 domain had not been identified.  
 
Mice homozygous for the truncated Nbr1 protein (trNbr1) displayed an age 
dependent increase in bone mass and bone mineral density that became apparent at 
three months of age (Whitehouse et al., 2010).  Micro-quantitative computed 
tomography (µQCT) showed there were significant increases in trabecular bone 
volume (Tb.BV), trabecular number (Tb.N) and a decrease in trabecular separation 
(Tb.Sp) (Whitehouse et al., 2010).  Calcein labelling identified an increase in bone 
formation rate in truncated mice compared with WT at two and seven months of age 
and an increase in serum osteocalcin levels was also identified (Figure 1.12).  In vitro 
analysis of osteoblast precursors derived from neonatal calvaria displayed increased 
osteoblast differentiation and mineralisation as demonstrated by ALP and von Kossa 
staining however there was no difference in osteoblast proliferation rate (Whitehouse 
et al., 2010).  Quantitative PCR also demonstrated an increase in the expression of 
osteoblast marker genes ALP, osteocalcin and Atf4 whereas levels of Runx2 were 
unaltered. These data established that truncation of Nbr1 causes an increase in bone 
formation due to an increase in osteoblast differentiation and activity (Whitehouse et 
al., 2010).  The osteoclast phenotype of these mice was also analysed and whilst at 
two months of age, there was an increase in osteoclast activity in vivo (analysed by 
osteoclast surface and mean erosion depth) in mutant mice compared with WT, this 
was transient and there were no significant differences at either six or eleven months 
of age between the genotypes (Whitehouse et al., 2010).  In vitro analysis of 
osteoclast function revealed a slight enhancement of osteoclast resorption activity 
Chapter 1                                                                                                     Introduction 
72 
 
(Whitehouse et al., 2010).  Collectively, these data suggests that there is an alteration 
in the homeostatic set point in trNbr1 mice, resulting in an increase in bone 
formation but no corresponding increase in bone resorption (Whitehouse et al., 
2010). 
 
Osteoblasts derived from trNbr1 mice also displayed enhanced and prolonged p38 
MAPK activation but ERK signalling was not affected in this cell type (Whitehouse 
et al., 2010).  Furthermore, full length Nbr1 but not trNbr1 can form a complex with 
phosphorylated p38 MAPK.  Additionally, osteoclasts from trNbr1 mice, stimulated 
with RANKL displayed an increase in p38 MAPK and ERK1/2 activation compared 
to WT controls (Whitehouse et al., 2010). p38 MAPK is activated during osteoblast 
differentiation in response to BMPs (Guicheux et al., 2003) and regulates osteoblast 
differentiation through the activation of the transcription factor osterix (Wang et al., 
2007). In addition, p38 MAPK-mediated signals are essential for RANKL induced 
osteoclast differentiation but not function (Li et al., 2002).  p38 MAPK is also 
activated in osteoblasts stimulated with the proinflammatory cytokines IL-1 and 
TNFα and inhibition of p38 MAPK prevents bone resorption in the presence of IL-1 
and TNFα (Kumar et al., 2001).   
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1.7.5. The role of Nbr1 in muscle 
The PB1 domain of NBR1 interacts with the serine-threonine kinase domain (TK) of 
the giant sarcomeric protein titin, suggesting a role for NBR1 in muscle (Lange et al., 
2005). The smallest contractile unit of skeletal muscle is the sarcomere, which is 
composed of many different, highly ordered proteins.  Titin is the third most 
abundant protein in striated muscle after myosin and actin and in developing muscle 
is thought to act as a template for the assembly of the sarcomere (Lange et al., 2006; 
Tskhovrebova and Trinick, 2003) (Figure 1.13). 
 
Under basal conditions, NBR1 interacts with titin and subsequently forms a complex 
with p62 and the E3 ligase MuRF2 at the M-band of the sarcomere.  This allows the 
serum response factor (SRF) transcription factor to activate gene transcription 
(Figure 1.14).  Upon mechanical inactivity, this complex dissociates and MuRF2 
translocates from the cytosol to the nucleus where it interacts with SRF and prevents 
gene transcription (Lange et al., 2005). This suggests that NBR1 acts as a scaffold to 
target p62 and MuRF2 to the TK region of titin and therefore modulate muscle gene 
expression.  A point mutation in the TK region of titin was found in patients 
suffering from hereditary myopathy with early respiratory failure (HMERF).  This 
mutation dramatically reduces NBR1 binding and results in the mislocalisation of 
NBR1 causing the loss of sarcomere structure. p62 and MuRF2 are no longer 
recruited to the signalling complex and NBR1 and p62 are found to accumulate in 
vesicular structures (Lange et al., 2005).  This strongly suggests a role for NBR1 in 
regulating muscle gene expression via the correct targeting of signalling complexes.  
The expression of Nbr1, p62 and LC3 in early cardiac differentiation parallels that of 
MuRF2 suggesting an important role for ubiquitin-mediated protein turnover at this 
early stage of development (Perera et al., 2011).  
 
Chapter 1                                                                                                     Introduction 
75 
 
Chapter 1                                                                                                     Introduction 
76 
 
1.7.6. Additional roles for Nbr1 
Since the outset of this project, further roles for Nbr1 have been identified, some of 
which will be discussed here and others will be discussed in subsequent chapters. 
 
1.7.6.1. Nbr1 and receptor trafficking 
NBR1 (aa835-966) has been identified as an interacting partner of the Sprouty 
related with Ena/VASP homology 1 domain 2 (SPRED2) protein (Mardakheh et al., 
2009).  This interaction is dependent on the EVH1 domain of SPRED2 and SPRED2 
colocalises with NBR1-positive late endosomal vesicles.  Sprouty related proteins are 
known to inhibit ERK1/2 signalling downstream of  FGF (Minowada et al., 1999) 
and when overexpressed with SPRED2, NBR1 further enhances SPRED2-mediated 
ERK1/2 inhibition.  Furthermore, there was a reduction in endogenous FGF receptor 
2 (FGFR2) in SPRED2 expressing cells, however, knock-down of NBR1 
significantly reduced this effect.  In the absence of SPRED2 there was also a 
reduction of FGFR2 that localised to LAMP2 positive endosomes.  This data 
suggests that through its interaction with NBR1, SPRED2 directs activated FGF 
receptors to the lysosomal degradation pathway therefore inhibiting ERK1/2 
signalling (Mardakheh et al., 2009).  SPRED2 has also been implicated in bone 
formation as mice lacking functional SPRED2 display a dwarfism phenotype.  This 
is due to increased ERK phosphorylation in FGF stimulated chondrocytes suggesting 
that SPRED2 negatively regulates signalling downstream of FGF to ensure correct 
bone formation (Bundschu et al., 2005). 
 
Further evidence now shows that Nbr1 has a direct effect on receptor tyrosine kinase 
(RTK) trafficking (Mardakheh et al., 2010).  Live cell imaging demonstrated that 
ectopic expression of Nbr1 inhibited ligand-mediated degradation of epidermal 
growth factor receptor (EGFR) by trapping it at the cell surface, resulting in 
enhanced ERK1/2 signalling.  This effect was minimal when cells were pretreated 
with Bafilomycin A1 suggesting the effect is due to inhibition of lysosomal 
degradation.  Furthermore, the UBA domain is essential for inhibition of receptor 
degradation but not sufficient whilst both the UBA and a region 10 amino acids N-
terminal of the UBA named JUBA (juxta-UBA) are important for the late endosomal 
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localization of Nbr1.  Together with the work by Mardakheh et al 2009, this provides 
evidence that the normal function of Nbr1 is to inhibit receptor degradation.  The 
interaction of NBR1 with SPRED2 alters this inhibitory function, causing enhanced 
receptor degradation (Mardakheh et al., 2010). 
 
1.7.6.2. Nbr1 and T helper cell differentiation 
Evidence has also come to light for the role of Nbr1 in T helper 2 (Th2) cell 
differentiation (Yang et al., 2010).  Yang et al. generated an activated T-cell specific 
Nbr1-deficient mouse model that exhibited impaired lung inflammation and 
defective Th2 cell differentiation.  They showed that in Nbr1 deficient T cells, 
GATA3 and NFATc1 nuclear levels are reduced but NFκB and p38 signalling was 
unaffected.  This suggests that Nbr1 plays a role in modulating signalling pathways 
important for Th2 differentiation and the immune response.  Cell polarity, a 
mechanism whereby essential regulators are located to the immunological synapse 
(IS) is also important for T-cell activation.  Yan et al. showed that NBR1 and p62 are 
recruited to the IS upon T cell activation and that NBR1 recruitment is dependent on 
p62 whilst p62 recruitment is dependent on NBR1.  Additionally, lack of NBR1 or 
p62 leads to a reduction in the recruitment of the cell polarity markers talin and 
scribble to the IS (Yang et al., 2010). 
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1.8. Project Aims 
Nbr1 is a ubiquitously expressed scaffold protein known to be involved in the 
maintenance of muscle and bone.  The truncated Nbr1 mouse model has identified 
Nbr1 as a regulator of bone mass and bone mineral density however, the molecular 
mechanisms by which it exerts its function are still unclear.  Through its interaction 
with polyubiquitin and SPRED2, Nbr1 has been implicated in protein degradation 
and modulation of signalling pathways by regulation of receptor internalisation. 
 
The aims of this thesis were to gain further insight into the function of Nbr1 with 
particular interest in the regulation of bone.  This was addressed using a number of 
different strategies: 
 
• Nbr1 is a scaffold protein, involved in a number of protein-protein interactions, 
therefore yeast-2-hybrid screens were performed using previously uncharacterised 
regions of Nbr1 as bait with the goal of identifying new interacting partners.  
Putative interactions were further validated to gain information on Nbr1 function.  
• A knock-in mouse model containing the D50R mutation in Nbr1 that abolishes its 
interaction with p62 was analysed to investigate the role of this interaction in the 
regulation and maintenance of bone. 
• Due to the known roles of Nbr1 in bone remodelling, genomic DNA from a cohort 
of individuals with idiopathic high bone mass (HBM) was sequenced to identify any 
sequence variation in the coding exons of NBR1 which may be contributing to the 
skeletal phenotype. 
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Chapter 2. Materials and Methods 
2.1. Molecular biology 
All chemicals were obtained from Sigma and enzymes from New England Biolabs 
(NEB) unless otherwise stated.  All buffer constituents are shown in Table 2.23 (page 
112). 
 
2.1.1. Polymerase chain reaction (PCR) 
PCR was performed for cloning, screening of bacterial colonies, genotyping and 
patient sequencing. Pfu (Stratagene) DNA polymerase was used for cloning as it 
possesses 3‘ to 5‘ exonuclease proof reading activity and therefore reduces the 
possibility of mutations being introduced.  Taq DNA polymerase (Bioline) was used 
for all other PCR reactions.  The standard PCR reaction mix was set up as shown in 
Table 2.1.  DNA amplification was carried out in a PTC-100 thermal cycler (MJ 
Research, Inc) using the standard conditions shown in Table 2.2.  Primer annealing 
temperatures were specific for each amplicon whilst a one minute extension time was 
used per Kb of template. 
 
Reagent Volume 
10x buffer (Bioline) 5 µl 
Primer (100ng/µl) 2.5 µl 
Primer (100ng/µl) 2.5 µl 
dNTPs (10mM, Amersham) 1 µl 
taq (Bioline,5U/µl) 0.5 µl 
DNA (100ng plasmid or, 1µg 
genomic DNA) 
1 µl 
H2O 37.5 µl 
                    Table 2.1. Standard PCR reaction mix. 





1 95°C for 2 minutes 
2 95°C for 30 seconds 
3 Tm (-5°C) for 1 minute 
4 
72°C for 1 minute/Kb of 
template 
5 Go to step 1 x30 
6 72°C for 10 minutes 
                                Table 2.2. Standard PCR conditions 
 
2.1.2. Colony PCR 
Bacterial colonies were picked using a pipette tip and transferred into 100 µl LB 
broth supplemented with appropriate antibiotic. The tip was then transferred into 40 
µl of H2O, mixed and the LB culture incubated at 37°C for 4 hours with shaking.  
The H2O containing bacterial cells was boiled at 95ºC for 2 minutes, centrifuged for 
5 minutes at 1500 xg and 10 µl of the resulting supernatant was used in a subsequent 
PCR reaction.  Overnight cultures were prepared from positive clones determined 
from the PCR reaction and DNA extracted using a QIAprepMiniprep Kit according 
to manufacturer‘s instructions. 
 
2.1.3. Agarose gel electrophoresis 
Typically, agarose (Invitrogen) was dissolved at 1% in 1x TAE buffer (Table 2.23), 
0.1 µg/ml ethidium bromide added and the gel set at room temperature in a gel 
former.  The appropriate volume of 5x DNA sample buffer was added to each sample 
and loaded into the wells.  An appropriate molecular marker (NEB) was loaded 
alongside the samples (100 bp or 1 Kb ladder).  Electrophoresis was carried out at 
100 V until DNA fragments had separated adequately.  DNA was then visualised 
using a Kodak UV gel documentation system. Molecular markers of known 
molecular weight enabled the size of the DNA fragments to be determined.  Where 
appropriate, DNA bands were excised from the gel using a UV light box and purified 
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using a QIAquick Gel Extraction Kit (250, Cat no. 28706) according to 
manufacturer‘s instructions. 
 
2.1.4. Restriction enzyme digest 
PCR product or plasmid DNA was digested using the appropriate NEB restriction 
enzyme and buffer.  The standard reaction mixture used is shown in Table 2.3.  




10x appropriate buffer 3µl 
DNA 1µg 
10x BSA (if necessary) 3µl 
restriction enzyme 5 units 
H2O Up to 30µl 
                           Table 2.3. Standard restriction enzyme digest 
 
2.1.5. DNA ligation reactions 
Following digestion with appropriate restriction enzymes, separation by gel 
electrophoresis (section 2.1.3) and gel purification using the QIAquick gel extraction 




T4 ligase buffer (NEB) 1µl  
T4 ligase (NEB) 1µl 
vector DNA (50ng/µl) 1µl  
DNA insert at a molar ratios of 
1:1, 1:3, 1:5 with vector 
variable 
H2O Up to 10 µl 
                    Table 2.4. Standard ligation reaction 
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Reactions were incubated at 16°C for 12 hours and transformed into chemically 
competent bacteria as described in section 2.1.8. 
 
2.1.6. Purification of PCR products using ExoSAP-IT 
PCR product was purified using ExoSAP-IT (USB).  ExoSAP-IT contains 
Exonuclease I which removes residual single-stranded primers and any extraneous 
single-stranded DNA produced during the PCR reaction and Shrimp Alkaline 
Phosphatase (SAP) which removes the remaining, unincorporated dNTPs from the 
PCR mixture. A standard reaction was set up (Table 2.5) and incubated at 37°C for 
15 minutes and at 80°C for 15 minutes.  3.5 µl of reaction mix was then used in a 
standard sequencing reaction (Table 2.6). 
 
Reagent Volume 
ExoSAP-IT 0.25 µl 
PCR product 1 µl  
H2O 5.75 µl 
                           Table 2.5. Standard ExoSAP-IT reaction 
 
2.1.7. DNA sequencing 
A standard sequencing reaction was set up (Table 2.6) using the Dye Terminator 
V3.1 cycle sequencing kit (ABI) and carried out on a PTC-100 thermal cycler (MJ 
Research) using the cycling conditions in Table 2.7. 
 
Reagent Volume 
Big dye mastermix 0.25 µl 
5x sequencing buffer 1.25 µl  
Primer (100ng/µl) 0.25 µl 
DNA (0.5µg/µl) 1 µl 
H2O 3.25 µl  
                           Table 2.6. Standard sequencing reaction 
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C for 30 seconds   
2 48
o
C for 30 seconds 
3 60
o
C for 4 minutes 
4 Go to step 1 x20 
                          Table 2.7. Standard sequencing programme 
 
DNA was precipitated in 25 µl 95% ethanol and 1 µl 3M NaOAc per sequencing reaction.  
Samples were then centrifuged at 1500 xg for 30 minutes at 4°C and the supernatant 
removed.  100 µl of 70% ethanol was added to each sample to wash the DNA and the sample 
was again centrifuged at 1500 xg for 15 minutes at 4°C and the supernatant removed.  The 
pellet was air dried and resuspended in 10 µl of HiDi (ABI).  Sequencing was performed on 
an ABI 3730xl, 96 capillary sequencer according to manufacturer‘s instructions. 
 
2.1.8. Preparation and transformation of chemically competent 
bacteria 
DH5α bacterial cells were streaked onto LB agar (Table 2.23) and incubated at 37°C 
overnight.  The following day, one colony was used to inoculate 30 ml of LB broth 
(Table 2.23) and incubated overnight at 37°C with shaking at 180 rpm.  100 ml of 
LB broth (Table 2.23) was inoculated with 1 ml of overnight culture and incubated at 
37°C, shaking at 180 rpm for 2-4 hours until the OD550 reached 0.48. The OD550 was 
measured in a 6300 Spectrophotometer (Jenway).  The bacteria were then incubated 
on ice for 15 minutes and centrifuged at 1500 xg for 10 minutes at 4°C.  The 
supernatant was discarded and cells resuspended in 40ml of ice cold TfbI buffer 
(Table 2.23).  The bacteria were again incubated on ice for 15 minutes and 
centrifuged at 2500 xg for 10 minutes at 4°C.  The supernatant was discarded and 
4ml of TfbII buffer (Table 2.23) was used to resuspend the bacteria.  The bacteria 
were then incubated on ice for a further 15 minutes, separated into 50 µl aliquots and 
frozen on dry ice before being stored at –80oC. 
 
One aliquot of chemically competent bacteria was thawed on ice for each sample of 
DNA transformed.  5 ng of DNA was added to each vial and mixed gently by 
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tapping.  Cells were then incubated on ice for 30 minutes, heat shocked at 42°C for 
30 seconds then placed on ice for a further 2 minutes.  250 µl of pre-warmed LB 
broth (Table 2.23) was added to the bacteria and the bacteria were incubated at 37°C 
for 1 hour, shaking at 180 rpm.  Between 20 µl and 200 µl of each transformation 
was plated onto LB agar containing appropriate antibiotic (50 µg/ml).  The plates 
were inverted and incubated at 37°C overnight. Plasmids were then extracted from 
cells using the TENS method (section 2.1.10) or a QIAprep Miniprep Kit (Cat no. 
27106) or High Speed Maxi Kit (Cat no. 12662) according to manufacturer‘s 
instructions.  The nucleic acid concentration was determined using a Nanodrop 1000 
spectrophotometer (Thermo Fisher Scientific). 
   
2.1.9. Preparation and transformation of electrocompetent bacteria 
DH5α bacterial cells were cultured on LB agar (Table 2.23) as in section 2.1.8.  10 
ml of LB broth was then inoculated with one colony and incubated overnight at 
37°C, shaking at 180 rpm.  The overnight culture was used to inoculate 1 L of LB 
broth and incubated at 37°C, shaking at 180 rpm for 2-4 hours until the OD600 
reached 0.5. The OD600 was measured in a 6300 Spectrophotometer (Jenway).  
Bacteria were chilled on ice and centrifuged at 1500 xg for 15 minutes at 4
o
C.  The 
supernatant was discarded and cells resuspended in original volume of ice cold 10% 
glycerol, 1mM Hepes (pH7).  Bacteria were then centrifuged at 1500 xg for 15 
minutes at 4°C.  This was repeated twice more.  The bacteria were then resuspended 
in 1/50 original volume of ice cold 10% glycerol and centrifuged at 1500 xg for 15 
minutes at 4°C.  The bacteria were then resuspended in 1/500 original volume of 
10% glycerol.  Cells were then divided into 50 µl aliquots, frozen on dry ice and 
stored at –80°C. 
 
One aliquot of bacteria was thawed on ice per DNA sample to be transformed.  5 ng 
of DNA was transferred to a pre-chilled 0.2 cm electroporation cuvette (Biorad) and 
the thawed bacteria added to the DNA and gently mixed by tapping.  The cuvette 
was then placed into the Biorad gene pulser II electroporator and bacteria 
electroporated at 2.5 kV; 25 capacitance; 200 low range; 500 high range.  200 µl of 
LB broth (Table 2.23) was then added and bacteria were incubated at 37°C, shaking 
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at 180 rpm for 1 hour and subsequently plated onto LB agar (Table 2.23) containing 
appropriate antibiotic (50 µg/ml).  Plates were inverted and incubated at 37°C 
overnight.  Plasmids were then extracted from cells using the TENS method (section 
2.1.10) or a QIAprep Miniprep Kit according to manufacturers instructions.  The 
nucleic acid concentration was determined using a Nanodrop 1000 
spectrophotometer (Thermo Fisher Scientific). 
 
2.1.10. TENS preps 
LB broth (5 ml) containing the appropriate antibiotic was inoculated with one 
successfully transformed bacterial colony and incubated overnight at 37°C, shaking 
at 180 rpm.  1.5 ml of the overnight culture was centrifuged at 16000 xg for 30 
seconds.  The majority of the supernatant was removed, leaving 50-100 µl in the 
tube.  The tube was briefly vortexed to resuspend the cell pellet and then 300 µl of 
TENS buffer (Table 2.23) and 150 µl 3M NaAc (pH 5.2) was added to each sample 
and vortexed briefly to precipitate the protein.  The sample was then centrifuged at 
16000xg for 5 minutes to pellet the cell debris.  The supernatant was transferred to a 
new tube and 0.9 ml 100% ice cold ethanol added to precipitate out the nucleic acid.  
The samples were centrifuged for 10 minutes at 16000 xg, the supernatant discarded 
and the pellet washed in 0.5 ml 70% ethanol and centrifuged at 16000 xg for 10 
minutes.  The supernatant was again removed and the pellet air dried and then 
dissolved in 100 µl H2O and stored at –20
o
C.   
 
2.1.11. DNA extraction from mouse ear clippings 
Tail buffer (500 µl) (Table 2.23) was added to each ear clipping and incubated 
overnight at 50°C.  Resulting digested tissue was centrifuged at 16000 xg for 10 
minutes and the supernatant transferred to a new tube.  500 µl of 
phenol:chlorophorm:isoamylalcohol (25:24:1) was added to the supernatant, 
vortexed and centrifuged for 20 minutes at 13,000 rpm.  The resulting aqueous layer 
was transferred to a new tube and DNA was precipitated with 500 µl isopropanol.  
DNA was then centrifuged at 16000 xg for 30 minutes and washed with 500 µl 70% 
ethanol.  The DNA pellet was air dried and resuspended in 20 µl H2O.  The genotype 
of the mutant mice (generation of the mice is detailed in section 2.4) was then 
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determined using PCR (section 2.1.1) to amplify exons 3 and 4a and intron 3 of Nbr1 
and a StuI restriction digest (section 2.1.4) to distinguish between WT and the D50R 
mutant.  Mutant DNA had been engineered to contain a StuI restriction site, therefore 
upon restriction digest with StuI, two bands of 1134bp and 334bp could be visualised 
by gel electrophoresis (section 2.1.3) whereas the WT DNA could not be digested by 
the StuI enzyme and was visualised as a single band of 1470bp (see section 5.2).  
Primers utilized for genotyping are shown in Table 2.8.   
 
Primer Name Primer Sequence 
Intron2F7CW GCATTGAATCCCCAGCATCA 
Intron4aR1 ACTATGAAGTCCAGAGTGCC 
Table 2.8. Genotyping primer sequences.  Exons 3 and 4a 
and intron 3 of Nbr1 was amplified using these primers. 
 
2.1.12. Primers used for high bone mass patient sequencing of NBR1 
Primers were designed to have a melting temperature (Tm) of between 60 and 64°C.  
A at T were predicted to have a Tm 2°C and G and C were predicted to have a Tm of 
4°C.  Where possible, primers started and ended in C or G. 
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Table 2.9. Primers used for HBM patient DNA amplification and sequencing.  
Exon 1 corresponds to exon 1b of NBR1 which is out of the coding region of the 
protein but is included in the predominant NBR1 transcript. 
 
2.2. Protein methods 
2.2.1. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
A Biorad Mini-PROTEAN Tetra System was used to prepare appropriate resolving 
and stacking gels (Table 2.10) for the separation of proteins according to their size.  
Where appropriate, a gradient gel was prepared ranging from 5% to 20% acrylamide 
using gradient forming apparatus (Table 2.11).  SDS sample buffer (Table 2.23) was 
added to the protein samples, heated for 5 minutes at 95°C and loaded onto the gel 
along with 10 µl of known molecular weight protein markers (Amersham rainbow 
markers).  Electrophoresis was performed at 100 V for 2 hours at room temperature 
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Constituent  Resolving Gel  Stacking Gel 
 6% 10% 15% 5% 
1.5M Tris (pH 
8.8) 
7.6 ml 7.6 ml 7.6 ml - 
1M Tris (pH 6.8) - - - 1.25 ml 
20% SDS 150 µl 150 µl 150 µl 50 µl 
H2O 17.4 ml 14.5 ml 11.25 ml 7.3 ml 
40% Acrylamide 4.5 ml 7.5 ml 10.69 ml 1.3 ml 
10% APS 300 µl 300 µl 300 µl 100 µl 
Temed 12 µl 12 µl 12 µl 10 µl 
Table 2.10. SDS PAGE gel constituents. This makes up to three small 
(8.3cmx7.3cm) gels, 1.5mm thick. 
 
Constituent 5% Resolving Gel 20% Resolving Gel 
40% Acrylamide 2 ml 8 ml 
1M Tris (pH8.8) 5.6 ml 5.6 ml 
20% SDS 75 µl 75 µl 
Glycerol 0.45 g 3 g 
H2O 7.95 ml - 
Table 2.11. Gradient SDS PAGE gel constituents. This makes one small 
(8.3cmx7.3cm) gel, 1.5mm thick. 
 
2.2.2. Western blot analysis and enhanced chemiluminescence (ECL) 
A Biorad mini trans blot system was used to transfer the proteins from the SDS 
polyacrylamide gel onto a PVDF membrane (Millipore) which was prepared 
according to manufactures instructions.  Protein transfer was performed in 1 x 
transfer buffer (Table 2.23) at 100 V for 2 hours at room temperature or at 25 volts 
overnight at 4°C.   
 
The membrane was blocked in 5% milk, 0.1% Tween 20/PBS for 1 hour with gentle 
shaking followed by a brief wash with 1% milk/PBS.  The membrane was then 
incubated with the appropriate primary antibody (Table 2.16) diluted in 1% 
milk/PBS for 1 hour at room temperature with gentle shaking then subsequently 
washed three times for 5 minutes and once for 15 minutes in 1% milk/0.1% 
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Tween/PBS.  The appropriate secondary antibody (Table 2.17) was applied to the 
membrane, diluted in 1% milk/0.1% Tween/PBS and incubated at room temperature 
for 1 hour.  The membrane was again washed three times for 10 minutes and once for 
15 minutes in 1% milk/0.1% Tween/PBS. Amersham Western Blotting Detection 
Reagent Kit (RPN2209) was used to detect proteins using ECL.  The proteins were 
then visualised using Fuji X-ray film on a Laser 4S developer (IGP Ltd).  Where 
appropriate, protein levels were estimated by quantifying the protein band intensity 
using ImageJ and normalising to the β-actin control.  
 
2.2.3. Coomassie staining of polyacrylamide gels 
Polyacrylamide gels were prepared and run as in section 2.2.1.  The gel was then 
incubated in coomassie stain (National Diagnostics) (Table 2.23) for 1 hour with 
shaking at room temperature before being de-stained for 4 hours and visualised on a 
light box.  
 
2.2.4. Recombinant protein induction 
Chemically competent BL21 bacteria (Stratagene) were transformed with appropriate 
cDNA constructs (Table 2.12) and plated onto LB agar (Table 2.23) containing 
ampicillin or kanamycin (50 µg/ml).  Single colonies were cultured overnight in 20 
ml of LB broth at 37°C with shaking and then subcultured 1:10 into 100 ml LB broth 
(Table 2.23) containing appropriate antibiotic (50 µg/ml) and incubated for 1 hour at 
37°C with shaking.  Protein expression was then induced using IPTG at a final 
concentration of 1 mM and cultures incubated for a further 3-4 hours with shaking at 
37°C.  Cells were then centrifuged at 1500 xg for 15 minutes the supernatant 
removed and cell pellet stored at -20°C. 
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Table 2.12. Constructs made for binding assays.  The cloning strategy for each 
construct is shown detailing the template used for insert amplification, restriction 
sites, vector and antibiotic resistance. Vector maps are shown in Appendix A.3.  
PET6H and GST2C vectors were modified and kindly provided by M. Gautel. 
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2.2.5. Purification of recombinant GST tagged proteins 
Bacterial cell pellets were thawed on ice and resuspended in 10 ml TEDG buffer 
(Table 2.23) per 200 ml original culture volume and incubated with 500 µl of 
lysozyme (10 mg/ml) for 30 minutes at room temperature with rocking.  Samples 
were then sonicated three times at 4°C for 30 seconds with 30 second intervals and 1 
ml 10% Triton x100 added.  Following incubation for 30 minutes on ice, the 
resulting cell lysate was centrifuged for 30 minutes at 1500 xg at 4°C.  The 
supernatant (soluble fraction) was removed and incubated with 5 ml NETN buffer 
(Table 2.23) and 500 µl of a 50% glutathione sepharose (GST) bead slurry (Sigma) 
for 2 hours at 4°C with end-over-end rotation.  Beads were then washed three times 
with 5 ml H buffer (Table 2.23) and stored at 4°C in PBS containing 2mM azide and 
protease inhibitors.  An aliquot was run on an SDS PAGE gel (section 2.2.1) and 
proteins visualised using coomassie stain (section 2.2.3) and where appropriate, 
protein concentrations were estimated. 
 
2.2.6. Purification of histidine tagged MAP1B-LC1   
Bacterial cell pellet (from 500 ml culture) was resuspended in 20 ml of lysis buffer 
(Table 2.23).  5 ml of lysozyme (5mg/ml) was added to the sample and incubated for 
30 minutes at room temperature with rocking then sonicated three times for 30 
seconds with 30 second intervals.  The resulting cell lysate was centrifuged for 30 
minutes at 1500 xg at 4°C and the supernatant transferred to a new tube. 1 ml of a 
50% Ni Sepharose 6 Fast Flow bead slurry (Amersham Biosciences 17-5318-02) was 
added to the supernatant and incubated for 2 hours at 4°C with end-over-end rotation.  
Beads were then washed three times with 2 ml of low elution buffer (Table 2.23) and 
five times with 2 ml high elution buffer (Table 2.23).  Fractions from the high elution 
buffer were combined and dialysed overnight at 4°C into dialysation buffer (Table 
2.23).  The dialysed proteins were then stored at -80°C in 2mM azide until further 
use. 
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2.2.7. Purification of histidine tagged LC3 
Bacterial cell pellets (from 100 ml culture) were resuspended in 5 ml of Buffer A 
(Table 2.23) then sonicated twice for 10 seconds at 4°C.  5 ml of lysozyme (5mg/ml) 
was added and the lysate was made up to 35 ml with Buffer A (Table 2.23).  The 
contents of one 20 ml Talon single step column purification (Clontech) were added 
and the sample rotated at 4°C overnight.  The sample was then centrifuged for 5 
minutes at 700 xg, 4°C and the unbound supernatant was retained for later analysis.  
The pink resin was washed six times in 20ml of Buffer B (Table 2.23) for 5 minutes.  
The protein was eluted from the column in 2 x 3ml of Buffer C (Table 2.23) (rotating 
in Buffer C at 4°C for 10 minutes, for each elution).  Washes and elutions were 
dialysed in PBS with 10% glycerol overnight at 4°C and the frozen at -70°C.  This 
method was carried out by Dr Sarah Waters (KCL). 
 
2.2.8. Pulldown of YFP-LC3 by GST-NBR1 
NBR1-A 486-903aa, NBR1-B 681-903aa, NBR1-C 737-903aa and NBR1-D 729-
775) were cloned into pGST2C vector (Table 2.12).  YFP-LC3 (a kind gift from 
Marco Sandri, Padova, Italy) was transfected into COS-7 cells that had previously 
been seeded into 6-well culture dishes (section 2.5.2).  Cells were lysed after 24 
hours in 400µl IP lysis buffer 1 (Table 2.23) per well for 20 minutes on ice.  Lysate 
was centrifuged at 16000 xg for 10 minutes at 4°C and then incubated with 3 µg GST 
only, GST-NBR1–A, GST-NBR1-B, GST-NBR1-C or GST-NBR1-D for 2 hours at 
4°C.  Beads were then washed three times with 1 ml IP wash buffer 1 (Table 2.23) 
and bound proteins resolved by SDS PAGE and proteins visualised using a mouse 
monoclonal antibody that recognises GFP and YFP (Table 2.16).  This method was 
carried out by Dr Sarah Waters (KCL).   
 
2.2.9. Pulldown of MAP1B-LC1-myc by GST-Nbr1 
The novel region of Nbr1 (aa346-498) was cloned into the pGEX2T vector (Table 
2.12) and MAP1B-LC1 (aa2216-2464) was cloned in to the pcDNA3.1 vector (Table 
2.15).  GST-tagged recombinant proteins were expressed and purified as described in 
sections 2.2.4 & 2.2.5.  MAP1B-LC1-myc was transfected (section 2.5.2) into COS-
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7 cells that had previously been plated into 6-well culture dishes (using Fugene 6, 
Roche).  Cells were lysed after 24 hours in 200 µl (per well of cells) IP lysis buffer 2 
(Table 2.23).  Lysate was centrifuged at 13,000 xg for 10 minutes at 4°C and 
incubated with GST only, GST-Nbr1-novel, GST-Nbr1-UBA or GST-Nbr1-aa1-135 
(Table 2.12) at 4°C for 2 hours with end-over-end rotation.  Beads were washed three 
times with IP wash buffer 2 (Table 2.23) and bound proteins resolved by SDS PAGE 
then visualised using a mouse monoclonal antibody (9E10) that recognises the myc 
tag (Table 2.16).  
  
2.2.10. Pulldown of HA-Nbr1 by GST-osteocalcin and GST-cystatin 
C 
Fragments of osteocalcin and cystatin C were cloned in to the pGEX2T vector (see 
Table 2.12) and GST-tagged recombinant proteins were expressed and purified as 
described in section 2.2.5  HA-Nbr1 was transfected into COS-7 cells that had 
previously been plated into 6-well culture dishes (using Fugene 6, Roche).  Cells 
were lysed after 24 hours in 200 µl (per well of cells) lysis buffer 1 (Table 2.23).  
Lysate was centrifuged at 16000 xg for 10 minutes at 4°C and subsequently 
incubated with the GST-tagged purified proteins at 4°C overnight with end-over-end 
rotation.  Beads were washed three times with 1ml IP wash buffer 1 (Table 2.23) and 
bound proteins resolved by SDS PAGE, Western blotted and probed with a rat 
polyclonal antibody that recognises the HA tag (Table 2.16).  
  
2.2.11. Recombinant His-tagged LC3 binding assay 
GST binding assays were performed as in section 2.2.8 but incubated with His-
tagged LC3 (cleaved form) in IP buffer 1 (Table 2.23) for 2 hours at 4°C.  Beads 
were washed three times with 1ml of wash buffer (Table 2.23) and bound proteins 
resolved by SDS PAGE, Western blotted and probed with an antibody that 
recognises LC3 (Table 2.16).  This method was carried out by Dr Sarah Waters 
(KCL). 
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2.2.12. Recombinant His-tagged MAP1B-LC1 binding assay 
GST binding assays were performed as in section 2.2.10 but incubated with His-
tagged MAP1B-LC1 in IP buffer 2 (Table 2.23) for 2 hours at 4°C.  Beads were 
washed three times in 1 ml of IP lysis buffer 2 (Table 2.23) and bound proteins 
resolved by SDS PAGE, Western blotted and probed with a mouse monoclonal 
antibody that recognises the His tag (Table 2.16). 
 
2.2.13. Coimmunoprecipitation  
For MAP1B-Nbr1 coimmunoprecipitation, COS-7 cells were seeded and transfected 
with HA-Nbr1 and MAP1B-LC1-myc as in section 2.4.2 and for Nbr1-p62 
coimmunoprecipitation, mouse embryonic fibroblasts (MEFs) were prepared as in 
section 2.4.4 and seeded into 6-well tissue culture dishes.  Both cell types were 
grown to 90% confluency and lysed in 200 µl IP lysis buffer 2 (Table 2.23) and the  
lysate centrifuged at 16000g for 10 minutes at 4°C.  Lysate was then precleared with 
appropriate species of IgG and 40 µl of protein A beads (50% slurry-Millipore).  
Supernatant was removed and incubated with the appropriate antibody (Table 2.16) 
overnight at 4°C with end-over-end rotation (Table 2.13) 
 
Tube Components 
1 MEFs cell lysate + anti-p62 antibody 
(mouse monoclonal) 
2 MEFs cell lysate only 
3 MEFs cell lysate + non specific 
antibody (anti-myc mouse monoclonal) 
4 COS-7 cell lysate + anti-myc (A-14) 
antibody 
5 COS-7 cell lysate only 
6 COS-7 cell lysate + rabbit IgG 
                    Table 2.13. Conditions for coimmunoprecipitation. 
 
The following day, 40 µl of protein A beads (50% slurry) was added to each sample 
and incubated for a further 2 hours at 4°C with end-over-end rotation.  Beads were 
then washed three times with 1 ml IP lysis buffer 2 (Table 2.23) and bound proteins 
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resolved by SDS PAGE, Western blotted and membranes probed with appropriate 
antibodies (Table 2.16). 
 
2.3. Yeast-two-hybrid methods 
The GAL4 Two-Hybrid System 3 was used for the yeast-2-hybrid screens.  This 
technique can identify any proteins that interact with a protein of interest.  A 
pretransformed 7 day old mouse calvaria cDNA library (cloned into the pGADT7 
vector) was kindly supplied by Prof. Ikramuddin Aukhil (College of Dentistry, 
University of Florida) in the AH109 yeast strain. The bait constructs; murine Nbr1 
aa355-694, and Nbr1 aa495-924 were cloned by Dr Caroline Whitehouse 
(Department of Medical and Molecular Genetics).  Nbr1 aa346-498 was cloned into 
the pGBKT7 (kanamycin) vector using the EcoRI and SalI restriction sites and the 
HA-Nbr1 construct as a template for insert amplification.  Y187 and AH109 yeast 
strains were streaked onto YPDA agar and incubated at 30°C for 3-4 days. 
 
2.3.1. Phenotyping yeast strains 
The yeast strains used for the yeast-2-hybrid assay (Y187 & AH109) are auxotrophic 
for leucine, tryptophan, histidine and adenine.  In order to verify this phenotype, 
YPDA medium (50 µl) was inoculated with one yeast colony from each strain and 
vortexed to disperse cells. 100µl was then plated onto SD/-leucine, SD/-tryprophan, 
SD/-histidine, SD/-adenine and SD/-uracil agar and incubated at 30°C for 4 days. 
 
2.3.2. Production and transformation of chemically competent yeast  
Several 2-3mm colonies from Y187 and AH109 were used to separately inoculate 
1ml of YPDA medium (Table 2.23) and vortexed to disperse cells.  Cells were 
transferred to a sterile flask containing 50ml of YPDA medium (Table 2.23) and 
incubated for 16-18 hours at 30°C, shaking at 250 rpm until the OD600 reached >1.5.  
YPDA (300 ml) was then inoculated with the overnight culture to an OD600 of 0.2-
0.3.  Cells were incubated at 30°C, 250 rpm until the OD600 reached 0.5 ± 0.1 (2-4 
hours).  The OD600 was measured in a 6300 Spectrophotometer (Jenway).  Cells were 
subsequently centrifuged at 1000 xg for 5 minutes at room temperature.  The 
Chapter 2                                                                                    Materials and Methods 
97 
 
supernatant was discarded and cells resuspended in 30 ml sterile H2O.  Cells were 
again centrifuged at 1000 xg for 5 minutes at room temperature, supernatant 
discarded and cells resuspended in 1.5 ml 1x TE/LiAC.
 
 
To transform, 1 µg of each DNA construct was mixed with 0.1 mg of herrings testes 
carrier DNA.  The appropriate chemically competent yeast strain (0.1 ml) was added 
and vortexed, followed by the addition of 0.6 ml of PEG/LiAc solution.  Cells were 
incubated at 30°C for 30 minutes shaking at 200 rpm.  DMSO (70 µl) was added and 
gently mixed.  Cells were heat shocked at 42°C for 15 minutes, chilled on ice for 2 
minutes and centrifuged at room temperature for 5 seconds at 16000 xg.  The 
supernatant was removed and cells resuspended in 0.5 ml 1x TE.  Cells were plated 
on either SD/-leucine or SD/-tryptophan depending on the construct being 
transformed.  The pGBKT7 vector contains the tryptophan gene and the pGADT7 
vector contains the leucine gene, therefore, successfully transformed yeast will grow 
in the absence of these amino acids.  Successfully mated yeast will grow in the 
absence of both these amino acids. 
 
2.3.3. Preparation of yeast for protein extraction 
One large colony from each of the transformed yeast plates and untransformed Y187 
was used to inoculate 5ml of appropriate SD or YPDA medium respectively (Table 
2.23).  The inoculated medium was vortexed and incubated for 16-18 hours at 30
o
C 
with shaking (250 rpm).  For each clone to be assayed, 50 ml of YPDA medium 
(Table 2.23) was separately inoculated with the entire overnight culture.  Cells were 
incubated at 30°C, with shaking at 250 rpm until the OD600 reached between 0.4 and 
0.6 (4-8 hours).  The OD600 units were then calculated (OD600 x total culture 
volume).  The culture was immediately poured into a centrifuge tube half filled with 
ice to chill the cells.  The cells were then centrifuged at 1000 xg for 5 minutes at 4
o
C.  
The supernatant was discarded and the cell pellet resuspended in 50ml ice cold H2O.  
The cells were again centrifuged at 1000 xg for 5 minutes at 4°C, the supernatant 
discarded and the pellet frozen on dry ice and stored at –80oC until required for 
protein extraction. 
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2.3.4. Yeast protein extraction (urea/SDS method) 
Cracking buffer (Table 2.23) was prewarmed to 60°C. The cell pellets were 
immediately thawed by adding 100 µl of cracking buffer (Table 2.23) per 7.5 OD600 
units and the cell suspension transferred to a 1.5ml microcentrifuge tube containing 
80 µl of glass beads per 7.5 OD600 units of cells.  Each sample was heated at 70°C for 
10 minutes and vortexed vigorously for 1 minute.  Cell debris and unbroken cells 
were pelleted by centrifugation at 16000 xg for 5 minutes at room temperature.  The 
resulting supernatant was transferred to a new microcentrifuge tube and placed on ice 
(first supernatant).  The tubes containing the cell debris were then heated at 100°C 
for 5 minutes, vortexed vigorously and centrifuged at 16000 xg for 5 minutes at room 
temperature.  The resulting supernatant was combined with the corresponding first 
supernatant.  Samples were briefly heated at 95°C for 1 minute and stored at –80oC, 
ready to be analysed by SDS PAGE and Western blot using an antibody that 
recognises the GAL4 binding domain (BD) (Table 2.16). 
 
2.3.5. Small scale yeast matings 
Yeast matings were prepared between yeast strains expressing constructs in Table 
2.14.  One large colony (~3mm) from each transformed yeast plate were mated 
together by inoculating 0.5 ml of 2 x YPDA medium (Table 2.23) and incubating for 
20-24 hours with shaking (200 rpm).  Each mating culture was then diluted 1:10 with 
0. 5ml YPDA medium (Table 2.23) and 30 µl spread onto SD minimal agar: SD/-
leucine-tryptophan; triple drop-out media (TDO) - SD/-leucine-tryptophan-histidine 
supplemented with 1 mM, 3 mM, 5 mM, 8 mM and 15 mM 3-amino-1,2,4-triazole 
(3-AT) and quadruple drop-out media (QDO) - SD/-leucine-tryptophan-histidine-
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AH109 Strain Y187 Strain  
pGADT7 pGBKT7 Negative control 
pGADT7 pGBKT7-Nbr1 aa355-694 Check for autoactivation 
pGADT7 pGBKT7-Nbr1 aa495-924 Check for autoactivation 
pGADT7 pGBKT7-Nbr1 aa346-498 Check for autoactivation 
pGADT7-T-antigen pGBKT7-p53 Positive control 
   Table 2.14. Constructs used in small scale yeast matings 
 
2.3.6. Large scale pretransformed yeast-2-hybrid library screen 
SD/-tryptophan medium (50 ml) (Table 2.23) was inoculated with one large colony 
of Y187 expressing the appropriate Nbr1 bait construct.  This was incubated at 30°C 
for 16-18 hours, shaking at 250 rpm until an OD600 of >0.8 was reached.  The culture 
was centrifuged at 1000 xg for 5 minutes, the supernatant removed and the cell pellet 
resuspended in the residual liquid by vortexing.   
 
The pretransformed library culture (1 ml) was thawed at room temperature in a water 
bath and gently vortexed.  A 10 µl aliquot was transferred into a microcentrifuge 
tube and kept on ice for later library titration.  2 x YPDA medium (45 ml) (Table 
2.23) containing kanamycin was inoculated with both the pretransformed library and 
the bait culture in a 2L flask.  The culture was incubated at 30°C for 24 hours with 
shaking at 30 rpm and then centrifuged at 1000 xg for 10 minutes at room 
temperature.  The supernatant was removed and the cells resuspended in 100ml of 2 
x YPDA medium (Table 2.23).  Cells were centrifuged again for 10 minutes at 1000 
xg at room temperature.  The supernatant was discarded and the cells resuspended in 
10ml of 0.5x YPDA medium (Table 2.23) containing kanamycin.  The total volume 
of cells and medium was noted. 
 
100µl of a 1:10000, 1:1000, 1:100 and 1:10 dilution of the mating mixture was 
spread onto SD minimal agar SD/-leucine; SD/-tryptophan; SD/-leucine-tryptophan 
to calculate mating efficiency (section 2.3.7).  The remaining mating mixture was 
spread in 200 µl aliquots onto 50 150 mm petri dishes containing TDO media and 3 
mM 3-AT.  Plates were incubated at 30°C for 3-8 days until colonies were visible.  
Chapter 2                                                                                    Materials and Methods 
100 
 
Colonies were picked and re-plated onto TDO containing 3 mM and 6 mM 3-AT and 
incubated at 30
o
C for 3-11 days.  Colonies were then re-plated a further three times 
to remove multiple AD/library plasmids. 
 
2.3.7. Library titration and calculating mating efficiency  
The 10µl aliquot of the library that was retained in section 2.3.6 was transferred to 
1ml of YPDA medium (Table 2.23) containing kanamycin and vortexed gently 
(Dilution A).  10µl of this dilution was removed and added to 1 ml YPDA medium 
(Table 2.23) containing kanamycin and gently vortexed (Dilution B).  10 µl of 
Dilution A was added to 50µl of YPDA medium (Table 2.23) containing kanamycin 
(Dilution C) and the entire mixture was spread onto SD/-leucine (Table 2.23).  50 µl 
and 100 µl of dilution B were spread separately onto SD/-leucine (Table 2.23) plates.  
Plates were incubated at 30°C for 3-5 days.  The number of colonies on each plate 
was then counted and the titration value calculated: 
 
No. viable colonies (cfu)/ml) = (cfu x 1000µl/ml)/ (volume plated (µl) x dilution  
  factor) 
 
No. clones screened = No. cfu/ml of diploids x resuspension volume 
 
2.3.8. Extraction of plasmids from yeast cells 
A 1cm
2
 patch of each yeast colony was scraped from the plates and vortexed in 
200µl of H2O.  200 µl of lysis solution (Table 2.23) was added, vortexed vigorously 
and 400 µl of phenol:chloroform: isoamyl (25:24:1) and a spoonful of glass beads 
were added and vortexed vigorously for 1 minute.  Each sample was centrifuged at 
13000rpm for 20 minutes at room temperature.  The resulting aqueous layer was 
transferred to a new microcentrifuge tube and 800 µl of absolute ethanol and 1.5 µl 
3M NaAc added to precipitate the DNA.  Samples were then incubated at –20°C for 
1 hour and centrifuged at 16000 xg for 20 minutes at room temperature.  The 
supernatant was removed and 0.5ml 70% ethanol added to the DNA pellet, mixed 
and spun at 16000 xg for 10 minutes at room temperature.  The supernatant was 
again removed and the pellet left to air dry.  20 µl of H2O was added and the samples 
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stored at –20°C.  1 µl was used to transform the plasmid into electrocompetent cells 
(section 2.1.9).  Bacteria were plated onto LB agar (Table 2.23) supplemented with 
ampicillin to select for those containing the pGADT7 vector and thus the ampicillin 
resistance gene.  Plasmids were then extracted from transformed cells using the 
TENS method (section 2.1.10) and sequenced (section 2.1.7) using the T7 primer 
(TAATACGACTCACTATAGGGC).  The NCBI BLAST tool (www.ncbi.nlm.gov/ 
BLAST/Blast.cgi) was used to search the Mus musculus genome for any genes with 
homology to the plasmid insert.  
 
2.4. Animal Methods 
2.4.1. Generation of the D50R knock-in mouse model 
The Nbr1
D50R
 knock-in mouse was generated by introducing the D50R mutation into 
exon 3 of Nbr1 (targeting vector construction and ES clone analysis was performed 
by Dr. C. Whitehouse, KCL).  The targeting vector was inserted into the genome of 
mouse embryonic stem (ES) cells via homologous recombination and correctly 
targeted embryonic stem (ES) cells were selected for using thymidine kinase (TK) 
and neomycin.  Two different ES cell clones were chosen, injected into mouse 
blastocysts and transferred into pseudo-pregnant females.  Resulting chimeras were 
bred to produce heterozygote founder (F1) mice.  The F1 generation were 
subsequently bred with Flp recombinase expressing mice to remove the neomycin 
cassette (generation of targeted mice was performed by GenoWay, Lyon, France) 
(Figure 2.1). Heterozygote mice were then crossed and offspring were born in 
expected Mendelian ratios (1:2:1; wild type:heterozygous:homozygous) 
demonstrating that the mutation had no effect on viability during development (data 
not shown).  All animal procedures were carried out under the Animal (Scientific 
Procedures) Act 1986 under project license number PPL70/6766.  The genotype of 
each mouse was verified as described in section 2.1.11.  Cells were extracted from 
mice and differentiated into osteoblasts or osteoclasts as described in section 2.5.5 
and 2.5.6. 
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2.5. Cell biology methods 
2.5.1. Cell line culture 
COS-7 cells (African green monkey fibroblasts) and PC12 cells (a rat neuronal cell 
line derived from a pheochromocytoma) were maintained in sterile plastic tissue 
culture flasks in Dulbecco‘s Modified Eagle Medium (DMEM) supplemented with 
10% Fetal Calf Serum (FCS), penicillin/streptomycin and L-glutamine at 37ºC in a 
humidified atmosphere of 5% CO2.  Cells grew as a monolayer and were regularly 
passaged up to 25 times. 
 
For long term storage, cells were detached with trypsin, washed in DMEM media 
and centrifuged at 1000 xg for 5 minutes.  Cells were then resuspended and stored in 
liquid nitrogen at a concentration of 2-4x10
6
 cells/ml in 90% FCS, 10% DMSO.  
2.5.2. Cell transfections 
COS-7 cells were plated at 2x10
5
 in 6-well tissue culture dishes and left to adhere 
overnight.  Transfections were performed using FuGENE 6 (Roche) typically at a 
FuGENE (µl):DNA (µg) ratio of 3:1 as per manufacturer‘s instructions.  Table 2.15 
defines the constructs used for transfection.  Vector maps are shown in appendix A.3.  
 










































Table 2.15. Constructs used for transfections in COS-7 cells. The cloning strategy 
for each construct is shown including the template used for insert amplification, 
restriction sites and vector.  Vector maps are shown in Appendix A.3. 
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2.5.3. Cell treatments 
PC12 cells or MEFs were treated with either Bafilomycin A1 (0.2 µM) for 8 hours or 
serum starved in Hanks Balanced Salt Solution for 4 hours.  For Western blot 
analysis of protein levels, PC12 cells were lysed directly into SDS sample buffer 
(Table 2.23).  
  
2.5.4. Isolation and culture of mouse embryonic fibroblasts (MEFs) 
All animal procedures conformed to the Animal (Scientific Procedures) Act 1986 
under project license number PPL70/6766.  13.5 day old embryos of each genotype 
(WT and Nbr1
D50R
) were isolated from pregnant females and head and guts were 
removed.  Remaining tissue was homogenised and incubated at 37°C in 10x trypsin 
(PAA) for 30 minutes (3ml per 5-10 embryos).  Cell culture media (DMEM, 
supplemented with 10% Fetal Calf Serum (FCS), penicillin/streptomycin and L-
glutamine) was added and cells transferred into a T75 tissue culture flask and 
cultured overnight at 37°C in a humidified atmosphere (5% CO2).  Media was 
replaced the following day and cells passaged as required.  
 
2.5.5. Isolation and culture of primary osteoclasts 
Generation of enriched populations of osteoclasts in vitro was achieved by culturing 
bone marrow macrophages in the presence of M-CSF and RANKL to promote 
differentiation (Teitelbaum, 2007).  Male mice of each genotype (WT and Nbr1
D50R
) 
were culled by dislocation of the neck and the femur and tibia isolated.  Bone 
marrow was subsequently flushed into culture media (α-MEM, 10% FCS, 1x P/S, 1x 
L-glut, 50 ng/ml M-CSF) using a 25 gauge needle and syringe.  Cells were cultured 
overnight at 37°C in a humidified atmosphere (5% CO2).  The following day, all 
non-adherent cells were harvested, counted and plated into 96-well culture dishes 
lined with or without dentine slices at 5x10
4
.  Cells were then cultured for a further 4 
days in α-MEM, supplemented with 10% Fetal Calf Serum (FCS), 
penicillin/streptomycin, L-glutamine and 50 ng/ml M-CSF (R&D) before 5ng/ml of 
RANKL (R&D) was added to the media and the concentration of M-CSF reduced to 
25 ng/ml.  After a further 4 days, cells plated on plastic were fixed in 4% PFA whilst 
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those on dentine were cultured for a further three days in media containing 
concentrated HCl (8.2 µl/10ml).  Cells were then fixed and TRAP stained (section 
2.4.7.1).  Using an Olympus CK40-F200 inverted phase contrast microscope with a 
Nikon D5-L2 digital camera, cells were counted and those on plastic scored for the 
number of nuclei.  Dentine slices were then sonicated and resorption pits stained with 
1% toluidine blue/0.1% sodium borate and imaged using a BX60 system microscope, 
Olympus Optical CO.(UK), SpectaMaster-1 wavelength dialled white-light source 
(Perkin Elmer, Cambridge, UK), Nikon 990 digital camera (Nikon UK, Kingston, 
UK) and Sony Trintron monitor.  The total magnification before pit quantification 
was x72.  Resorption pits were quantified using the point counting method.  A grid 
(composed of 0.5cmx0.5cm squares) was superimposed onto the image, the number 
of occasions a pit crossed the middle of a square was quantified and the percentage 
resorbed area was calculated ((number of squares crossed by a pit/total number of 
squares) x 100).  
 
2.5.6. Isolation and culture of primary osteoblasts 
Mesenchymal stem cells in the bone marrow have the ability to differentiate into 
osteoblasts in vitro when cultured in media containing ascorbic acid and β-
glycerophosphate (Pittenger et al., 1999).  Male mice from each genotype (WT & 
Nbr1
D50R
) were culled and bones flushed as in section 2.4.5.  Cells were plated at 
2x10
6
 per well into a 6-well tissue culture plate in α-MEM supplemented with 10% 
Fetal Calf Serum (FCS), penicillin/streptomycin, L-glutamine, 50 µg/ml ascorbic 
acid and 10 mM β-glycerophosphate.  Media was replaced every four days and cells 
were cultured at 37°C in a humidified atmosphere (5% CO2).  After nine or 15 days 
in culture, cells were fixed in 4% PFA and stained for alkaline phosphatase or von 
Kossa (section 2.5.7). 
 
2.5.7. Cell staining 
2.5.7.1. TRAP staining of osteoclasts in vitro 
TRAP is synthesized and secreted by mature osteoclasts and acts to degrade bone 
matrix, therefore is a good marker for osteoclast differentiation.  Cells isolated and 
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cultured as in section 2.5.5 were fixed and stained using the Acid Phosphatase Kit 
(Sigma, Cat no. 387A) with 50 mM tartrate solution. 
 
2.5.7.2. Alkaline phosphatase (ALP) staining 
Cells fixed as per section 2.4.6 were washed with H2O for 15 minutes.  The H2O was 
then removed and alkaline phosphatase (ALP) stain (Table 2.23) was added and 
incubated for 15 minutes at room temperature.  The stain was removed and cells 
were washed three times with H2O before being stored dry at 4°C.  Cells were 
imaged using a HP Scanjet G4050 and staining quantified using Image J; the image 
was converted to grey scale and a threshold most representative of the staining was 
used to calculate the percentage area covered by the ALP stain (for the 9 day ALP 
staining the threshold was 116, for 15 day ALP staining the threshold was 95 and for 
the von Kossa staining, the threshold was 35).  
 
2.5.7.3. Von Kossa staining 
Following staining for alkaline phosphatase, cells were covered with 2.5% silver 
nitrate and incubated for 30 minutes in the absence of light.  Silver nitrate was 
subsequently removed and cells were washed three times with distilled H2O.  Cells 
were then covered with sodium carbonate formaldehyde solution (25 ml 
formaldehyde, 5g Na2CO3, 75 ml H2O) for 2-5 minutes until the mineralised colour 
had deepened sufficiently.  Cells were washed three times in H2O and stored at 4°C 
before the percentage area mineralised was quantified using ImageJ as described in 
section 2.5.7.2.  
 
2.5.8. Immunostaining 
Cells were seeded onto glass coverslips, incubates overnight to adhere and 
subsequently treated (section 2.5.3).  Cells were fixed in 4% PFA/PBS for 10 
minutes, washed with PBS and permeabilised in 0.1% Triton X 100/PBS for 5 
minutes at room temperature.  Cells were subsequently washed with PBS and 
blocked for 1 hour at room temperature in a blocking solution of 10% FCS/PBS.  
Block was removed and cells incubated with appropriate antibody diluted in 10% 
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FCS/PBS for 1 hour at room temperature.  Cells were then washed three times in 
PBS, incubated with appropriate secondary antibody diluted in 10% FCS/PBS for 1 
hour in the absence of light, then washed with PBS and DNA was stained with 1 mM 
Hoechst/PBS for 5 minutes.  Cells were then washed in PBS and coverslips mounted 
on microscope slides using Fluorescent Mounting Medium (Dako S3023).  Cells 
were imaged using a Zeiss LSM 510 confocal microscope in sequential scanning 
mode using a 63x oil immersion objective. 
 
2.5.9. Antibodies 
Primary and secondary antibodies used throughout this thesis are listed in Tables 
2.16 and 2.17. 
Protein Species raised in WB ICC Origin 
GAL4 (DBD) Mouse monoclonal 1 in 500 - Santa Cruz 
GFP Mouse polyclonal 1:1000 - Roche 
HA Rat monoclonal 1 in 1000 - Roche 
His Mouse monoclonal 1:1000 - Novagen 
LC3 Rabbit polyclonal 1:400  Cell Signalling 
MAP1B-HC Rabbit polyclonal 1 in 10,000 - P. Gordon-
Weekes 
MAP1B-HC Goat polyclonal - 1 in 50 Santa Cruz 
MAP1B-LC Rabbit polyclonal 
(H-130) 
- 1 in 200 Santa Cruz 
MAP1B-LC Goat polyclonal 
(C-20) 
1 in 500 - Santa Cruz 
Myc Rabbit polyclonal 
(A-14) 
1 in 1000 - Santa Cruz 
Myc Mouse monoclonal 
(9E-10) 
1 in 1000 - Santa Cruz 
Nbr1 Mouse monoclonal 1 in 1000 1 in 100 Abcam 
Nbr1 Rabbit polyclonal 
(3517) 
1 in 500 - C. Whitehouse 
P62 Mouse monoclonal 1 in 1000 - Abnova 
P62 Rabbit polyclonal - 1 in 200 M. Gautel 
β-actin Rabbit polyclonal 1 in 2000 - Abcam 
Table 2.16. Primary antibodies utilized. Antibody dilutions for Western blot (WB) 
and immunocytochemistry (ICC). 
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Conjugate Species  Dilution Origin 
Alexa Fluor 488 Donkey anti mouse 
polyclonal 
1 in 1000 Invitrogen 
Alexa Fluor 488 Donkey anti goat 
polyclonal 
1 in 1000 Invitrogen 
Alexa Fluor 555 Donkey anti rabbit 
polyclonal 
1 in 1000 Invitrogen 
Alexa Fluor 555 Donkey anti goat 
polyclonal 
1 in 1000 Invitrogen 
Horse radish 
peroxidase 
Swine anti rabbit 
polyclonal 
1 in 2000 Dako 
Horse radish 
peroxidase 
Rabbit anti mouse 
polyclonal 
1 in 2000 Dako 
Horse radish 
peroxidase 
Rabbit anti rat 
polyclonal 
1 in 2000 Dako 
Horse radish 
peroxidase 
Rabbit anti goat 
polyclonal 
1 in 2000 Dako 
Table 2.17. Secondary antibodies utilised. 
 
2.6. Bone methods 
2.6.1. Specimen preparation 
Male mice from D50R knock-in mice (Mut) and wild type (WT) controls were culled 
using carbon dioxide (death was confirmed by cessation of circulation) at three, six 
or nine months of age (Table 2.18).  They were then weighed before all skin and 
internal organs were removed and the remaining skeleton fixed in 70% EtOH for at 
least 1 month and stored at 4°C.  Right femurs and tibias were then removed and 
stripped of all soft tissue in preparation for analysis. 
 
Table 2.18. Numbers of mice used of each age and genotype for ex vivo bone 
analysis. 
 
Mouse Genotype 3 Months old 6 Months old 9 Months old 
WT 9 6 6 
Mutant 8 8 7 
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2.6.2. Physical measurements 
All femurs and tibiae were measured using GuoGen MC 01120028 digital calipers 
with a resolution of 0.01 mm and a reproducibility of 0.2 mm.  Distance measured 
for the femur and tibia is shown in Figure 2.2.  
 
                                                                                     
Figure 2.2. Regions measured for femur and tibia length 
 
2.6.3. Radiographs 
Radiographs were taken in a cabinet X-ray system (Hewlett Packard Faxitron X-ray 
Cabinet model 43855A).  Specimens were exposed to 30kv for 45 seconds and films 
processed in a Curex 60 processor (AGFA). 
 
2.6.4. Micro computer tomography (MicroCT) 
3D MicroCT images of femurs and tibiae were captured using a SkyScan 1172 
Desktop X-ray system (SkyScan).  All specimens were scanned in plastic containers 
using a medium camera, 360
o
 rotation and a 0.5 mm filter with a resolution of 4.4µm 
for high resolution scans and 17.2µm for low resolution scans.  The scans were then 
reconstructed using NRecon Version1.4.1.0 and analysed using CT Analyser version 
1.10.1.0.  Thresholds for whole bones, cortical and trabecular parameters are 

















17.2 0.16 92-255 
Femur 
Trabecular 
4.4 0.16 92-255 
Femur Cortical 4.4 0.16 110-255 
Tibia Trabecular 4.4 0.16 92-255 
Tibia Cortical 4.4 0.16 110-255 
      Table 2.19. Threshold values for reconstruction and analysis. 
 
Analysis of the reconstructions was carried out by initially drawing the region of 
interest (ROI).  For whole bones, all cross sections were considered, however, for 
cortical and trabecular analysis a distinct region of the bone was taken into account, 
measured from a reference point.  Reference points and regions analysed are 
summarised in Table 2.20. 
 





























               Table 2.20. Cortical and trabecular ROI settings. 
 
The ROIs were then analysed on CT Analyser using Batch Manager (BATMAN).  
For all parameters except endosteal and periosteal diameters, analysis settings were 
as follows; Thresholding (see Table 2.19 for specific thresholds), Despeckle (remove 
white speckles with volume less that 10 voxels within the 3D space) and 3D analysis.  
The parameters calculated were cortical bone volume (Ct.BV), cortical thickness 
(Ct.Th), trabecular bone volume/tissue volume (Tb.BV/TV) trabecular thickness 
(Tb.Th), trabecular number (Tb.N) and trabecular separation (Tb.Sp).  Settings used 
to calculate endosteal and periosteal diameters are shown in Tables 2.21 and 2.22 
respectively. 
 





Despeckle Sweep within 3D space all except larges 
object 
Despeckle Remove white speckles within 2D with 
space less than 1000 pixels 
Morphological Operations Type: close in 2D space; Kernel:round with 
a radius of 20; Apply to image. 
Morphological Operations Type: open in 3D space; Kernel:round with 
a radius of 4; Apply to image. 
Bitwise Operations Image=NOT image 
Despeckle Remove outer objects from 2D space 
Individual Object Analysis 2D space 




Despeckle Sweep within 3D space all except largest 
object 
Despeckle Remove white speckles within 2D with 
space less than 1000 pixels 
Morphological Operations Type: close in 2D space; Kernel:round with 
a radius of 20; Apply to image. 
Morphological Operations Type: open in 3D space; Kernel:round with 
a radius of 4; Apply to image. 
Despeckle Remove pores from 2D space 
Individual Object Analysis 2D space 
   Table 2.22. Periosteal analysis settings 
 
Bone mineral density for all bone regions analysed was calculated from a 
hydroxyapatite standard.  Two samples of known density were scanned using the 
same parameters used for all specimens and hydroxyapatite estimated using 
CTAnalyser version 1.10.1.0 and the thresholds in Table 2.19. 
 
2.6.5. Statistical analysis 
All statistical analysis was carried out using GraphPad Prism.  Where data were 
normally distributed and variance homogenous, an unpaired student‘s t-test was 
used, otherwise, a Mann-Whitney U test was employed.  All error bars are shown as 
standard deviation (SD). 
  




2.7.1. Generation of a linkage disequilibrium map 
A linkage disequilibrium (LD) map of the NBR1 gene was generated using 
Haploview version 4.2 from the CEU (Caucasian European) HapMap population 
data (www.HapMap.org) of version 27 of the HapMap project.  The chromosomal 
region used was Chr17: 41321910-41371844 bp. 
 
2.7.2. Power calculations 
The following calculation was used to estimate the power of identifying known SNPs 
in the high bone mass cases sequenced in Chapter 6: 
 
Power = 1 - (1-p)
2N
 where p = minor allele frequency and N = no. of individuals. 
 
2.7.3. Predicting the effect of amino acid substitutions 
Polyphen (http://genetics.bwh.harvard.edu/pph2/index.htm) and SIFT (http://sift.jc 
vi.org/www/SIFT_enst_submit.html) were used to predict the effect of the amino 
acid substitution identified in a high bone mass patient. 
 
2.8. Buffers and solutions 
All buffers and solutions (Table 2.23) were made with deionised water unless 




Buffer A 50 mM sodium phosphate (pH7), 300 mM NaCl, 5% 
glycerol, 10 mM β-mercaptoethanol, EDTA free 
protease inhibitors (Roche) 
Buffer B 50 mM sodium phosphate (pH7), 300 mM NaCl, 5% 
glycerol, 35 mM Imidazole, 10 mM β-mercaptoethanol, 
EDTA free protease inhibitors (Roche) 
Buffer C 50 mM sodium phosphate (pH7), 300 mM NaCl, 5% 
glycerol, 250 mM Imidazole, 10 mM β-
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mercaptoethanol, EDTA free protease inhibitors (Roche) 
Coomassie Stain 50% Methanol, 10% Acetic Acid, 0.05% Brilliant Blue 
Cracking Buffer Stock solution: 8 M urea, 5% SDS, 40 mM Tris-HCl 
(pH6.8), 0.1 mM EDTA, 0.4mg/ml bromophenol blue. 
1 ml stock solution, 10 µl β-mercaptoethanol, protease 
inhibitors (Roche) 
De-stain 45% Methanol, 10% Acetic Acid 
Dialysation Buffer  50 mM Tris-HCl (pH7.5), 150 mM NaCl 
High Elution Buffer 100 mM NaH2PO4, 10 mM Tris-HCl (pH8), 250 mM 
Imidazole (pH8), 6 M Urea, EDTA protease inhibitors 
(Roche) 
H Buffer 20 mM Hepes (pH7.7), 50 mM KCl, 20% Glycerol, 
0.1% NP-40, 0.007% B-mercaptoethanol (7 µl in 
100ml), protease inhibitors 
IP lysis buffer 1 10 mM Tris pH 7.5, 150 mM NaCl, 2 mM MgCl, 1% 
Triton, 1 mM sodium orthovanodate and protease 
inhibitors 
IP lysis buffer 2 50 mM Tris (pH7.5), 150 mM NaCl, 0.5% NP-40, 
protease and phosphatase inhibitors (Roche) 
IP wash buffer 1 10 mM Tris pH 7.5, 150 mM NaCl, 1% Triton 
IP wash buffer 2 50 mM Tris (pH7.5), 200 mM NaCl, 0.5% NP-40 
Lysis Buffer  100 mM NaH2PO4, 10 mM Tris-HCl (pH8), 6M Urea, 5 
mM Imidazole (pH8), EDTA free protease inhibitors 
(Roche) 
Lysis Solution (yeast): 2% triton (BDH Laboratory Supplies), 4% SDS, 100 
mM NaCl (BDH), 10 mM Tris (pH8.0), 1 mM EDTA 
NETN Buffer 0.5% NP-40, 20 mM Tris-HCL (pH8), 100 mM NaCl, 1 
mM EDTA, protease inhibitors 
PBS 1 tablet of phosphate buffer saline (Sigma P4417)  per 
200 ml H20 
PEG/Lithium Acetate 8 ml of 50% Polyetheleneglycol, 1 ml of 10x TAE, 1 ml 
10x LiAc 
SDS Sample Buffer  62.5 mM Tris-HCl (pH6.8), 6 M Urea, 2% SDS, 2% 
NP-40, 5% β-mercaptoethanol, bromophenol blue. 
Tail Buffer 100 mM Tris-HCl pH8, 5 mM EDTA, 0.2% SDS, 200 
mM NaCl, proteinase K (100 µg/ml) 
TEDG Buffer 50 mM Tris-HCl (pH7.4), 1.5 mM EDTA, 10% 
Glycerol, 0.4 mM NaCl, 1 mM DTT, protease inhibitors 
TENS Buffer 10 mM tris (pH8), 1 mM EDTA, 0.1 M NaOH (BDH), 
0.5% SDS 
Transfer Buffer 50 mM Tris, 380 mM Glycine, 0.1% SDS, 20% 
methanol 
Low Elution Buffer 100 mM NaH2PO4, 10mM Tris-HCl (pH8),  6M Urea, 20 
mM Imidazole (pH8), EDTA free protease inhibitors 
(Roche) 
5x DNA Sample Buffer  33% glycerol, 3.75x TAE, 125 mM EDTA (pH 8), 
0.008% bromophenol blue (BDH) 
Minimal SD agar (pH 46.7 g/l minimal SD agar (Clonetech cat. 630412), 2% 
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5.8) glucose , appropriate dropout supplement 
Minimal SD medium (pH 
5.8) 
26.7 g/l minimal SD base (Clonetech cat. 630411), 2% 
glucose (Sigma), Appropriate dropout supplement 
TfbI Buffer (pH 5.8) 30 mM potassium acetate (BDH), 100 mM rubidium 
chloride (Sigma), 10 mM calcium chloride (BDH), 50 
mM magnesium chloride (BDH), 15% glycerol (BDH) 
TfbII Buffer (pH 6.5) 10 mM MOPS (Sigma), 75 mM calcium chloride, 10 
mM rubidium chloride, 15% glycerol 
YPDA Agar (pH 6.5) 
  
20 g/l Difco peptone (BD), 10 g/l yeast extract (BD), 20 
g/l bacto agar (BD), 2% glucose, 0.003% adenine 
hemisulfate (Sigma) 
YPDA Medium (pH 6.5)       20 g/l Difco peptone (BD), 10 g/l yeast extract (BD), 2% 
glucose, 0.003% adenine hemisulfate (Sigma) 
LB Agar (pH 7) 15 g/l bacto agar in LB broth 
LB Broth (pH 7) 10g bacto tryptone (BD), 5 g bacto yeast extract, 10 g 
NaCl 
10x Running Buffer 0.25 M Tris, 2 M Glycine, 1% SDS  
10x Lithium Acetate  (pH 
7.5) 
1 M lithium acetate adjust to pH7.5 with dilute acetic 
acid. 
50x TAE 242 g/l Tris base, 57.1 ml/l acetic acid, 100 ml/l 0.5M 
EDTA 
50% PEG Prepare in deionised water and heat to 50
o
C to go into 
solution 
PEG/lithium acetate 8 ml 50% PEG, 1 ml 10x TE, 1 ml 10x LiAc 
10x TE 0.1 M Tris HCl pH7.5, 10 mM EDTA 
Alkaline phosphatase 
stain 
5 mg Naphtol AS MX-PO4, 200 µl N, N-
Dimethylformamide, 25 ml 0.2 M Tris-HCl (pH8.3), 30 
mg Red Violet LB salt.  Make up to 50 ml with H2O and 
filter using Whatman‘s No1 filter paper. 
Table 2.23. Buffers and solutions.
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Chapter 3. Identification of Interacting Partners of 
the Central Region of Nbr1 
3.1. Introduction  
Protein-protein interactions are central to virtually every cellular process and 
alterations or inhibition of these can contribute to a diverse range of diseases.  The 
yeast-2-hybrid method is widely used to screen protein libraries against a bait protein 
of interest in order to identify new interacting partners and gain further insight into 
protein function.  This system has previously been employed to identify proteins that 
interact with Nbr1 (Figure 3.1).  Full length human NBR1 was used to screen a 
human placental library and identified fasciculation and elongation protein zeta-1 
(FEZ1) and calcium and integrin binding protein (CIB) as interacting partners 
(Whitehouse et al., 2002).  A region of NBR1 that excluded the UBA and PB1 
domains (aa93-903) was used to screen a human cardiac muscle library and 
identified interactions between Nbr1, a ubiquitin specific peptidase (USP8), and a 
ubiquitin conjugating enzyme (E2B) (Waters, 2009).  Furthermore, a mouse calvarial 
library was screened using the UBA domain of Nbr1 and identified ubiquitin as an 
interacting partner.  Collectively, these suggest a role for Nbr1 in ubiquitin mediated 
protein degradation (Waters et al., 2009).  Finally, the N-terminal 135 amino acids of 
Nbr1 were used to screen a mouse calvarial library and identified the sumoylation 
enzyme UBC9 as an interacting partner (L. Bentley, Kings College London, 
unpublished data). 
 
Nbr1 contains a number of conserved protein domains however the central region 
(aa355-924) is largely uncharacterised.  This fragment was therefore used in a yeast-
2-hybrid assay to probe a bone enriched cDNA library for novel interacting partners.  
The truncated Nbr1 (trNbr1) mouse model has a high bone mass phenotype 
(Whitehouse et al., 2010) however the molecular mechanisms involved are still 
unclear therefore bone specific protein interactors were of specific interest. 










The yeast-2-hybrid technique was first pioneered by Fields and Song in 1989 (Fields 
and Song, 1989) and is used to identify novel protein-protein interactions.  This 
system utilizes the GAL4 protein from Saccharomyces cerevisiae which is a potent 
activator of transcription.  The N-terminal region of the GAL4 protein binds to DNA 
in a sequence specific manner but fails to activate transcription, while the C-terminal 
domain contains the activating region but is unable to activate transcription alone.  
These two domains can be expressed independently in yeast and will only activate 
transcription when they are brought into close proximity.  A protein of interest can 
therefore be fused to the GAL4 DNA binding domain (BD) and screened against a 
library of proteins fused to the GAL4 activation domain (AD).  When two fusion 
proteins interact, transcription of up to four reporter genes; HIS3, ADE2, MEL1 and 
LACZ can occur resulting in the expression of proteins involved in the biogenesis of 
histidine, adenine, β-galactosidase (LacZ product) and α-galactosidase (MEL1 
product). This enables yeast strains auxotrophic for histidine and adenine to grow on 
selection media deficient in these amino acids.  α-galatosidase is a secreted enzyme 
and can be detected by the addition of X-α-gal to the media which is subsequently 
hydrolysed by α-galactosidase and manifests as blue coloured yeast colonies.  This 
system enables the selection of yeast clones expressing two interacting proteins. 
 
3.2.1. Yeast Phenotyping  
Initially, it was important to determine the phenotype of the yeast strains and confirm 
that they were unable to grow on specific selection media.  The yeast strains Y187 
(MATα) and AH109 (MATa) were utilized in this screen to enable single 
transformations and subsequent matings, resulting in diploid cells.  The phenotype of 
the yeast was confirmed by plating on minimal dropout media (SD) deficient in 
amino acids required for growth (Table 3.1).  Both yeast strains failed to grow in the 
absence of leucine, tryptophan or adenine, showed minimal growth in the absence of 
histidine and grew in the absence of uracil.  These results were expected as AH109 
and Y187 are auxotrophic for leucine, tryptophan, histidine and adenine but not for 
uracil.  Minimal growth was observed in the absence of histidine as the yeast display 
‗leaky‘ histidine production which will be addressed in section 3.2.2.   
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Yeast strain SD/-Leu SD/-Trp SD/-His SD/-Ade SD/-Ura 
AH109 no growth no growth 
a few small 
colonies 
no growth growth 
Y187 no growth no growth 
a few small 
colonies 
no growth growth 
Table 3.1. Analysis of yeast phenotype. Yeast strains were streaked onto minimal 
dropout media (SD) lacking each of the essential amino acids. Yeast were not able to 
grow in the absence of leucine, tryptophan or adenine, could grow in the absence of 
uracil and showed limited growth in the absence of histidine. 
 
3.2.2. Autoactivation and 3-AT Titration 
The large central region of Nbr1 (aa355-924) was previously shown to autonomously 
activate the reporter genes (C. Whitehouse, unpublished data), therefore this region 
was split into two overlapping segments encoding aa355-694 and aa495-924 and 
cloned into the pGBKT7 vector (containing the GAL4 BD and the TRP1 nutritional 
marker).  To establish if the new bait constructs autoactivated, they were transformed 
into yeast strain Y187.  Resulting transformants were used in small scale matings 
with yeast strain AH109 transformed with the pGADT7 empty vector (containing the 
GAL4 AD and the LEU2 nutritional marker).  The SV40 Large T-antigen fused to 
the GAL4 AD (Clontech) and p53 protein (aa72-390) fused to the GAL4 BD 
(Clontech) were used as a positive control as they are known to interact. Empty 
vectors pGADT7 and pGBKT7 were used as a negative control (Table 3.2). 
 
Small scale matings were plated onto double drop out (DDO) media deficient in 
leucine and tryptophan to confirm that matings had been successful.  They were also 
plated onto triple drop out media (TDO) deficient in leucine, tryptophan and histidine 
supplemented with a range of 3-Amino-1,2,4-triazole (3-AT) concentrations.  3-AT 
is a competitive inhibitor of imidazoleglycerol-phosphate dehydratase, a catalytic 
enzyme required for the sixth step of histidine production.  Supplementing the media 
with 3-AT ensures that yeast have to produce a higher than background level of 
histidine (i.e. one reminiscent of a protein-protein interaction) in order to grow.   
 
Table 3.2 shows the extent of colony growth on SD/-Leu/-Trp/-His media containing 
increasing concentrations of 3-AT.  The bait construct, Nbr1-aa355-694 (also 
containing a highly conserved region of Nbr1, discussed in chapter 4) was shown to 
Chapter 3                                                                                                             Results 
119 
 
autoactivate as growth was observed on all 3-AT concentrations and in the absence 
of adenine.  Nbr1-aa355-694 was therefore not used in the final library screen.  The 
bait construct containing aa495-924 of Nbr1 did not autoactivate as growth was 
reduced with increasing 3-AT concentrations.  A concentration of 3mM 3-AT was 
used for the final library screen as minimal colony growth was observed and this 
reduced the risk of ablating weak interactions.  As expected, the positive control 
(p53+SV40 large T-antigen) showed growth on all concentrations of 3-AT and in the 
absence of adenine, while the negative control (pGADT7+pGBKT7) failed to grow 
in the absence of histidine or adenine (Table 3.2). 
























√ √ √ √ √ √ √ √ 
pGBKT7 + 
pGADT7 








√ Growth drops off with increasing 3-AT concentration X 
Table 3.2. 3-AT titration and test for bait autoactivation. Yeast were singly 
transformed with constructs shown, mated and plated on SD media lacking different 
combinations of amino acids.  Yeast containing the bait construct, Nbr1 aa 355-694 
and pGADT7 grew on all concentrations of 3-AT and without adenine suggesting 
autoactivation. Yeast containing the bait construct Nbr1 aa495-924 and pGADT7 
showed growth dropping off with increased 3-AT concentration.  The positive 
control grew on all concentrations of 3-AT and in the absence of adenine and the 
negative control did not grow in the absence of histidine or adenine, as expected. 
 
3.2.3. Confirmation of bait protein expression 
 
To verify that yeast were expressing the bait protein of interest (Nbr1 aa495-924 
fused to GAL4 BD), protein was extracted (section 2.3.3/4), resolved by SDS PAGE 
and visualised by Western blot using an antibody that recognises the GAL4 BD.  A 
protein band of ~58kDa was identified which is the same size as predicted for the 
bait protein (Nbr1 aa495-924) fused to the GAL4 BD thus confirming successful 
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3.2.4. Yeast-2-Hybrid Library Screen 
The bait construct (Nbr1 aa495-924 fused to GAL4 BD) was transformed into yeast 
strain Y187 and the resulting transformants were mated with a pretransformed 7 day 
old mouse calvaria cDNA library (cloned into the pGADT7 vector) in the AH109 
yeast strain (kindly supplied by Prof. Ikramuddin Aukhil, College of Dentistry, 
University of Florida).  The resulting diploid yeast were subjected to nutritional 
selection by plating onto SD–Leu/-Trp/-His media supplemented with 3mM 3-AT.  
An estimated 5 x 10
6
 yeast clones were screened which is considered to be the 
minimum required to screen the cDNA library to saturation (Van Criekinge and 
Beyaert, 1999).  
 
Initially, 334 positive clones grew within 1-2 weeks of plating on nutritional 
selection media.  These clones were restreaked onto SD–Leu/-Trp/-His containing 
3mM 3-AT three times to selectively eliminate any multiple library plasmids and a 
total of 158 regrew on the TDO media.  DNA was extracted from the yeast clones, 
transformed into E.coli and the DNA extraction repeated.  All positive clones were 
analysed by sequencing.  Clones where the DNA insert was out of frame with the 
GAL4 AD were discarded as false positives (27).   
 
This yeast-2-hybrid screen identified many candidate genes as putative interactors of 
Nbr1.  The most biologically relevant proteins are shown in Table 3.3 and discussed 
in more detail below.  All other proteins identified but not discussed are shown in 
Table A.1 (Appendix). 
 




Accession No. Gene ID No. of Clones 
NM_173755.3 Ubiquitin conjugating enzyme E20 
(UBE20) 
2 
NM_025735.1 Microtubule associated protein 1 light 
chain 3 (LC3) 
3 
NM_153762.3 Ring finger protein 26 (Rnf26) 1 
NM_007541.2 bone gamma-carboxyglutamate 
protein 1/2 (Osteocalcin) 
2 
NM_009976.3 Cystatin C 1 
Table 3.3. Positive clones identified from the yeast-2-hybrid library screen.   
 
3.3 Putative interacting partners of Nbr1 
3.3.1. Proteins involved in protein degradation 
The yeast-2-hybrid screen performed in this study, has identified a number of 
proteins involved in both the autophagy pathway and the UPS as putative interactors 
of Nbr1. 
 
Microtubule-associated protein light chain 3 (LC3) was identified in three of the 
yeast clones (aa18-end - deduced from the isolated yeast-2-hybrid clone).  LC3 
localizes to autophagosomal membranes (Kabeya, 2000), and its conjugation to the 
phospholipid PE is essential for autophagosomal formation (Sou et al., 2008).  p62 
has previously been shown to directly interact with LC3 (Pankiv et al., 2007b) and 
through this interaction is thought to tether ubiquitinated proteins to the forming 
autophagosome.   
 
UBE20 (also known as UBE2-230K) is an E2 ubiquitin conjugating enzyme that is 
part of the enzyme cascade that transfers ubiquitin residues to proteins that are 
subsequently targeted for degradation.  The human UBE20 homologue contains a 
conserved cysteine residue which represents the putative active site for thio-
esterification of ubiquitin (Yokota et al., 2001).  The functions of E2 enzymes have 
mainly been studied in yeast and E2-deficient yeast mutants exhibit defects in DNA 
repair, organelle biosynthesis and the stress response (Jentsch, 1992).  UBE20 is 
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ubiquitously expressed (Yokota et al., 2001) and along with one other E2 enzyme; 
E2-20K, UBE20 expression is specifically upregulated in differentiating 
reticulocytes (immature red blood cells), a stage when enhanced protein degradation 
has been observed (Wefes et al., 1995). 
 
The ring finger protein 26 (Rnf26) was first cloned in 2001 by Katoh and is 
upregulated in a number of cancer cell lines (Katoh, 2001) however very little is 
known about its function.  The ring finger is a zinc-binding domain that can interact 
with E2 ubiquitin conjugating enzymes and is found in many proteins that act as E3 
ubiquitin ligases (reviewed in (Freemont, 2000).  E3 ubiquitin ligases are responsible 
for substrate recognition and promoting polyubiquitin ligation to a substrate. They 
are also known to regulate diverse cellular processes including DNA repair, 
signalling and the cell cycle (Joazeiro and Weissman, 2000).   
 
3.3.2. Putative interactors involved in bone biology 
The yeast-2-hybrid screen carried out in this study identified full length bone 
gamma-carboxyglutamate protein (also known as osteocalcin) and cystatin C (aa78-
140) as putative interactors of Nbr1.  Both proteins are known to be involved in bone 
formation and remodelling and therefore represent plausible candidates for a true 
Nbr1 interaction.  They were of specific interest due to the high bone mass 
phenotype of the truncated Nbr1 (trNbr1) mouse model (Whitehouse et al., 2010). 
 
Osteocalcin is the most abundant non-collagenous protein present in the extracellular 
bone matrix and is secreted by osteoblast cells in the later stages of maturation (Liu 
et al., 1994).  It is synthesized as a prepromolecule which consists of an N-terminal 
signal peptide that is cleaved following translation.  The resulting propeptide is 
further processed which results in a mature protein that is secreted from the cell 
(Gundberg and Clough, 1992a).  The majority of the secreted protein is incorporated 
into the extracellular bone matrix, however a small proportion leaks into the blood 
circulation where it can be detected and used as a marker of bone formation (Seibel, 
2005).  Osteocalcin expression is regulated by the Runx2 and ATF4 transcription 
factors (Xiao et al., 2005) and promotes cell adhesion and differentiation of the 
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preosteoblastic cell line MC3T3-E1 (Kim et al., 2007b).  The exact function of 
osteocalcin is still unclear, however the use of knock-out mice have shed further light 
on possible functions.  Osteocalcin deficient mice exhibit a high bone mass 
phenotype characterised by increased cortical thickness and an increase in 
mineralized bone matrix.  This suggests that osteocalcin is a negative regulator of 
bone formation and may act by a negative feedback mechanism (Ducy et al., 1996).  
There is also a growing body of evidence suggesting that osteocalcin has an 
endocrine function.  It was demonstrated that osteocalcin deficient mice display 
glucose intolerance, insulin resistance and increased fat mass.  This indicates that 
along with playing a functional role in bone formation, osteocalcin can also regulate 
energy metabolism (Lee et al., 2007b). 
 
Cystatin C is a type 2 cystatin (Yamaza 2001) that has a variety of tissue specific 
functions and altered expression can lead to a number of human pathologies 
including aberrant kidney function (Laterza et al., 2002), and cancer (Strojan et al., 
2004).  Most interestingly for this study, cystatin C is expressed (mRNA) by 
osteoblasts early in differentiation (Candeliere et al., 1999) and is secreted by 
osteoclasts into the bone resorption lacunae under the ruffled border where it acts to 
inhibit bone resorption (Yamaza et al., 2001).  It has been postulated that this is 
through the inhibition of cathepsin K, a cysteine protease that functions to degrade 
bone matrix (Brand et al., 2004).  Cystatin C can also stimulate osteoblast 
differentiation and mineralisation activity in vitro (Danjo et al., 2007).  Cystatin C 
localizes to the ER, Golgi apparatus, secretory and endocytic vesicles, granules and 
vacuoles throughout the cytoplasm of osteoclasts (Yamaza et al., 2001).  
  
3.4 Nbr1 interacts with LC3 
Due to the identification of LC3 as an interacting partner of p62 (Pankiv et al., 
2007a), it was hypothesised by other members of the laboratory that Nbr1 may also 
interact with LC3.  The interaction of Nbr1 with LC3 was therefore confirmed by Dr 
Sarah Waters (Ellen Solomon laboratory, KCL) using in-vitro binding assays.  
Purified GST tagged regions of NBR1 bound to glutathione beads were incubated 
with lysate from COS-7 cells expressing YFP-LC3.  Beads were subsequently 
Chapter 3                                                                                                             Results 
126 
 
washed and bound proteins were resolved by SDS-PAGE and visualized by Western 
blot using an antibody against GFP (which also recognizes YFP).  The three GST 
constructs containing an eight amino acid region of NBR1 (SEDYIIIL) were all able 
to bind to LC3 however deletion of this acidic-hydrophobic stretch (NBR1-C) 
abrogated binding (Figure 3.3).  This eight amino acid sequence was later termed the 
LC3 interacting region 1 (LIR1) by Kirkin et al. (Kirkin et al., 2009).  This 
interaction was also confirmed in a cell free environment showing that it is a direct 
protein-protein interaction (Figure 3.3C).  Subsequently, it was also demonstrated 
that NBR1 can bind six human ATG8 homologues; GABARAP, GABARAPL1, 
GABARAPL2, LC3A, LC3B and LC3C and that NBR1 has a second LC3 binding 
site (aa542-636) termed LIR2 (Kirkin et al., 2009). 
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3.5. Biochemical analysis of the potential interaction of 
Nbr1 with osteocalcin and cystatin C 
Due to the known roles for Nbr1 in bone remodelling (Whitehouse et al., 2010) and 
the lack of previously identified bone specific interactors of Nbr1, osteocalcin 
provided an interesting candidate for further investigation.  Additionally, the possible 
role of cystatin C in osteoblast differentiation and bone mineralisation suggests it is a 
key regulator of bone remodelling and therefore warranted further investigation. 
 
Biochemical analysis was used to validate these interactions further.  Full length 
mouse osteocalcin (aa1-95) the propeptide (aa24-95), the mature protein (aa46-95), 
and mature cystatin C (aa26-140) were cloned into a GST-tagged vector.  Purified 
GST-tagged proteins bound to glutathione beads were incubated with cell lysate from 
COS-7 cells overexpressing HA-Nbr1.  Beads were subsequently washed and bound 
proteins resolved by SDS PAGE, and visualized by Western blot using an antibody 
raised against the HA tag.  Under these conditions, full length osteocalcin bound 
weakly to Nbr1, however deletion of the signal peptide abolished this interaction 
(Figure 3.4).  An interaction between cystatin C and Nbr1 could not be confirmed 
using this method. 









The Nbr1 protein is comprised of numerous conserved protein domains including a 
C-terminal UBA domain, an N-terminal PB1 domain and two coiled-coil domains.  
However, the region in the centre of Nbr1 is largely uncharacterised.  A yeast-2-
hybrid screen was performed using this central region of Nbr1 to identify novel 
interacting partners.   
 
3.6.1. Interaction of Nbr1 with LC3 links it to autophagic protein 
degradation 
LC3 was identified as an interacting partner of Nbr1 in the yeast-2-hybrid screen 
described in this chapter.  p62 has previously been shown to interact with LC3 and 
other Atg8 homologues (Pankiv et al., 2007a).  An 11 amino acid conserved 
sequence containing three acidic residues (DDD) followed by two conserved 
hydrophobic residues (WXXL) were shown to be essential and sufficient for LC3 
binding to p62.  This region was referred to as the LC3 interaction region (LIR) 
(Ichimura et al., 2008).  Due to the structural homology of Nbr1 and p62, this data 
suggested that the putative interaction between LC3 and Nbr1 warranted further 
investigation.  Other members of my laboratory had previously shown that Nbr1 and 
LC3 colocalise to discreet punctate vesicles in COS-7 cells (Waters et al., 2009), 
therefore biochemical studies were already underway to determine if Nbr1 and LC3 
interact (Dr Sarah Waters, KCL).  Using GST binding assays, the LC3 interaction 
region in NBR1 was mapped to an eight amino acid stretch (729-736 in human 
NBR1), C-terminal to the second coiled-coil domain (Figure 3.3).  This region 
consists of two acidic residues at positions 730 and 731 and an aromatic residue at 
position 732 (SEDYIIIL).  During this study, Kirkin et al. also reported a direct 
interaction between NBR1 and six Atg8 homologues including LC3 (Kirkin et al., 
2009).  Mutation of the aromatic tyrosine residue in NBR1 (aa732), corresponding to 
the acidic tryptophan residue in the LIR of p62 abolished LC3 binding (Kirkin et al., 
2009).  In addition to the primary LC3 binding region in NBR1, Kirkin et al. 
identified a secondary LC3 binding site corresponding to amino acids 542-636 of 
human NBR1 (LIR2).  Interaction of LC3 with this region was much weaker, 
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therefore aa729-736 corresponding to LIR1 was considered as the major LC3 
interaction surface (Kirkin et al., 2009).  Subsequently, the structure of the 
GABARAPL-1/NBR1 complex has been determined and mutational analysis 
demonstrated that the presence of a tryptophan residue at position 732 of NBR1 
increased GABARAP-1 binding affinity (Rozenknop et al., 2011).  LIR motifs have 
been identified in a growing number of other autophagy receptors (discussed below) 
and therefore, the LIR motif is generally thought to consist of eight amino acids 
including at least one acidic residue and an aromatic residue at position four which is 
absolutely required for LC3 binding.  The amino acid conservation of the LIR can be 
illustrated by the sequence logo (Figure 3.5) compiled by Johansen et al. using 25 
LIR motifs from 21 different proteins (Johansen and Lamark, 2011). 
 
Our laboratory and others have observed that inhibition of autophagy by treatment of 
cells with Bafilomycin A1 stabilises Nbr1 protein levels suggesting that like p62, it is 
itself degraded by autophagy (Kirkin et al., 2009; Waters et al., 2009).  In 
conjunction with the yeast-2-hybrid carried out in this thesis, these data show that 
Nbr1 is targeted to the autophagosome for degradation via its interaction with LC3.  
Recent research has also identified homologues of Nbr1 throughout the eukaryotic 
kingdom, whilst p62 is largely confined to metazoans.  Furthermore, plant Nbr1 has 
hybrid properties of mammalian Nbr1 and p62 as it contains a conserved LIR which 
can bind Atg8 family members but can also homo-oligomerize via its PB1 domain  
(Svenning et al., 2011).  This highlights the importance of Nbr1 as an autophagic 
receptor.  Additionally, it has been shown that both Nbr1 and p62 can be targeted to 
the autophagosome formation site independently of Atg factors downstream of the 
PI3-kinase complex, but the LC3 interaction region is required for their degradation 
via the autophagosome (Itakura and Mizushima, 2011).  
 
At its C-terminus Nbr1 contains a UBA domain that facilitates the binding of 
monoubiquitin, K48- and K63-linked polyubiquitinated chains (Kirkin et al., 2009; 
Waters et al., 2009).  The UBA domain of Nbr1 is also essential for the formation of 
LC3 positive vesicles (Waters et al., 2009).  Together, these data suggest that like 
p62, Nbr1 acts via its interaction with LC3 as an autophagic receptor selectively 
targeting ubiquitinated proteins for autophagic degradation (Figure 3.6).  p62 is also 
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involved in other forms of selective autophagy and facilitates the degradation of 
peroxisomes (Kim et al., 2008b), mitochondria (Huang et al., 2011) and invading 
bacteria (Zheng et al., 2009).  Other LC3 interacting proteins have also been 
identified that link the target-receptor complex to the autophagic machinery.  Atg32 
and NIX, both tether mitochondria to the autophagic machinery (Novak et al., 2010; 
Okamoto et al., 2009) whilst NPD52 and optineurin target pathogens for autophagic 
degradation (Mostowy et al., 2011; Wild et al., 2011).  The selective targets of Nbr1 
are yet to be identified however it is known that Nbr1 does not play a major role in 
the selective autophagic degradation of the bacteria S. typhimurium (Zheng et al., 
2009).  Recent data has demonstrated that p62 is also able to target specific proteins 
for degradation via its PB1 domain independent of ubiquitination (Watanabe and 
Tanaka, 2011). Interestingly, in some fungi, the UBA domain of Nbr1 has been lost 
suggesting that in these organisms Nbr1  may be able to bind cargo directly without 
requiring ubiquitination (Svenning et al., 2011).  Through a mechanism similar to 
p62, it is likely that Nbr1 is able to interact directly with and target proteins for 
autophagic degradation independent of a polyubiquitin signal. 
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3.6.2. Potential interaction of Nbr1 with components of the 
ubiquitination machinery 
Ubiquitination is an important post-translational modification that requires the 
coordinated action of three enzymes that facilitate the transfer of ubiquitin to a target 
protein.  Polyubiquitination acts as a signal for protein degradation via the 
autophagosome or the proteasome (Tan et al., 2008; Thrower et al., 2000).  The 
yeast-2-hybrid performed in this study has identified proteins of the ubiquitination 
machinery as putative interactors of Nbr1. 
 
Members of the ubiquitination machinery are known to interact with adaptor proteins 
and this can regulate polyubiquitination.  p62 binding to the E3 ligase TRAF6 is 
required for TRAF6 polyubiquitination  (Sanz et al., 2000; Wooten et al., 2005).  
Additionally, the interaction of MdmX with the E3 ligase Mdm2 functions to 
enhance the ubiquitination potential of Mdm2 (Badciong and Haas, 2002) and p62 
interacts with the E3 ligase MuRF2 and targets it to a signalling complex in muscle 
(Lange et al., 2005).  The E2 ubiquitin conjugating enzyme (UBE2O) and the ring 
finger protein Rnf26 (that displays characteristics of an E3 ligase) were identified in 
this study as interacting partners of the central region of Nbr1 (Table 3.3).  This 
suggests that Nbr1 could be acting as a scaffold to recruit ubiquitination machinery 
and regulate polyubiquitination.  UBE20 is ubiquitously expressed however its 
expression is also upregulated during reticulocyte differentiation (immature red 
blood cells) (Wefes et al., 1995), a stage when an upregulation of protein degradation 
and organelle clearance has been observed (Schweers et al., 2007).  Enhanced 
autophagic turnover of mitochondria, mediated by the autophagic receptor NIX has 
also been observed during reticulocyte differentiation (Schweers et al., 2007).  There 
are currently no known roles for Nbr1 in reticulocyte differentiation however, Nbr1 
is ubiquitously expressed and could function to target UBE20 to sites of action and 
therefore influence the polyubiquitination and subsequent degradation of proteins.  
 
The deubiquitination of target proteins can also regulate cellular signalling pathways 
and endosomal trafficking of membrane receptors.  This has been illustrated by the 
actions of the deubiquitinating enzyme USP10 which promotes endocytic recycling 
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of the CFTR chloride channel (Bomberger et al., 2009).  In addition, TRAF6 
ubiquitination is regulated by the deubiquitinating enzyme CYLD which acts to 
inhibit NFκB signalling (Sundaram, 2011).  USP8 has recently been identified as an 
interacting partner of Nbr1 (Waters et al., 2009).  This deubiquitinating enzyme has 
been implicated in the endocytic degradation of the EGFR receptor (Alwan and van 
Leeuwen, 2007).  Nbr1 is also involved in the modulation of EGFR receptor 
internalisation, functioning to inhibit receptor endocytosis and therefore enhancing 
ERK 1/2 signalling (Mardakheh et al., 2010).  It has not been identified whether this 
is regulated by ubiquitination however the interaction between Nbr1 and USP8 
suggests a functional relationship may exist in order to regulate the endocytosis and 
degradation of EGFR.  
 
The identification of E2 and E3 enzymes as putative interactors of Nbr1 in this thesis 
provides further evidence for the role of Nbr1 in regulating the ubiquitination status 
of proteins and has identified potential cell specific roles in reticulocyte 
differentiation.  I addition, Nbr1 has been found in protein aggregates induced by 
proteasomal inhibition suggesting that Nbr1 is degraded by the UPS (Wilde et al., 
2011).  
 
3.6.3. Interaction of Nbr1 with proteins involved in bone formation 
and remodelling 
Two proteins involved in the maintenance of bone have also been identified as 
putative interactors of Nbr1.  Biochemical binding assays could not confirm the 
interaction between the cysteine protease inhibitor cystatin C, but did identify a weak 
interaction between osteocalcin and Nbr1 (Figure 3.4).  Osteocalcin is synthesized as 
a prepromolecule, cleaved to form a promolecule which is subsequently γ-
carboxylated.  The propeptide is then removed and the mature protein secreted 
(Gundberg and Clough, 1992b).  Osteocalcin can affect bone formation rate, 
probably via a negative feedback loop (Ducy et al., 1996) and can also influence 
glucose tolerance, fat mass and energy expenditure in mice (Lee et al., 2007b).  
Secreted proteins are usually co-translationally delivered to the endoplasmic 
reticulum (ER).  This is mediated by the highly conserved signal-recognition particle 
(SRP) which recognizes the signal peptide sequence, halts translation and targets the 
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ribosomal complex to the ER membrane.  This results in the translocation of the 
target protein across the membrane and into the lumen of the ER (Saraogi and Shan, 
2011).  A large proportion of proteins can however be cotranslationally degraded 
(Turner and Varshavsky, 2000) and this can be facilitated by the eukaryotic 
elongation factor, eEF1A (Chuang et al., 2005).  Polyubiquitinated chains are well 
recognized as signals for cotranslational protein degradation, however direct binding 
of adapter proteins to their targets can also result in protein degradation (Watanabe 
and Tanaka, 2011).  This suggests that Nbr1, through its interaction with osteocalcin 
could be involved in the cotranslational degradation of this protein.  In addition, this 
could be facilitated by the putative interaction between Nbr1 and eEF1A (discussed 
in Chapter 4).  Further work is required in order to establish whether osteocalcin is 
degraded by either autophagy or the proteasome and whether this is dependent on 
Nbr1.  The truncated Nbr1 mouse model (lacking the osteocalcin binding site) 
displays increased levels of serum osteocalcin (Whitehouse et al., 2010), further 
suggesting that Nbr1 could be negatively regulating osteocalcin secretion and 
therefore osteoblast activity by targeting it for degradation. 
 
Cell specific expression of the osteoblast transcription factor ATF4 can be regulated 
post-translationally.  ATF4 mRNA is expressed in a variety of mouse tissues and cell 
lines however ATF4 is only detectable in osteoblastic cell lines (Yang and Karsenty, 
2004).  Inhibition of the proteasome or the specific E3 ligase β-TrCP1 resulted in 
detectable ATF4 protein levels in non-osteoblastic cell lines suggesting that the 
osteoblast specific levels of ATF4 are controlled by ubiquitin-dependent proteasomal 
degradation (Yang and Karsenty, 2004).  Nbr1 may act via a similar mechanism to 
specifically target yet to be identified proteins for degradation via either autophagy 
or the UPS in osteoblasts and therefore modulate osteoblast differentiation and 
function.    
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3.7. Future Work 
Nbr1 and p62 have previously been identified as interacting with members of the 
ubiquitination machinery (Sanz et al., 2000; Waters et al., 2009).  This yeast-2-
hybrid has identified a number of novel putative interactors of Nbr1 that are involved 
in ubiquitination of target proteins (UBE20 and Rnf26).  Validation of these 
interactors using GST binding assays and coimmunoprecipitation would shed further 
light on the specific roles of Nbr1 as a scaffold protein to facilitate ubiquitination.  
Colocalisation studies could also be used to establish if Nbr1 is localised to the same 
subcellular compartments as UBE20 and Rnf26 and thus determine if these 
interactions are plausible.  Additionally, it would be interesting to validate the 
putative interaction between Nbr1 and Tmp21 (Table A1, Appendix) as Tmp21 is 
involved in vesicular trafficking (Schimmoller et al., 1995). 
 
Data in this thesis identified osteocalcin as interacting weakly with Nbr1.  Further 
colocalisation studies in osteoblast specific cells would determine if these proteins 
are present in the same cellular compartments and therefore gain further evidence as 
to the likely interaction of these proteins in vivo.  Due to the putative link between 
Nbr1 and cotranslational degradation (see Chapter 4), siRNA knock-down of Nbr1, 
could be used to investigate if the degradation of osteocalcin is regulated by Nbr1.  
Additionally, proteasome inhibitors or bafilomycin could be used to block the 
degradation of proteins via the UPS and autophagy respectively to assess which 
degradation pathway is required for osteocalcin degradation. 
 
It could not be proven that Nbr1 interacts with cystatin C in vitro, however this could 
be due to the conditions of the GST binding assay used or the possible transiency of 
the interaction.  In addition, GST binding assays do not take into account possible 
posttranslational modifications, therefore, other assays such as FRET could be used 
to further validate this interaction. 
 
The bone specific ubiquitinated targets of Nbr1 are still unknown.  GST binding 
assays could be performed with the UBA domain of Nbr1 in primary osteoblasts. All 
bound proteins could then be resolved by SDS PAGE and identified by mass 
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spectrometry.  This would identify possible ubiquitinated or non-ubiquitinated 
targets of Nbr1 which could be further investigated with regards to its role in 
autophagic and proteasomal protein turnover. 
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Chapter 4. Identification of Interacting Partners of a 
Highly Conserved Region of Nbr1 
4.1. Introduction 
During the course of this project, evolutionary analysis was carried out on the NBR1 
protein by Dr R. Roberts (Kings College London).  This revealed that NBR1 is 
highly conserved throughout the eukaryotic kingdom, and NBR1-like architecture is 
present in animals, plants and fungi (Figure 4.1).  The plant Nbr1 contains an 
additional C-terminal UBA domain and fungi possess three extra ZZ domains.  
Along with the known protein domains, a conserved region (referred to from now on 
as the novel region) of approximately 110 amino acids consisting of an internal 
repeat of ~55 amino acids is present in NBR1 in the eukaryotic kingdom and also in 
a number of bacteria (Figure 4.2A).  It spans from amino acids 372-479 of human 
NBR1 and resides in the largely uncharacterised central region (Figure 4.1).  The 
novel region consists of a robustly predicted secondary structure of six β-strands.  
These six strands are predicted to form a compact ―sandwich‖ comprising of two 
three β-stranded sheets.  The only other known protein that contains the novel region 
is c6ORF106 however, the function of this protein is unknown (R. Roberts, 
unpublished data).  Figure 4.2B shows a schematic diagram of the bovine Niemann-
Pick C2 (NPC2) cholesterol-binding protein which contains a similar structure to that 
predicted for the novel region.  During this study, the novel region was also 
identified by others and given the name NBR1 box by Kraft et al. (Kraft et al., 2010) 
and subsequently the FW (Four W (tryptophan)) domain by Johansen et al. due to the 
four highly conserved tryptophan residues found in this domain (Johansen and 
Lamark, 2011).  This region is also absent in p62, suggesting it may mediate a 
functionally distinct role for Nbr1 (Svenning et al., 2011).  As it was not included in 
the yeast-2-hybrid screen described in Chapter 3, the novel region will be used as 
bait and a further screen performed using a bone calvarial library to identify any 















The phenotype of the yeast strains utilised (Y187 and AH109) were confirmed to be 
the same as described in section 3.2.1. 
 
4.2.1. 3-AT Titration and Autoactivation. 
The novel region of Nbr1 (aa346-498) was cloned into the pGBKT7 vector and 
transformed into yeast strain Y187.  To test for autoactivation and ‗leaky‘ histidine 
expression, successful transformants were mated with yeast strain AH109 
transformed with the pGADT7 empty vector (containing the GAL4 activation 
domain).  The SV40 Large T-antigen and p53 protein were used as a positive control 
as they are known to interact. Empty vectors pGADT7 and pGBKT7 were used as a 
negative control.  Table 4.1 shows the extent of colony growth with increasing 
concentrations of 3-AT.  No autoactivation was observed with the bait construct 
(Nbr1 aa346-498-GAL4 BD) and a 3-AT concentration of 3mM was chosen for the 
library screen. 
 
Mating      
-Leu/-












p53 + T-antigen √ √ √ √ √ √ 
pGBKT7 + 
pGADT7 
√ X X X X X 
Nbr1 aa346-
498+ pGADT7 
√ X X X X X 
Table 4.1. 3-AT Titration and test for bait autoactivation. Yeast were 
transformed with constructs indicated, mated and plated on SD media lacking 
different combinations of amino acids as shown.  The positive and negative controls 
grew as expected.  The bait construct (Nbr1aa346-498) exhibited no autoactivation 
and did not grow in the absence of histidine or adenine. 
 
4.2.2. Confirmation of bait protein expression. 
To verify that the transformed yeast (Y187) were expressing the bait protein of 
interest (GAL4BD-Nbr1 aa346-498), protein was extracted from transformed yeast, 
resolved by SDS PAGE and visualised by Western blot using an antibody that 
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recognises the GAL4 BD. A protein band of ~38kDa was identified which is the 
same size as predicted for the bait protein, thus confirming successful expression in 
Y187 yeast cells (Figure 4.3). 
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4.2.3. Yeast -2-Hybrid Library Screen 
Y187 yeast expressing the bait protein (GAL4 BD-Nbr1 aa346-498) were mated with 
a pretransformed 7 day old mouse calvaria cDNA library (cloned into the pGADT7 
vector) transformed into the AH109 yeast strain, kindly supplied by Prof. Ikramuddin 
Aukhil (College of Dentistry, University of Florida).  The yeast from this mating 
were plated onto SD–Leu/-Trp/-His media supplemented with 3mM 3-AT.  The 




A total of 83 positive clones grew on SD–Leu/-Trp/-His media supplemented with 
3mM 3-AT and were restreaked onto SD–Leu/-Trp/-His media supplemented with 
3mM 3-AT a further three times to eliminate any multiple library plasmids.  This 
resulted in the regrowth of 59 clones. Plasmid DNA was extracted from these 59 
yeast clones, transformed into chemically competent E.coli, the DNA extracted and 
sequenced.  Clones that were out of frame with the GAL4 AD were discarded. 
 
Twenty two proteins were identified as putative interactors of the novel region of 
Nbr1. The most biologically relevant candidates were microtubule associated protein 
1B (MAP1B) and eukaryotic translation elongation factor 1A (eEF1A) (Table 4.2).  
Other candidates included a number of muscle specific proteins (Table 4.2), 
suggesting that the calvarial library was contaminated with muscle. Known false 
positives that often arise from yeast-2-hybrid assays independent of bait sequence 
(such as actin and procollagen) were also identified and not investigated any further 
(Hengen, 1997).  All other proteins that will not be discussed are listed in Table A.2 
(Appendix).  









NM_010106.2 Eukaryotic translation 
elongation factor 1A 
1 
NM_023374.3 Succinate dehydrogenase 
complex subunit B 
1 
NM_001085509 Myomesin family member 3 2 
NM_001033621.2 Myotilin (Myot) 1 





 Actin α 1 (skeletal muscle) 5 
NM_007742.3
¥
 Procollagen type 1 α 1 1 
            Table 4.2. Positive clones identified from the yeast-2-hybrid screen.  
            ¥ indicates likely false positives. 
 
4.3. Putative Interacting Partners of Nbr1 
4.3.1. Eukaryotic translation elongation factor 1A (eEF1A) 
The novel region of Nbr1 interacts with the C domain (aa283-400 - this was deduced 
from the isolated yeast-2-hybrid clone) of the eukaryotic translation elongation factor 
1A (eEF1A).  eEF1A is ubiquitously expressed (Lee et al., 1992) and traditionally 
known for its involvement in protein synthesis where it catalyses the first step of the 
elongation cycle (Lamberti et al., 2004).  It is composed of three domains; the 
catalytic domain (G-domain), the middle domain (M-domain) and the C-terminal 
domain (C-domain).  These domains are important for the binding of eEF1A to 
aminoacyl-tRNA during the elongation cycle (Berchtold et al., 1993).  eEF1A is also 
involved in a number of other cellular functions including embryogenesis, cell 
proliferation and tumorigenesis (Lamberti et al., 2004).  Most interestingly for this 
project, eEF1A has been linked to ubiquitin mediated protein degradation and this 
will be discussed further in section 4.8.  
  
4.3.2. Microtubule associated protein 1B (MAP1B) 
Microtubule associated protein (MAP1B) was first described over 20 years ago 
(Bloom et al., 1985) and is one of three high molecular weight MAP1 isoforms.  It is 
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transcribed as a single mRNA, translated into a polypeptide of 2464 amino acids 
(mouse) which is subsequently cleaved at approximately aa2215.  This produces a 
heavy chain - MAP1B-HC (2214aa) and a light chain - MAP1B-LC1 (250aa) (Tögel 
et al., 1999).  Both the MAP1B-HC and –LC1 can bind to microtubules 
(Hammarback et al., 1991; Noiges et al., 2002) and to each other (Tögel et al., 1998).  
The light chain stabilises microtubules and this function is inhibited by the heavy 
chain (Tögel et al., 1998).   
 
Much of the literature to date has focused on the function of MAP1B in the central 
nervous system due to its high expression during neuronal development (Schoenfeld 
et al., 1989) and in areas of high regenerative activities in adult brain (Viereck et al., 
1989). Complete knock-out of the MAP1B gene in mice established that it is 
essential for the development and function of the nervous system as animals 
displayed impaired brain development (Meixner et al., 2000).  An inhibition of axon 
formation and decreased microtubule synthesis and dynamics have also been 
observed in neurons deficient in MAP1B (Gonzalez-Billault et al., 2001).  
Additionally, MAP1B is present in Lewy bodies which contain increased levels of 
ubiquitin conjugates and are pathological hallmarks of Parkinsons disease and 
dementia (Jensen et al., 2000).   
 
MAP1B has also been implicated in the regulation of autophagy.  MAP1B-HC and 
its phosphorylated form (MAP1B-P) were identified as interacting partners of LC3 
(Wang et al., 2006).  In mice with degenerating axonal swellings of the nervous 
system, there was an accumulation of MAP1B-P that colocalised with LC3, therefore 
suggesting that the MAP1B-P-LC3 interaction provides a mechanism for targeting 
autophagosomes to axon terminals during neurodegeneration (Wang et al., 2006). 
 
Nbr1 interacts with residues 2238-2465 of MAP1B (this was deduced from the 
isolated yeast-2-hybrid clone) which correspond to the light chain.  The role of 
MAP1B-LC1 in autophagy has not been previously investigated however the known 
involvement of Nbr1 and microtubules in autophagy suggests this interaction 
warrants further investigation. 
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4.4. Nbr1 is found in a complex with MAP1B-LC1 
A coimmunoprecipitation experiment was performed to establish if MAP1B-LC1 
could be found in a complex with Nbr1.  Lysate from COS-7 cells expressing HA-
Nbr1 and MAP1B-LC1-myc was incubated with an antibody that recognises the myc 
tag. MAP1B-LC1 was immunoprecipitated and the immunocomplex bound to 
protein A beads.  Bound proteins were resolved by SDS PAGE and subsequently 
visualised by Western blot using antibodies against the myc and HA tags.  This 
demonstrated that MAP1B-LC1-myc was successfully immunoprecipitated (Figure 
4.4, lanes 3&6) and that HA-Nbr1 was coimmunoprecipitated along with MAP1B-
LC1-myc (Figure 4.4, lane 6).  This result was specific to Nbr1 as an unrelated HA-
tagged protein (HA-LacZ) could not be coimmunoprecipitated along with MAP1B-
LC1-myc (Figure 4.4, lane 3).   
 
4.5. Nbr1 interacts with the light chain of MAP1B  
Biochemical analysis was used to further validate the interaction between MAP1B-
LC1 and Nbr1.  Lysate from COS-7 cells expressing MAP1B-LC1-myc was 
incubated with purified GST-Nbr1 aa346-498, GST alone or other regions of Nbr1 
(aa1-135 and the UBA domain).  GST beads were washed and bound proteins were 
resolved by SDS PAGE and visualised by Western blot using an antibody against the 
myc-tag.  Under these conditions, the novel region of Nbr1 interacted with the 
MAP1B-LC1 (Figure 4.5A).  Unexpectedly, the Nbr1 UBA domain also bound 
MAP1B-LC1. 
 
To verify the interaction between the novel region of Nbr1 and MAP1B-LC1 in a 
cell free environment, MAP1B-LC1 was cloned into a His-tagged vector, expressed 
in bacteria and purified (sections 2.2.4 & 2.2.6).  The purified protein was then 
incubated with GST-Nbr1 aa346-498 or GST alone.  GST beads were washed and 
samples were analysed by SDS PAGE and visualised by Western blot using an 
antibody that recognises the His-tag.  Under these conditions, the novel region of 
Nbr1 interacts with MAP1B-LC1 confirming that this was a direct protein-protein 
interaction (Figure 4.5B). 
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4.6. MAP1B-LC1 protein levels during inhibition of 
autophagic protein degradation 
It has previously been observed that MAP1B-HC is not degraded by autophagy 
(Wang et al., 2006) however, it has not been reported whether the same is true for 
MAP1B-LC1.  To determine if the function of the interaction between MAP1B-LC1 
and Nbr1 is to facilitate the degradation of MAP1B-LC1 via autophagy, MAP1B-
LC1 protein levels were analysed under conditions where autophagic protein 
degradation was blocked.  PC12 cells (a rat neuronal cell line derived from a 
pheochromocytoma, known to express high levels of MAP1B) were treated with 
either Bafilomycin A1 or DMSO as a control.  Bafilomycin A1 causes the 
accumulation of autophagosomes by inhibiting the vacuolar ATPase that drives the 
acidification of lysosomes, causing a reduction in lysosomal pH and the inhibition of 
protein degradation (Bowman et al., 1988).  Cell lysates were resolved by SDS 
PAGE and proteins visualised by Western blot using antibodies that recognise p62, 
Nbr1, MAP1B-HC, MAP1B-LC1 or β-actin (Figure 4.6).  Protein band intensity was 
quantified to estimate protein levels.  Upon Bafilomycin A1 treatment, the levels of 
both Nbr1 and p62 increased by 130% and 60% respectively (relative to a β-actin 
control).  Nbr1 and p62 are both degraded by autophagy, therefore this demonstrated 
that protein degradation via autophagy was inhibited by Bafilomycin A1 treatment.  
MAP1B-HC and MAP1B-LC1 protein levels showed a small but discernable 
increase upon the blockage of autophagic degradation relative to the β-actin control 
(10% and 20% respectively). 
 
Analysis of MAP1B in primary osteoblasts was also attempted however protein 
levels could not be reproducibly detected by either Western blot or 
immunoflourescence.   
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4.7. Localisation of Nbr1 and MAP1B in mammalian cells. 
Due to the direct interaction of Nbr1 and MAP1B-LC1, it was important to 
determine whether they colocalised in vivo and under what conditions.  MAP1B has 
been widely studied in neuronal cells and is highly expressed in PC12 cells.  This 
cell line was therefore utilised for endogenous protein colocalisation studies.  Nbr1 
and MAP1B-HC are both involved in the autophagy pathway.  As MAP1B-LC1 
interacts with MAP1B-HC, the cellular colocalisation of these two proteins was 
initially investigated under conditions where autophagy was blocked or induced.  
Cells were treated with DMSO (vehicle control), Bafilomycin A1 or starved (to 
induce autophagy) then fixed and immunostained for endogenous proteins (Figure 
4.7).  MAP1B-HC and MAP1B-LC1 colocalise under all treatment conditions 
suggesting that the two MAP1B chains predominantly function as one unit.   
However, there were distinct areas where there was a lack of colocalisation.   
 
MAP1B-HC and MAP1B-LC1 colocalise under conditions of autophagic inhibition 
and induction, which lead to the hypothesis that the interaction between Nbr1 and 
MAP1B-LC1 could be important for autophagic protein degradation.  PC12 cells 
were treated as above and immunostained with antibodies against MAP1B-LC1 and 
Nbr1.  Under starvation conditions, Nbr1 punctae often appeared adjacent to 
MAP1B-LC1 positive structures rather than directly colocalising (Figure 4.8).  
During conditions where protein degradation was blocked, MAP1B-LC1 was often 
excluded from Nbr1 positive vesicles.  Under basal conditions (DMSO), Nbr1 
showed a staining pattern more reminiscent of MAP1B-LC1 compared with the 
treatments to block or induce autophagy.  
 
As MAP1B-HC and Nbr1 both interact with LC3 (Wang et al., 2006), the 
localisation of MAP1B-HC and Nbr1 was also studied.  PC12 cells were prepared as 
above and stained with antibodies against MAP1B-HC and Nbr1.  Cells treated with 
DMSO and Bafilomycin A1 did not display any colocalisation however when cells 
were starved, Nbr1 and MAP1B-HC colocalised in distinct perinuclear vesicular 
structures (Figure 4.9).   
















Recent evolutionary studies performed in collaboration with Dr R. Roberts, KCL 
have identified a highly conserved region, located in the previously uncharacterised 
central region of Nbr1 (unpublished data).  This domain, termed the novel region, is 
also present in a range of bacteria and contains two internal repeats of ~55 amino 
acids.  It also has a predicted secondary structure consisting of two, three β-stranded 
sheets.  Due to its high conservation and unknown function, a yeast-2-hybrid screen 
was carried out using a mouse calvarial library to identify interacting proteins of the 
novel region.  This yeast-2-hybrid did not screen the cDNA library to saturation (Van 
Criekinge and Beyaert, 1999) therefore, some interacting partners may not have been 
identified. 
 
4.8.1. Nbr1 interacts with the light chain of MAP1B 
The light chain of MAP1B was identified as a putative interacting partner of the 
novel region of Nbr1 (Table 4.2).  Subsequent coimmunoprecipitation and GST 
binding assays confirmed this direct interaction (Figures 4.4 and 4.5).  MAP1B is a 
scaffold protein, transcribed as a single mRNA and subsequently cleaved to produce 
a heavy chain and a light chain.  Both the heavy and light chains can bind to 
microtubules (Hammarback et al., 1991; Noiges et al., 2002) and to each other 
(Tögel et al., 1998).  The microtubule network is known to facilitate autophagosomal 
formation (Fass et al., 2006; Köchl et al., 2006), the movement of mature 
autophagosomes towards lysosomes (Geeraert et al., 2010) and the recruitment of 
protein aggregates (Kawaguchi et al., 2003).  The binding of adaptor proteins such as 
FYCO1 to both LC3 and microtubule motor proteins has also been suggested as a 
mechanism by which preautophagosomal membranes are targeted to sites of 
autophagosomal formation (Pankiv et al., 2010).  This led to the hypothesis that the 
interaction between Nbr1 and MAP1B-LC1 could facilitate the targeting of 
ubiquitinated protein aggregates to the microtubule network, where they can be 
transported to sites of autophagosomal formation.  In further support of this 
hypothesis, a similar mechanism has been proposed whereby MAP1B-HC is able to 
target autophagosomes to axon terminals during neurodegeneration through its 
interaction with LC3 (Wang et al., 2006).  MAP1B has also been predicted to interact 
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with Atg12 and Atg3 suggesting that in addition to LC3, it is important for the 
targeting of other components of the autophagosome machinery to sites of 
autophagosomal formation (Behrends et al., 2010).   
 
MAP1B-HC and MAP1B-LC1 are known to interact (Tögel et al., 1998) therefore, 
their localisation was assessed in PC12 cells.  Under basal conditions and when 
autophagy was induced or blocked, MAP1B-HC and –LC1 colocalise (Figure 4.7).  
This suggests that indeed, MAP1B-LC1 could be acting together with MAP1B-HC 
in the recruitment of the autophagosomal machinery or autophagic receptors and 
their cargo to the microtubule network.  However, distinct areas were observed 
where there was no colocalisation suggesting that they are also performing functions 
independent of each other.  Analysis of Nbr1 and MAP1B-LC1 intracellular 
localisation demonstrated that under conditions where autophagy is blocked, Nbr1 
and MAP1B-LC1 rarely colocalised and MAP1B-LC1 was often excluded from 
Nbr1 positive vesicles. Under conditions of autophagic induction, Nbr1 vesicles were 
largely observed adjacent to MAP1B-LC1 positive structures (Figure 4.8).  This 
could suggest that the interaction between MAP1B-LC1 and Nbr1 is transient and 
occurs at the very early stages of autophagosome formation.  Furthermore, under 
basal conditions, protein levels of Nbr1 were lower and staining was more 
reminiscent of MAP1B-LC1 localisation suggesting that the interaction between 
Nbr1 and MAP1B-LC1 could be prior to the recruitment of Nbr1 into autophagic 
vesicles.   
 
Analysis of MAP1B-LC1 protein levels demonstrated that when autophagic protein 
degradation was blocked, there was a small but discernable increase in MAP1B-LC1 
levels (Figure 4.6).  This was not however comparable to the large increase observed 
in the protein levels of Nbr1 and p62 which are known to be degraded by autophagy.  
The small increase in MAP1B-LC1 after Bafilomycin A1 treatment suggests that the 
primary role of the Nbr1-MAP1B-LC1 interaction is not to target MAP1B-LC1 for 
degradation via autophagy.  Blockage of autophagosomal degradation also results in 
a reduction of protein turnover via the UPS (Qiao and Zhang, 2009), therefore as 
MAP1B-LC1 is degraded by the UPS (Allen et al., 2005), this could suggest that 
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Bafilomycin A1 treatment results in the inhibition of MAP1B-LC1 degradation by 
the proteasome rather than by autophagy.   
 
The UBA domain of Nbr1 also interacted with MAP1B-LC1 in the GST binding 
assay (Figure 4.5).  The ubiquitin scaffolding protein gigaxonin interacts with both 
the E1 ubiquitin-activating enzyme and MAP1B-LC1.  This facilitates the 
degradation of MAP1B-LC1 in neuronal cells via the UPS.  Proteasome inhibition 
results in an increase in MAP1B protein levels which leads to neuronal cell death, a 
hallmark of mental retardation (Allen et al., 2005).  This suggests that via a similar 
mechanism to gigaxonin, Nbr1 could also be acting as a scaffold protein, interacting 
with both E2 and E3 enzymes and MAP1B-LC1 to facilitate the ubiquitin-mediated 
degradation of MAP1B-LC1.  As MAP1B-LC1 interacts with two different regions 
of Nbr1 (Figure 4.5) either directly or indirectly, this could also indicate a regulatory 
mechanism similar to that of p62 and TRAF6.  The UBA domain and TRAF6 
binding domain of p62 are required for TRAF6 polyubiquitination whilst the binding 
of TRAF6 to p62 is also required for the correct assembly of the receptor signalling 
complex that is responsible for the activation of the NF-κB pathway (Wooten et al., 
2005; Wooten et al., 2001). 
 
Under conditions of autophagic induction, Nbr1 colocalises in discreet perinuclear 
vesicular structures with MAP1B-HC (Figure 4.9).  To confirm if these structures 
represent the autophagosome, localisation with autophagosomal markers would be 
required.  However, MAP1B-HC interacts in vivo with LC3, and as Nbr1 also 
interacts with LC3, these proteins could be part of one protein complex.  Although it 
is not known whether Nbr1 forms a direct interaction with MAP1B-HC, the 
colocalisation studies carried out in this thesis could suggest that MAP1B-HC and 
Nbr1 are together involved in autophagosomal vesicle formation and the targeting of 
protein for degradation.  In support of this hypothesis, a recent study has 
demonstrated a similar mechanism whereby the ubiquitously expressed MAP1B 
homologue MAP1S facilitates autophagic degradation of mitochondria.  This is 
thought to be through the interaction of MAP1S-HC with LC3 which functions to 
target LC3 to the microtubule network (Xie et al., 2011). 
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4.8.2. Potential interaction of Nbr1 with protein synthesis machinery 
The yeast-2-hybrid screen described in this chapter also identified eukaryotic 
translation elongation factor 1A as a putative interacting partner of Nbr1 (Table 4.2).  
Although no further validation was performed, this interaction provides an 
interesting point for discussion.  The primary and perhaps most well known function 
of eukaryotic elongation factor 1A (eEFlA) is to catalyze the first step of the 
elongation cycle during protein synthesis (Lamberti et al., 2004).  In addition to this, 
eEF1A has also been implicated in ubiquitin-mediated protein degradation.  Since up 
to 50% of all newly synthesised polypeptides can be cotranslationally degraded 
(Turner and Varshavsky, 2000), eEF1A is a likely candidate for the facilitation of 
this process as it interacts with both the proteasome and ubiquitinated proteins in the 
presence of protein synthesis inhibitors (Chuang et al., 2005).  It can also function as 
an isopeptidase to enable proteins to be degraded by the proteasome (Gonen et al., 
1996).  As Nbr1 is a scaffold protein known to bind ubiquitinated proteins and 
potentially members of the ubiquitination machinery, it is interesting to speculate 
that Nbr1 may act as a scaffold to target the ubiquitination machinery to sites of 
cotranslational degradation via its interaction with eEF1A.  Alternatively, Nbr1 could 
aid in the shuttling of ubiquitinated proteins from sites of protein translation to sites 
of protein degradation.  p62 is known to bind to parts of the proteasome (Seibenhener 
et al., 2004), and although often classed as false positives (Hengen, 1997), a 
proteasomal subunit was identified as an interacting partner of Nbr1 in the yeast-2-
hybrid screen described in Chapter 3 of this thesis (Table A.1).  Together, these data 
suggest that like p62, Nbr1 could shuttle proteins for proteasomal degradation, 
facilitated by putative interactions with the proteasome and eEF1A.   
 
4.8.3. Mitochondrial proteins  
Mitochondrial proteins are identified in many yeast-2-hybrid screens and are 
generally considered to be false positives (Hengen, 1997).  The screen carried out in 
this study was no exception, identifying a COX11 homolog (cytochrome c oxidase 
assembly protein) and succinate dehydrogenase complex subunit B as potential Nbr1 
interaction partners.  However, these proteins may be of relevance due to recent 
unpublished data presented at the 42
nd
 Hardan Conference by Ivan Dikic (2010).  It 
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was shown that the novel region of Nbr1 specifically binds the phospholipid, 
cardiolipin.  Cardiolipin is located on the inner membrane of mitochondria and is 
required for the optimal activity of a number of mitochondrial proteins including 
cytochrome c oxidase (Paradies et al., 2010).  Dikic et al. demonstrated that Nbr1 
colocalises with damaged mitochondria in cells treated with the mitochondrial 
disruptor CCCP.  This suggests that via its interaction with cardiolipin, Nbr1 is able 
to target damaged mitochondria for degradation via autophagy.  The Niemann-Pick 
C2 (NPC2) protein has a similar structure to that predicted for the novel region of 
Nbr1 (Figure 4.2) and interacts with cholesterol; this provides further evidence for 
the likely role of the novel region of Nbr1 in lipid binding (Ko et al., 2003).  
Additionally, a number of highly conserved aromatic residues were important for 
NPC2 cholesterol binding  (Ko et al., 2003).  It may be that the highly conserved 
tryptophan residues in the novel region of Nbr1 are important for lipid binding or 
indeed other interactions such as that with MAP1B-LC1. 
 
 4.9. Future Work 
Nbr1 was demonstrated to interact with MAP1B-LC1 however colocalisation was 
not observed under conditions of autophagic induction.  To further investigate 
whether the Nbr1-MAP1B interaction is involved in targeting ubiquitinated proteins 
for autophagic degradation, live cell imaging could be used.  This would enable the 
live visualisation of MAP1B-LC1 and Nbr1 and other members of the early forming 
autophagosome.  Knock-down of MAP1B using siRNA would also establish if 
MAP1B is required for the correct localisation of Nbr1.  Nbr1 protein levels could 
also be analysed in the absence of MAP1B to determine if MAP1B is required for the 
autophagosomal degradation of Nbr1.  The novel region of Nbr1 is highly conserved 
therefore it is likely that specific residues within this region could be important for 
MAP1B binding.  This could be addressed by mutating residues such as the four 
tryptophans and subsequently assessing the effects of MAP1B-LC1 binding.  As 
MAP1B-HC was demonstrated to colocalise with Nbr1, it would be interesting to 
investigate whether it also interacts with Nbr1.  To investigate if either MAP1B-LC1 
or MAP1B-HC is required to target Nbr1 to the microtubule network, fractionation 
experiments could be performed with purified microtubules in the presence and 
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absence of MAP1B.  Finally, Nbr1 may regulate the degradation of MAP1B-LC1 via 
the UPS.  To investigate this, overexpression or siRNA knockdown of Nbr1 could be 
used to analyse the effects on MAP1B protein levels in the presence or absence of 
proteasomal inhibitors.   
 
To further validate the interaction between Nbr1 and eEF1A, in-vitro GST binding 
assays and coimmunoprecipitation could be implemented.  Additionally, cellular 
colocalisation experiments under conditions where protein synthesis is inhibited 
would assess whether Nbr1 specifically localises with eEF1A under these conditions.  
Binding assays could also be performed with Nbr1 and the proteasomal subunit 
identified in the yeast-2-hybrid screen in Chapter 3 (Table A.1).  This would further 
establish if Nbr1 is involved in the degradation of proteins by the proteasome. 
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Chapter 5. Phenotypic Analysis of the Nbr1
D50R
 
Knock-in Mouse Model 
5.1. Introduction 
Nbr1 and the structurally similar protein p62 have been identified as key factors in 
the regulation of bone formation.  Mice deficient in p62 have a defect in 
osteoclastogenesis (Duran et al., 2004), whilst a truncated Nbr1 (trNbr1) mouse 
model exhibits an increase in bone mass and bone mineral density due to an increase 
in osteoblast differentiation and activity (Whitehouse et al., 2010).  Despite this, the 
molecular mechanisms by which Nbr1 acts are largely unclear.   
 
Nbr1 and p62 both contain a PB1 domain at their N-terminus.  This domain is a 
protein-protein interaction module found in a range of proteins (Moscat et al., 2006).  
It is highly conserved and adopts a ubiquitin-like β-grasp fold and either contains an 
acidic OPCA motif (type I), an invariant lysine residue on the first β strand (type II) 
or both of these motifs (type I/II) (Sumimoto et al., 2007).  Nbr1 has a type I PB1 
domain (Figure 5.1) and through this forms a polar heterodimeric interaction with the 
type I/II PB1 domain of p62.  The aspartic acid residue at position 50 of human 
NBR1 is essential for the NBR1-p62 interaction as when this is mutated to an 
arginine (D50R), the interaction is completely abolished (Lamark et al., 2003).  This 
residue is also conserved in murine Nbr1 and the same mutation was confirmed by 
yeast-2-hybrid to inhibit the Nbr1 and p62 interaction (Louise Bentley, Ellen 
Solomon Laboratory, KCL). 
 
The PB1 domain of p62 is important for a number of signalling pathways including 
the activation of NF-κB through its interaction with the MAP kinase kinase MEKK3 
(Nakamura et al., 2010).  Additionally, the interaction between Nbr1 and p62 is 
involved in muscle signalling (Lange et al., 2005) however its role in bone is 
unknown.  The trNbr1 mouse model still contains a functional p62 interacting 
domain,  therefore to investigate the significance of the p62-Nbr1 interaction, a 
knock-in mouse model was generated that contains a mutation in amino acid 50 of 
Nbr1 (Nbr1
D50R
) (Figure 5.2).  The strategy used to generate the Nbr1
D50R
 mouse is 
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outlined in section 2.4.1.  Due to the known importance of Nbr1 and p62 in bone 
formation, the bone phenotype of these mice will be analysed.  Micro Computer 
Tomography (MicroCT) will be used to determine cortical and trabecular bone 
parameters whilst in vitro assays will be used to gain an insight into the osteoblast 
and osteoclast cellular phenotype. 
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5.2. Confirmation of mouse genotype 
Mouse tissue was obtained by ear punch biopsy and genomic DNA extracted.  PCR 
and subsequent restriction digest was performed to confirm mouse genotypes.  
Primers used for PCR amplification were located in intron 2 and intron 4a of Nbr1 
(Figure 5.3A), and were used to amplify the genomic region encoding the Nbr1
D50R
 
mutation (exon 3 and 4a).  The resulting PCR product was digested with the StuI 
restriction enzyme and visualised by agarose gel electrophoresis.  The absence of 
StuI restriction sites in the WT allele enabled it to be distinguished from the mutant 
allele which contained two engineered StuI sites either side of a LoxP site.  The 
expected wild type (WT) allele PCR product size was 1470 bp whilst the mutant 
PCR product sizes were 1133 bp and 334 bp after StuI digestion (Figure 5.3B).  
Sequencing analysis confirmed the presence of the mutation (Figure 5.3C). 
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5.3. Confirmation that the Nbr1
D50R
 mutation inhibits the 
interaction between Nbr1 with p62 
 
To confirm that the Nbr1-p62 interaction was inhibited in our mouse model, a co-
immunoprecipitation between Nbr1 and p62 was performed.  Prior to this, it was 
important to establish whether the Nbr1 antibody detected the mutant protein 
effectively.  To test this, mouse embryonic fibroblasts (MEFs) were isolated from 
both WT and Nbr1
D50R
 homozygous mutant mice, lysed and proteins resolved by 
SDS PAGE, then visualised by Western blot using the rabbit polyclonal antibody, 
3517 that recognises Nbr1.  This antibody was raised against a recombinant protein 
encoding aa 57-266 of Nbr1 which is outside the mutated region (made in-house by 
Dr Caroline Whitehouse).  Protein band intensities were quantified and established 
that the mutant protein could be detected with 90% efficiency compared with WT 
(Figure 5.4A).  This could suggest that the mutant protein levels are 10% less than 
WT.  Alternatively, the antibody may not be detecting the mutant protein as 
effectively as the WT protein.  Due to the lack of other efficient antibodies raised to 
domains outside of the mutated region, and to the small differences in detection 
efficiency between the WT and mutant protein, the 3517 antibody was used for the 
detection of Nbr1 in the subsequent coimmunoprecipitation experiment.   
 
The ability of Nbr1
D50R
 to form a complex with p62 was examined by 
coimmunoprecipitation.  Wild type and Nbr1
D50R 
MEFs were treated with either 
DMSO or Bafilomycin A1 (to increase Nbr1 and p62 protein levels) then lysed.  p62 
was immunoprecipitated and the immunocomplex bound to protein A beads.  Beads 
were washed and bound proteins resolved by SDS PAGE then visualised using 
Western blot and the 3517 antibody raised against Nbr1 (Figure 5.4B).  The amount 
of Nbr1 protein bound to p62 was calculated relative to the amount of p62 
immunoprecipitated.  In WT cells, Nbr1 coimmunoprecipitated with p62 as expected 
(Figure 5.4B, lane 3).  In mutant cells, Nbr1
D50R
 was also coimmunoprecipitated with 
p62 (Figure 5.4B, lane 4) however this was at a significantly lower level (~20%) 
compared with WT (Figure 5.4B).  Cells treated with DMSO gave similar results to 
those treated with Bafilomycin A1 (data not shown).  The very weak binding 
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observed in mutant cells could be attributable to the newly identified interaction 
between the UBA domains of Nbr1 and p62 (Whitehouse et al., 2010).  Additionally, 
Nbr1 and p62 could be in a complex together due to common interacting partners 
such as LC3.  Overall, it is clear that the Nbr1
D50R
 mutation is having a strong 
negative effect on the interaction between Nbr1 and p62. 
 
MEFs from WT and Nbr1
D50R
 homozygous mutant mice were treated with DMSO or 
Bafilomycin A1 then fixed and immunostained with antibodies against p62 and Nbr1.  
WT cells display a high degree of colocalisation between the two proteins.  In mutant 
cells however, although Nbr1 can still form punctate vesicles, its colocalisation with 
p62 is almost completely abolished (Figure 5.5).  This finding is in agreement with 
Lamark et al. (Lamark et al., 2003) and again confirms the abrogation of the 
interaction between the PB1 domains of Nbr1 and p62 in the Nbr1
D50R
 knock-in 
mouse model.  
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5.4. Ex vivo bone phenotypic analysis 
To establish if the p62-Nbr1 interaction is important for the formation and 
maintenance of bone tissue, it was necessary to perform detailed ex vivo analysis on 
femurs and tibiae from WT and Nbr1
D50R
 mutant (Mut) mice.  These bones were 
selected as they are routinely used to establish whether bone formation is altered in 
mouse models (Whitehouse et al., 2010; Williams et al., 2011).  A cohort of three, 
six and nine month old animals from each genotype were used for ex vivo bone 
analysis (numbers of animals per group analysed is described in section 2.6.1).  
These age groups were chosen because the previous Nbr1 mouse model (trNbr1) 
displayed an age-dependent increase in bone mass and bone mineral density that 
became evident at three months of age (Whitehouse et al., 2010).  All mice used in 
this study were male and either WT or homozygous for the Nbr1
D50R
 mutation. No 
significant differences were seen in total body weight between WT and mutant mice 
of all ages (Figure 5.6).   
 
5.4.1. Physical measurements and radiography 
Femur and tibia length was measured using digital calipers following dissection.  
There were no significant differences in femur lengths of three (p=0.227), or six 
(p=0.282) month old WT compared to mutant mice however, at nine months of age, 
mutant mice had a slight but significant increase in femur length compared to WT 
(p=0.008, 2.9%).  There was a slight significant decrease in tibia lengths of three 
month old mutant mice compared to WT (p=0.039, 1.7%), but no significant 
difference at six (p=0.265) or nine (p=0.068) months of age between the genotypes 
(Figure 5.7).  Overall, there was a general trend for reduced long bone length at three 
months of age and a general increase in long bone length at six and nine months of 
age in mutant mice compared to WT however these differences were small. 
 
Radiographs were taken of femurs (Figure 5.8) and tibiae (Figure 5.9) of three, six 
and nine month old mice.  Whilst some variation was observed between bones, as 
viewed by eye, there were no consistent differences between WT and mutant mice at 
all ages. 
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5.4.2. Micro Computer Tomography (MicroCT) 
In this study, low resolution (17µm) Micro Computer Tomography (microCT) 
images were acquired of whole femur and tibiae to gain information on whole bone 
volume and bone mineral density (BMD).  High resolution (4.4µm) imaging was 
subsequently performed to allow analysis of cortical and trabecular bone parameters.   
 
5.4.2a. Whole bone analysis 
Whole bone volumes and BMD were obtained from the low resolution scans.  Whilst 
there was variation within groups, no significant differences were observed in whole 
bone volume in femurs of six month (p=0.751) or nine month old (p=0.492) mutant 
mice compared with WT.  There were also no significant differences in whole bone 
volume of tibiae from six month (p=0.650) or nine month old (p=0.692) mutant mice 
compared with WT (Figure 5.10).  At three months of age there was a significant 
decrease in whole bone volume in the tibiae of mutant mice compared with WT 
(p=0.036, 12%) and although the same trend was observed, there was no significant 
difference in whole bone volume in femurs from three month old mutant mice 
compared with WT (p=0.139) (Figure 5.10).  Overall, whole bone volumes exhibited 
significant differences at three months of age but not at six and nine months of age 
between genotypes. 
 
Whole BMD (as compared with that of a hydroxyapatite standard-section 2.6.4) 
established no significant difference between genotypes in femurs of six month 
(p=0.727) or nine month old animals (p=0.606) or in the tibiae of six month 
(p=0.589) or nine month old animals (p=0.457).  At three months of age, both femurs 
and tibiae showed a significant decrease in whole BMD in mutant mice compared 
with WT (p=0.009 and 0.005 respectively) (Figure 5.11).  However, these 
differences were small (2% and 2.5% respectively). 
 
Overall, the whole bone analysis revealed there is a significant decrease in bone 
volume and bone mineral density in three month old mutant mice compared with WT 
and this difference is resolved by six months of age.  The trend in whole bone 
volume and BMD with age between the genotypes was comparable, with an increase 
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between three and six months and a decrease between six and nine months of age.  
This suggests that, unlike the truncated mouse model, there appears to be an early 
reduced bone volume and BMD. Further analysis of younger mice is required to 
confirm the age of onset.  There was also some variation within groups and although 
group size was within the range used by others (Hoff et al., 2002; Rauch et al., 2010), 
it would be useful to analyse more mice. 
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5.4.2b. Cortical and trabecular bone analysis 
Low resolution scans are useful to determine differences in whole bone parameters 
however the resolution is not high enough to accurately analyse the cortical and 
trabecular bone parameters.  Any differences in trabecular bone may be masked by 
the cortical bone.  Therefore, high resolution scans (4.4µm) were performed on all 
bones to establish whether the inhibition of the p62-Nbr1 interaction has any effect 
on cortical or trabecular bone. The distal and proximal ends of femurs and tibiae 
respectively were scanned, reconstructed and parameters were calculated using a 
region of interest (ROI) selected as described in section 2.6.4.  
  
5.5.2b.i Cortical analysis 
There were no significant differences observed in cortical bone volume (Ct.BV) 
between femurs from WT and mutant three month old mice (p=0.640).  A significant 
decrease in femur cortical thickness (Ct.Th) (p<0.001, 14%) in three month old 
mutant mice compared with WT was however observed (Figure 5.12A and B).  
Tibiae from three month old mutant mice displayed a significant decrease in both 
Ct.BV (p=0.028, 13%) and Ct.Th (p=0.014, 8%) compared with WT (Figure 5.12A 
and B).  There were no significant differences in femur or tibia Ct.BV from six 
month (p=0.163 and p=0.148 respectively) or nine month old mutant mice compared 
with WT (p=0.230 and p=0.476 respectively) (Figure 5.12A).  There were also no 
significant differences in femur or tibia Ct.Th in six (p=0.862 and p=0.081 
respectively) or nine month old mutant mice compared with WT (p=0.064 and 
p=0.365 respectively) (Figure 5.12B).  These data support the whole bone analysis 
where there were significant differences at three months of age and no significant 
differences at six and nine months of age between WT and mutant mice. 
 
To explain the apparent decrease in Ct.Th observed in femurs from three month old 
mutant mice but no accompanying difference in Ct.BV, endosteal and periosteal 
diameters were calculated from three regions spanning the cortical ROI.  These were 
the distal most cross section, the proximal most cross section and a cross section in 
the middle.  No significant differences were observed in endosteal diameters at any 
of the regions studied but a significant increase was observed in the periosteal 
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diameter at only the proximal most section studied in mutant mice compared with 
WT (Figure 5.12C).  This slight increase could be contributing to the lack of 
differences in bone volume observed in the Ct.Th from three month old femurs 
between genotypes.  It is important to note that the endosteal and periosteal analysis 
highlights the heterogeneity within the bones and although there was largely no 
differences in these parameters between genotypes, only a very small section of the 
bone was analysed compared with a much larger area studied for the other cortical 
parameters. 
 
There was a significant decrease in Ct.BMD in femurs (p=0.0004, 2.6%) and tibiae 
(p=0.009, 2%) of three month old mutant mice compared to WT (Figure 5.12D).  
This is in agreement with the small decrease in whole BMD observed in the whole 
bone scans (Figure 5.12D).  At six months of age there was no significant difference 
in cortical BMD in femurs (p=0.751) and a small increase in tibiae (p=0.029, 3%) in 
mutant mice compared with WT.  At nine months of age, there was a small but 
significant decrease in femur Ct.BMD (p=0.013, 3%) but no difference in tibiae 
Ct.BMD (p=0.713) in mutant mice compared with WT.   
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5.4.2b.ii. Trabecular analysis 
At three, six and nine months of age in both femur and tibiae, no significant 
differences were observed in Trabecular Bone Volume/Tissue Volume (BV/TV) 
(Figure 5.13A), Trabecular Separation (Tb.Sp) (Figure 5.13B), or Trabecular 
Number (Tb.N) (Figure 5.13C) in mutant mice compared with WT.  No differences 
were observed in trabecular thickness (Tb.Th) in six and nine month old mutant mice 
compared with WT or in the tibiae of three month old mutant mice compared to WT.  
There was a significant decrease in Tb.Th (6%) and Tb.BMD (2.5%) in femurs from 
three month old mutant mice compared with WT (Figure 5.13D&E).  There was also 
a significant decrease (4%) in the Tb.BMD of femurs from nine month old mutant 
mice compared to WT (Figure 5.13E).  All statistical p values for trabecular 

















0.271 0.224 0.068 0.015 0.002 
3 Month 
Tibiae 
0.207 0.078 0.091 0.147 0.558 
6 Month 
Femurs 
0.227 0.755 0.345 0.652 0.313 
6 Month 
Tibiae 
0.476 0.965 0.706 0.140 0.282 
9 Month 
Femurs 
0.422 0.753 0.295 0.300 0.007 
9 Month 
Tibiae 
0.145 0.612 0.247 0.981 0.803 
Table 5.1. Statistical analysis results for trabecular bone parameters of three, 
six and nine month old WT and Nbr1
D50R
 mutant mice. Values in bold are 
statistically significant (p<0.05).     
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 5.5. In vitro bone analysis  
MicroCT analysis has established that three month old Nbr1
D50R
 mutant mice have 
reduced Ct.Th, Tb.Th and BMD compared with WT controls and that this effect is 
resolved at six and nine months of age.  To establish the cellular mechanisms 
involved, bone marrow stromal cells were isolated from WT and mutant mice, and 
osteoclast and osteoblast differentiation assays were performed.  Due to the apparent 
early phenotype of the Nbr1
D50R
 knock-in mouse model, all in vitro analysis was 
carried out using one month old male animals.  
 
5.5.1. Analysis of osteoclast differentiation from bone marrow 
stromal precursor cells derived from WT and Nbr1
D50R 
mutant mice 
In vitro generation of osteoclasts from M-CSF- and RANKL-dependent bone 
marrow precursors was utilised to analyse osteoclast differentiation in Nbr1
D50R
 
mutant cells compared to WT (section 2.5.5).  TRAP staining revealed that mutant 
cells were much larger in size than WT (Figure 5.14A).  Subsequent quantification 
demonstrated the number of cells with 10-19 nuclei and 20 or more nuclei were 
significantly increased in mutant cultures compared to WT (p=0.008 and 0.012 
respectively) (Figure 5.14B).   
 
To establish whether osteoclast resorption activity was significantly different in 
Nbr1
D50R 
mutant osteoclasts compared to WT, bone marrow precursor cells were 
plated onto dentine slices, TRAP +ve cells were counted and resorption activity 
quantified (section 2.5.5). There was a significantly greater number of TRAP +ve 
mutant cells per dentine slice compared with WT (p=0.029) (Figure 5.15B).  No 
significant difference in total resorption area was observed between genotypes 
(Figure 5.15C).  It is important to note that the number of osteoclasts on each dentine 
slice did not appear to correlate with the level of resorption.  The giant osteoclast 
phenotype observed in mutant cells cultured on plastic was not observed when 
cultured on dentine. 
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5.5.2. Analysis of osteoblast differentiation from bone marrow 
stromal precursor cells derived from WT and Nbr1
D50R 
mutant mice 
To establish if the reduced Tb.Th, Ct.Th and BMD observed in younger mutant 
animals compared with WT was due to reduced osteoblast differentiation and 
activity, an in vitro colony forming unit (CFU) assay was performed and cells were 
stained with ALP and von Kossa.  After nine days in culture, fewer ALP positive 
colonies were observed in mutant cultures compared with WT (p=0.0009) however, 
this difference was resolved after 15 days, as a greater number of ALP positive 
colonies in the mutant cultures was observed compared with the WT (p=0.03). The 
mutant cells also displayed significantly fewer von Kossa positive colonies compared 
with WT at 15 days (p=0.002) (Figure 5.16).  Overall this data suggests that there is 
an early osteoblast differentiation defect in the Nbr1
D50R
 mutant cells that is resolved 
later in differentiation. 
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5.6. Discussion  
The adult skeleton is continually undergoing self renewal and remodelling at a rate of 
10%/year (Manolagas, 2000).  The process of bone resorption and formation is 
tightly coupled and an imbalance can give rise to a broad spectrum of skeletal 
pathologies (Harada and Rodan, 2003; Janssens and Van Hul, 2002).  The generation 
of mutant mouse models has proven invaluable for understanding the molecular 
mechanisms governing the regulation of bone and has therefore aided the 
identification of therapeutic targets to treat human skeletal diseases. 
 
Nbr1 and p62 are both involved in different aspects of bone remodelling.  Published 
data suggests that Nbr1 regulates osteoblast differentiation and activity whilst p62 is 
involved in regulating osteoclastogenesis. These proteins interact via their PB1 
domains however, the importance of this interaction in the regulation of bone was 
previously unknown.  To study this interaction further, a knock-in mouse model was 
generated.  Affected mice have a mutation in amino acid 50 of Nbr1 (D50R) that 
inhibits its interaction with p62.  The effectiveness of this mutation in disrupting this 
interaction between Nbr1 and p62 was confirmed by yeast-2-hybrid, co-
immunoprecipitation (Figure 5.4) and immunofluorescence (Figure 5.5).  MicroCT is 
widely used to study bone microarchitecture and was utilised in this investigation to 
analyse the effects of the Nbr1
D50R
 mutation on bone structure.  A cohort of three, six 
and nine month old mice from each genotype were studied due to the age dependent 
phenotype of the truncated Nbr1 mouse model (Whitehouse et al., 2010).  
 
5.6.1. Abrogation of the p62-Nbr1 interaction causes an age 
dependent osteoporotic phenotype 
MicroCT analysis of whole femurs and tibiae established that the Nbr1
D50R
 mutation 
results in a decrease in whole bone volume (Figure 5.10) and BMD (Figure 5.11) at 
three months of age.  Ct.Th and Tb.Th were also significantly reduced at three 
months of age (Figure 5.12 & 5.13).  Interestingly, this phenotype appeared to 
resolve itself and by six months of age there were largely no differences between WT 
and mutant mice.  An early bone phenotype that alters with age has previously been 
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documented in a number of other mouse models.  The postnatal osteoblast specific 
disruption of the BMP type 1A receptor (BMPR1A) causes a decrease in bone 
volume and formation rate in younger (up to 6 months) mutant mice due to a 
decrease in the ability of osteoblasts to form bone.  This difference resolved as mice 
aged and by 10 months there was an increase in bone volume in mutant mice 
compared with WT.  This was due to a decrease in bone resorption by osteoclasts 
(Mishina et al., 2004).  These data demonstrate that BMP signalling can regulate 
osteoblast function in an age-dependent manner, initially by supporting bone 
formation and then later by regulating the osteoblast control of osteoclast function 
(Mishina et al., 2004).  Mice deficient in the P2X2 receptor display a significant 
increase in BMD at 2 months of age however, these differences decreased in 
magnitude as the animals aged, suggesting a compensatory mechanism to overcome 
receptor deletion (Orriss, 2005).  Finally, Apolipoprotein E deficient mice had 
decreased Ct.Th at 10 weeks of age but by 40 weeks, the Ct.Th was increased in 
mutant mice compared with WT. In addition, mutant femurs were shorter than 
controls at ten weeks of age but there was no difference observed at 40 weeks of age 
between genotypes.  This was attributed to an increase in the adaptational response in 
ApoE deficient mice compared to WT controls (Robertson, 2004).  The mouse 
models discussed above suggest that molecules and signalling pathways important 
for bone formation and remodelling can have differing effects depending on the age 
of mice.  The early osteoporotic phenotype observed in the Nbr1
D50R
 mutant mouse 
model in this study suggests that similar to the BMPR1A deficient mice, the p62-
Nbr1 interaction could be involved in the regulation of bone mass by different 
mechanisms depending on mouse age.  Alternatively, the resolution of the 
osteoporotic phenotype in the Nbr1
D50R
 mutant mice could be due to a compensatory 
mechanism that is counteracting the effect of abrogating the Nbr1-p62 interaction in 
older mice. 
   
5.6.2. Bone length 
X-rays of femurs and tibiae from WT and Nbr1
D50R
 mutant mice showed no 
consistent structural differences between genotypes (Figure 5.8 & 5.9).  Initial 
physical measurements established a small but significant decrease in the tibia 
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lengths of three month old mutant mice and a small but significant increase in femur 
length of nine month old animals (Figure 5.7).  These data suggest that the Nbr1
D50R
 
mutation is having a small but negative effect on bone length in early development 
which is compensated for by six months of age.  During endochondral ossification, 
the proliferation and differentiation of chondrocytes is carefully coordinated and 
regulates the rate of longitudinal bone growth which occurs at the epiphyseal plate, a 
thin layer of cartilage at the distal end of long bones (Emons et al., 2011).  Given the 
slight differences in long bone length observed between WT and Nbr1
D50R
 mutant 
mice, the interaction between Nbr1 and p62 could be contributing to the regulation of 
this process.  Mutations targeting fibroblast growth factors (FGFs) result in a variety 
of skeletal malformations (Ornitz and Marie, 2002).  Mice lacking the FGF receptor 
three (FGFR3) display an increase in bone length (Deng et al., 1996) whilst mice 
overexpressing FGF2, showed a shortening of long bones (Coffin et al., 1995).  
Interestingly, Nbr1 has been implicated in the regulation of FGF2 signalling 
(Mardakheh et al., 2009), suggesting the interaction between Nbr1 and p62 may 
influence FGF signalling in chondrocytes of the growth plate.   
 
Furthermore, a mouse model with the FGFR3
Y367C
 mutation, causing constitutive 
activation of the receptor, displayed a delay in ossification at one week of age 
resulting in shorter long bone length.  However, an age-dependent acceleration in 
ossification in mutant mice was observed so that by six weeks of age, there was no 
difference in bone age between WT and mutant mice, although bone length was still 
significantly reduced (Pannier et al., 2010).  In the Nbr1
D50R
 mutant mice, the small 
decrease in bone length observed at three months is resolved by nine months of age 
as bone length in mutant mice increased compared with WT.  This suggests that 
similar to the FGFR3
Y367C
 mutant mice, there could be an age dependent 
misregulation of chondrocyte proliferation in Nbr1
D50R
 mutant mice, possibly due to 
changes in intracellular signalling that may affect the timing and regulation of gene 
expression.  This could result in the initial decrease in bone length and the 
subsequent acceleration so that by six months, there was no difference between 
genotypes.  There are a number of other growth factors and hormones that affect 
bone growth including VEGF, TGF-β, BMPs, Wnt, oestrogens and androgens 
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(Emons et al., 2011) and the actions of any of these could potentially be affected by 
the abrogation of the Nbr1-p62 interaction. 
 
5.6.3. Cellular effects of the abrogation of the p62-Nbr1 interaction 
Osteoclasts derived from bone marrow precursor cells of Nbr1
D50R
 mutant mice 
appeared larger and contained more nuclei when cultured on plastic compared to WT 
(Figure 5.14).  However when cultured on dentine, a more physiologically relevant 
environment, although there were a greater number of TRAP +ve cells suggesting a 
greater differentiation potential (Figure 5.15), the resorption area was comparable to 
WT cultures (Figure 5.15).  This suggests that the resorption activity per osteoclast 
was reduced.  There was however, variation between dentine slices which could have 
been masking a small affect.  Confirmation of this result is therefore required before 
any firm conclusions can be made as to the effect of the Nbr1
D50R
 mutation on 
osteoclast resorption activity.   
 
The clear morphological differences observed in TRAP +ve cells cultured on plastic 
from Nbr1
D50R
 mutant mice could suggest that the p62-Nbr1 interaction is involved 
in the regulation of osteoclast size and fusion.  Increased osteoclast size and numbers 
are a hallmark of disorders such as PDB and multiple myeloma (Ehrlich and 
Roodman, 2005).  Larger osteoclasts containing more nuclei have been observed in a 
mouse model harbouring a PDB mutation in p62 (Daroszewska et al., 2011) whilst 
p62 deficient mice display impaired osteoclastogenesis upon stimulation with PTHrP 
(Duran et al., 2004).  Additionally, overexpression of p62
P392L 
in osteoclasts causes 
an increase in osteoclast activity and survival as well as an increase in multinucleated 
cells that contain more nuclei (Chamoux et al., 2009). 
 
Together, these data suggest 
that p62 is involved in the regulation of osteoclastogenesis.  The work described in 
this thesis suggests that the interaction between Nbr1 and p62 is of specific 
importance to osteoclast differentiation.  The interaction between Nbr1 and p62 
could be involved in the assembly of signalling complexes similar to that described 
in muscle (Lange et al., 2005) and its abolition could result in changes in 
osteoclastogenesis.  Alteration of signalling pathways in osteoclasts has been 
demonstrated to influence osteoclast size as observed in Fra-2 deficient mice which 
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have larger osteoclasts and an increase in phosphorylated ERK1/2 (Bozec et al., 
2008).   
 
In vitro cellular assays also demonstrated that the early bone phenotype observed in 
the Nbr1
D50R
 mutant mouse model could be due in part to a defect in osteoblast 
function.  Bone marrow precursors from Nbr1
D50R
 mutant mice, stimulated with 
ascorbic acid and β-glycerophosphate showed an early reduction in ALP positive 
colonies and reduced mineralised bone nodule formation (Figure 5.16).  This 
suggests that there could be a defect in osteoblast differentiation and activity or a 
relative decrease in osteoblast precursor numbers in the bone marrow.  The 
resolution of the observed decrease in ALP positive colonies at a later time point 
suggests that there could be a compensatory mechanism taking place.  To establish if 
the mineralisation activity of the mutant osteoblasts also resolved with time, a later 
time point is required.  The reduced BMD observed in vivo at three months of age 
(Figure 5.11) suggests that the secretion of bone matrix components by osteoblasts is 
impaired which supports the reduction in osteoblast activity observed in vitro.   
 
Osteoblasts are responsible for bone formation and mineralisation and a reduction in 
their activity causes phenotypes observed in a number of mouse models.  Osteoblast 
precursors from the BMPR1A deficient mice (described above) formed fewer ALP 
positive colonies and showed weaker von Kossa staining suggesting a reduction in 
bone formation and mineralisation, which could explain the observed in vivo 
phenotype (Mishina et al., 2004).  In contrast, osteoblasts from mice deficient in the 
Wnt antagonist Frizzled-related protein 1 displayed an increase in osteoblast 
differentiation and mineralization, explaining the increase in BMD and trabecular 
bone volume observed in vivo (Bodine et al., 2004).  These data show that in vitro 
culture of osteoblasts can be a predictor of in vivo osteoblast activity and therefore 
suggests that the reduction in cortical and trabecular thickness observed in the 
Nbr1
D50R
 mutant mouse model could be the result of a decrease in osteoblast 
differentiation and activity. 
 
Protein degradation has been highlighted as an important regulatory mechanism for 
the modulation of signalling pathways.  Smurf1, an E3 ubiquitin ligase, interacts with 
Chapter 5                                                                                                             Results 
196 
 
Runx2 and Smad1 and facilitates their degradation in an ubiquitin- and proteasome-
dependent manner, thereby negatively regulating BMP signalling and osteoblast 
differentiation (Zhao et al., 2004; Zhao et al., 2003).  In addition, the proteasome 
inhibitor bortezomib is able to stimulate bone formation (Giuliani et al., 2007).  The 
cell specific accumulation of ATF4 is also important for osteoblast differentiation 
and this is controlled by the UPS (Yang and Karsenty, 2004).  Together, these data 
suggest that degradation of specific proteins is an important mechanism for 
regulating osteoblast differentiation and activity.  p62 is involved in the proteasomal 
degradation of polyubiquitinated proteins (Babu et al., 2005) and interacts with 
components of the proteasome (Seibenhener et al., 2004) whilst Nbr1 potentially 
interacts with components of the ubiquitination machinery (Chapter 3).  The p62-
Nbr1 interaction could be important for the facilitation of protein degradation and its 
abrogation may therefore result in protein accumulation and altered osteoblast 
activity.   
 
This study has made substantial progress towards the characterisation of the bone 
phenotype in the Nbr1
D50R
 mutant mouse model.  Figure 5.17 represents a schematic 
diagram of the proposed effects of abrogating the Nbr1-p62 interaction on osteoblast 
and osteoclast differentiation and activity and subsequently bone architecture.  
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5.7. Future work 
To fully confirm the observed phenotype of the Nbr1
D50R
 mouse model, additional 
experiments are required. 
 
There were slight differences observed in a number of cortical and trabecular 
parameters in the Nbr1
D50R
 mutant mice therefore, to confirm that these are not due 
to random variation, a larger number of mice at each age will need to be analysed.  
Unlike the trNbr1 mouse model, the Nbr1
D50R 
mice have an early phenotype that is 
resolved with age therefore to establish if this phenotype is also present earlier that 
three months of age, microCT analysis of mice at younger ages is required.  
Additionally, H&E staining would enable the analysis of overall bone structure in the 
mutant mice at different ages. 
 
Due to the differences observed between mutant and WT osteoclasts cultured on 
plastic, it is of paramount importance to assess the size, nucleation and morphology 
of mutant osteoclasts in vivo.  Electron microscopy is currently being performed in 
collaboration with Miep Helfrich, University of Aberdeen to address this question.  
Additionally, to examine the effects of the Nbr1-p62 interaction on signalling 
pathways in osteoclasts, in vitro analysis of the activation of signalling pathways 
such as NF-κB and ERK 1/2 should be performed.  As p62 is important in RANKL 
signalling, assessing the sensitivity of osteoclasts precursors to increasing levels of 
RANKL would be interesting to explore.   
 
Due to the observed in vitro osteoblast phenotype, dynamic histomorphometry could 
be used to assess if the bone formation rate is altered in vivo.  This could be analysed 
in mice of varying ages to establish if the number and activity of osteoblasts is 
influenced by the developmental stage.  An in depth analysis of the signalling 
pathways that govern osteoblast differentiation and activity such as Wnt, BMP and 
FGF would also need to be performed to determine which pathway(s) require the 
functional p62-Nbr1 interaction.  Additionally, differentiation and activity of 
osteoblasts derived from bone marrow stromal cells and calvaria should be analysed 
over a longer time course (21 days).  
 
Chapter 5                                                                                                             Results 
199 
 
To establish if the development of the growth plate is altered by the abrogation of the 
p62-Nbr1 interaction, histomorphological measurements could be carried out in 
young mice (~10 days) as the size of the growth plate is known to positively 
correlate with bone growth rate (Sanger et al., 2011).  Additionally, in situ 
hybridization experiments could be performed to establish if the expression of 
molecules such as osteocalcin, PTHrP, Indian hedgehog or collagen type I are 
affected.
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Chapter 6. Sequence Analysis of Individuals with 
High Bone Mass 
6.1. Introduction 
The maintenance of normal bone mass and skeletal integrity is reliant on the dynamic 
balance between bone formation (by osteoblasts) and bone resorption (by 
osteoclasts).  This is regulated by a complex network of signalling pathways, 
hormones and environmental factors.  An imbalance in this process can lead to a 
wide range of skeletal pathologies including the sclerosing bone dysplasias, 
characterised by an increase in bone mass (Van Wesenbeeck et al., 2003). 
 
Bone dysplasias are often caused by genetic mutations resulting in reduced bone 
resorption or increased bone formation (a selection of these are discussed here and in 
Chapter 1). Albers-Schonberg disease is characterised by sclerosing bone of varying 
degrees and is caused by mutations in CLCN7, encoding chloride channel 7, a 
transmembrane protein that permits the exchange of Cl
-
 ions across the osteoclast 
ruffled border (Kornak et al., 2001).  Furthermore, inactivating mutations in the 
carbonic anhydrase II enzyme can lead to defective hydrogen ion transport by 
osteoclasts resulting in increased bone mass due to impaired bone resorption (Sly et 
al., 1985).  Conversely, an increase in bone formation has been identified as a cause 
of some sclerosing bone disorders.  Activating mutations in LRP5 (low-density 
lipoprotein receptor-related protein 5) and de-activating mutations in the SOST gene 
(encoding sclerostin) lead to increased Wnt signalling resulting in high bone mass 
(Brunkow et al., 2001; Van Wesenbeeck et al., 2003).  Other signalling pathways can 
also be affected; mutations in TGF-β1 cause Camurati-Engelmann disease which is 
characterised by cortical thickening in a number of bones (Janssens et al., 2000).  
 
Genome wide association studies (GWAS) can be employed to identify genetic 
variants that may be contributing to common genetic traits or disease phenotypes.  A 
study by Duncan et al. focused on post-menopausal women with extreme high or low 
hip bone mineral density (BMD) and identified association at six new genetic loci.  
One of these was in the GALNT3 gene that encodes N-
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acetylgalactosaminyltransferase 3, an enzyme involved in O-glycosylation of serine 
and threonine residues.  A mouse model with a loss-of-function mutation in GALNT3 
displays a high bone mass phenotype, supporting the involvement of this gene in 
determining BMD (Duncan et al., 2011).  Previous sequencing analysis of the PB1 
and UBA domains of NBR1 in individuals with idiopathic Paget‘s disease of bone 
(PDB) failed to identify any disease causing mutations (C. Whitehouse, unpublished 
data) whilst GWAS studies on PDB have not yet found any association with 
sequence variation in or near NBR1 (Omar Albagha, personal communication). 
 
Whilst a number of sclerosing bone phenotypes can be accounted for by mutations 
such as those described above, there are many cases where HBM cannot be 
explained (Gregson et al., 2011).  As Nbr1 has been implicated in the regulation of 
bone mass and BMD in mice (Whitehouse et al., 2010), it could be hypothesised that 
genetic mutations in the NBR1 gene may account for some of the unexplained HBM 
phenotypes. In order to investigate this, DNA was obtained from a total of 82 
idiopathic HBM patients who participated in a larger study carried out at the 
University of Bristol, directed by Dr Celia Gregson (DNA kindly supplied by Prof. 
Jon Tobias).  All the exons, including the 5‘ untranslated region (UTR) of NBR1 
were sequenced with the aim of identifying potentially pathogenic novel mutations or 
genetic variations that may be affecting gene function.  Such findings could then lead 
to new and important insights into the molecular mechanisms that govern the 
regulation of bone mass and may identify new therapeutic targets. 
 
 6.2. Genomic Details of Nbr1 
The human NBR1 gene has 21 exons of varying sizes.  The first exon encodes the 5‘ 
untranslated region (5‘UTR) and the translational start methionine (ATG) resides in 
exon 2 (Figure 6.1).  Exon 1 was included in the sequencing analysis as it is possible 
that mutations in this region could infer alternative translational start sites, affect 
gene structure or alter mRNA stability.  NBR1 contains relatively few known exonic 
single nucleotide polymorphisms (SNPs) (Table 6.1) and as yet, none of these have 
been implicated in bone disease.  The frequency of all detectable NBR1 coding SNPs 
will be determined in the HBM patients sequenced in this study.  
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Table 6.1. Known exonic SNPs in NBR1. Compiled from dbSNP132 (*frequency 
not reported in the Caucasian European (CEU) population. 








rs11657883 C/T - 
T = 0.65 
C = 0.35 
c.165+9 Intron 4 




non-synonymous * p.112 6 





G = 0.992 





non-synonymous * p.204 8 




non-synonymous * p.312 10 













A = 1 





non-synonymous * p.716 17 









G = 0.66 
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To gain further information on the SNPs present in NBR1, a linkage disequilibrium 
(LD) map was generated from the CEU (Caucasian European) HapMap population 
data (www.HapMap.org) (Figure 6.2).  LD occurs when particular alleles at two or 
more neighbouring loci occur together with frequencies significantly different from 
those predicted from the individual allele frequencies.  Thus, LD maps establish the 
likelihood of alleles at two or more SNPs segregating together in the population.  LD 
can be measured using the correlation coefficient R
2
 of SNP genotypes from a large 
homogeneous population.  Maximum LD (R
2
 = 100%) is reached when two SNPs 
are completely correlated such that the presence of one allele at one SNP locus on the 
chromosome can predict the presence of the allele at the other locus in the same 
chromosome with 100% certainty.  The LD map of NBR1 reveals that it is largely 
within one LD block and there is limited recombination within the gene.   
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6.3. Patient Information 
NBR1 genetic screening was performed on 82 patients with unexplained HBM
1
 
defined by dual energy X-ray absorptiometry (DXA) as having (a) vertebrae L1 Z-
score of >+3.2 and total hip Z score of no lower than +1.2 or (b) a total hip Z score 
>+3.2 and an L1 Z score no lower than +1.2.  A total of 55 out of the 82 individuals 
analysed also had relatives with HBM suggesting an underlying genetic cause.  All 
individuals were white British and were recruited as part of a larger study directed by 
Dr Celia Gregson (University of Bristol) with the aim of identifying the clinical 
characteristics of HBM.  Compared to unaffected controls, individuals had increased 
odds of multiple HBM associated phenotypes including enlarged mandible, broad 
frame, misshapen or extra bone at the site of tendon and/or ligament insertion and 
larger shoe size.  They also reported increased odds of sinking when trying to swim, 
had an increased BMI and reduced odds of reporting a family history of fracture 
(Gregson et al., 2011). 
 
6.4. PCR Optimisation 
To sequence the exons of NBR1, the genomic DNA was amplified on an exon-by-
exon basis.  A standard PCR reaction was used (section 2.1.1) and the optimal primer 
annealing temperatures and MgCl2 concentrations were established (Table 2.9).  
 
To confirm successful DNA amplification, a proportion of the PCR product was 
analysed by agarose gel electrophoresis.  PCR product was purified using ExoSAP-
IT and sequenced using a standard sequencing reaction (section 2.1.6 and 2.1.7).  
Electropherograms were obtained for 95% of the amplicons and were analysed using 
the programme Sequencher version 4.10.1. 
 
                                                 
1
 Ethical approval was granted by COREC (Reference 05/Q2001/78 - Bath Research Ethics 
Committee).   
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6.5. Identification of Genetic Variation in High Bone Mass 
Patients 
Initially, genomic DNA was obtained from blood samples of 32 of the total 82 
individuals and all NBR1 exons were sequenced.  Subsequently, genomic DNA from 
a further 50 patients was obtained and due to time constraints the LC3 interacting 
region (LIR), PB1 and UBA domains of NBR1 were prioritised for sequencing.  
These regions were chosen due to their known importance to skeletal maintenance in 
the structurally similar protein p62.  Mutations in both the UBA domain and LIR of 
p62 have been identified in patients with Paget‘s Disease of Bone (PDB) (Falchetti et 
al., 2009; Goode and Layfield, 2010), whilst the PB1 domain is known to be 
important for the regulation of the NF-κB signalling pathway and osteoclast 
differentiation (Lamark et al., 2003; Puls et al., 1997; Sanz et al., 2000).  
  
6.5.1. Novel variations 
Sequencing of NBR1 in HBM individuals identified one novel non-synonymous 
variant (Figure 6.3) that had not previously been reported at the time of this study 
and was not present in any other DNA sample sequenced.  This variant was 
confirmed by repeating the PCR and sequencing in both directions in order to rule 
out polymerase error.  It is located in exon 8 at residue 182 in the NBR1 protein and 
results in a valine to leucine substitution.  Two online programmes were used to 
predict if this amino acid change is likely to be deleterious to protein function.  
PolyPhen2 predicted that this change is ‗benign‘ whilst SIFT predicted it to be 
‗tolerated‘. To determine if this residue was conserved, a cross species comparison 
was performed (Figure 6.4).  In all mammals analysed, this residue was conserved as 
a valine, however in chicken and zebrafish, the equivalent amino acid is an 
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6.5.2. Frequency of known exonic SNPs 
Using the reported allele frequencies (Table 6.1), and the formulae in section 2.6.2 it 
was predicted that there was sufficient power to detect rs8482 in the individuals 
sequenced in this study (80% is considered acceptable power).  All other SNPs are 
either not reported in the Caucasian European (CEU) population or their minor allele 
frequency is too low to have sufficient power to detect it in the number of individuals 
sequenced.  Analysis of the sequence variation in all individuals confirmed this 
prediction as rs8482 was the only SNP to be detected.  The allele frequency gained 
for rs8482 in the HBM individuals was the opposite to that reported on NCBI 
(www.ncbi.nlm.nih.gov) therefore to gain further reliability, additional HBM 
individuals and controls
2
 were genotyped and frequencies obtained are shown in 
Table 6.2.  This revealed that there was no difference between cases and controls and 
it was likely that the SNP allele frequency reported on NCBI was incorrect.  
Supporting this, an additional SNP residing in intron 4 of NBR1 (rs11657883) was 
found to be in complete LD with rs8482 in the first 32 individuals studied.  The 
frequency of the C allele of this SNP is reported as 0.35 in dbSNP, which is in 
agreement with the calculated frequency of the G allele of rs8482 from the HBM 
cases and controls in this study.  
 
 A/A A/G G/G Frequency of G allele 
Cases 54 55 14 0.34 
Controls 77 71 23 0.34 
Table 6.2.  Allele frequencies from HBM cases and controls for rs8482. 
                                                 
2
 Controls were obtained from Dr Natalie Prescott and Prof. Christopher Matthew, KCL (personal 
communication) from a similar study on inflammatory bowel disease where controls were taken from 
the 1958 British Cohort DNA Collection, funded by the Medical Research Council and Wellcome 
Trust).  




An imbalance in the bone remodelling process any time throughout life can lead to a 
large number of skeletal pathologies including the sclerosing bone dysplasias which 
are generally characterised by an increase in bone mass (de Vernejoul and Kornak, 
2010).  Mutations in a number of genes have been identified as contributing to HBM, 
however there are a growing number of cases where the cause is still unknown 
(Gregson et al., 2011).  Due to the previously identified roles of Nbr1 in bone 
remodelling (Whitehouse et al., 2010), this study aimed to identify mutations in the 
coding region of NBR1 that may be contributing to the HBM phenotype seen in some 
of these individuals.  
 
Sequencing of the NBR1 gene in individuals with HBM identified one novel genetic 
variation (Figure 6.3).  This resulted in a valine to leucine substitution at amino acid 
182 (V182L) of the NBR1 protein.  Valine and leucine have similar structures and 
properties as both are hydrophobic and neutral in charge.  This suggests that 
substitution from one to the other is less likely to alter protein structure and therefore 
function suggesting that this mutation is unlikely to cause disease.  Analysis of this 
mutation using two programs that predict the functional affect of coding mutations - 
PolyPhen and SIFT - predicted that this amino acid change is benign or tolerated 
respectively and therefore unlikely to have a large effect on protein structure and 
function.  Additionally, comparison of the amino acid sequence of this gene from 
several species (Figure 6.4) showed that valine 182 is not highly conserved in 
evolution.  The corresponding residue in chickens and zebrafish is an isoleucine or a 
cysteine respectively thus suggesting that valine 182 is not essential for protein 
function.  Isoleucine has very similar properties to leucine and valine and therefore is 
unlikely to alter protein function, cysteine is slightly more polar, however SIFT 
predicted that an amino acid change from valine to cysteine at this position in NBR1 
is also likely to be tolerated perhaps as expected due to its existence in zebrafish.  
Taken together, these data suggests that the novel variation identified in NBR1 is 
unlikely to be the primary cause of the high bone mass in this individual.   
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Following the completion of this sequencing analysis, in May 2011 the 1000 
genomes project (www.1000genomes.org) made public its latest SNP genotyping 
calls based on the pilot release of whole genome sequencing data in 1000 individuals 
and all new SNPs were entered into dbSNP.  This identified the V182L variant in 
two individuals (out of 120 CEU) and confirmed that it is indeed a SNP.  It was 
allocated the reference SNP number rs117060970 and the frequency of the V182L 
allele based on the 1000 genomes data is 0.008.  Using this reported SNP frequency, 
this study had 73% power to identify the variant in the 82 individuals sequenced.  As 
sample size can affect reported SNP frequencies, to fully confirm that this SNP is not 
associated with HBM, a larger number of cases will need to be sequenced to reliably 
report the allele frequencies in the HBM population. 
 
This study has shown that there is relatively little known genetic variation in NBR1 
(Table 6.1), especially in the Caucasian population.  The LD map based on common 
variation across NBR1 (Figure 6.2) shows that the gene is located in one LD block 
and recombination events within the gene are rare.  The recent GWAS by Duncan et 
al. (Duncan et al., 2011) could not detect any genetic association between common 
variants at the NBR1 locus and BMD in 1955 postmenopausal women with high or 
low BMD (1055 high, 900 low) suggesting that this gene is unlikely to be a major 
contributing factor to heritable differences in BMD in women of European origin.  
However, it is possible that rare mutations in NBR1 that are not covered by the 
various GWAS SNP arrays could underlie less common HBM phenotypes. 
 
There was sufficient power to detect only one of the known exonic SNPs in the 82 
individuals sequenced in this study.  This SNP was rs8482 and is of particular 
interest because it is non-synonymous and resides in the UBA domain of NBR1 
which is known to bind mono- and polyubiquitinated chains (Waters et al., 2009).  
Although this SNP does not affect ubiquitin binding as tested in an in vitro binding 
assay (Waters, 2009), it alters the protein sequence and could therefore still affect 
protein function in a way that is not yet understood.  Genotyping of this SNP in cases 
and controls showed that its frequency in HBM individuals did not differ 
significantly from normal (Table 6.2) suggesting that it is not important in 
determining bone mass. 




Overall, this study has been important in revealing that the idiopathic HBM 
phenotype seen in 82 individuals is unlikely to be caused by genetic mutations in the 
coding region of NBR1.  To fully confirm that any known genetic variation in NBR1 
is not associated with disease, a larger cohort of cases and controls will need to be 
analysed (see section 6.7).   
 
6.7. Future Work 
One novel variation was identified in the coding region of NBR1 that has now been 
reported as a SNP.  Due to the low amino acid conservation among species, this 
variation is unlikely to be the main cause of the HBM seen in the individuals in this 
study.  However, it would be useful to further genotype this SNP and the rest of the 
NBR1 gene in a larger number of cases and controls to establish if this or any other as 
yet undetected sequence variants are associated with HBM.  The number of 
individuals required to detect a specific SNP will very much depend on the frequency 
of the SNP in the population.   
 
Whole exome sequencing is now being used to identify genetic variation in 
individuals with unexplained disease phenotypes (Glazov et al., 2011).  Work is now 
underway at the University of Bristol to sequence the complete exome of individuals 
with HBM to try to identify the cause of the phenotype.  Many of the patients have 
affected relatives and therefore the cause is likely to be of genetic origin.   
 
Genome-wide association studies (GWAS) have been successful in identifying genes 
involved in disease and this has been illustrated by the recent study in PDB patients 
where the TNFRSF11A gene encoding RANK was shown to be associated with 
disease (Albagha et al., 2010).  GWAS studies in bone mineral density have yet to 
find any association with NBR1.  This is probably due to the presence of very few 
SNP markers in or near NBR1 in any of the GWAS SNP arrays and could suggest 
that a more detailed genotyping study is required in a larger cohort of HBM 
individuals. Due to the phenotype of the Nbr1
D50R
 knock-in mouse model, it would 
also be interesting to analyse patients with low bone mass. 
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Chapter 7. General Discussion 
Nbr1 is a ubiquitously expressed scaffold protein that contains numerous conserved 
protein domains.  At its N-terminus, Nbr1 has a PB1 domain and a ZZ zinc-finger 
domain whilst at its C-terminus it contains a ubiquitin-associated (UBA) domain.  
Two CC domains are also present, the first of which facilitates homodimerisation.  In 
bone, truncation of Nbr1 leads to an age dependent increase in bone mass and bone 
mineral density due to an increase in osteoblast activity and p38 MAPK activation 
(Whitehouse et al., 2010).  In muscle, Nbr1 interacts with the giant sarcomeric 
protein titin and is part of a signalling complex that can modulate gene transcription 
(Lange et al., 2005).  Nbr1 is also involved in receptor internalisation and 
degradation via endocytosis and can modulate signal transduction pathways 
(Mardakheh et al., 2010; Mardakheh et al., 2009).   
 
The studies presented in this thesis aimed to further investigate the roles of Nbr1 by 
identifying novel interacting partners and subsequently characterising their 
significance with respect to Nbr1 function.  Additionally, to advance the knowledge 
of Nbr1 with regard to bone, a knock-in mouse model that contained a mutation in 
the PB1 domain of Nbr1 resulting in the abrogation of the interaction between Nbr1 
and p62 was created.  This thesis describes the bone phenotypic analysis of this 
mouse.  Due to the high bone mass (HBM) phenotype observed in the truncated Nbr1 
mouse model, genomic DNA from individuals with idiopathic HBM was sequenced 
for genetic variation in the coding exons of NBR1. 
 
7.1. The interaction potential of Nbr1 
Nbr1 is a scaffold protein, likely to be involved in multiple protein-protein 
interactions.  Therefore, in the first two chapters of this thesis, yeast-2-hybrid screens 
were performed with regions of Nbr1 as bait.  A number of putative interacting 
partners were identified that provide further insight into the functions of Nbr1.  First, 
the autophagosomal marker LC3 was revealed as an interacting partner of Nbr1.  
Further in vitro binding assays determined that an eight amino acid region of Nbr1 
termed the LC3 interacting region (LIR) was required for the interaction with LC3 
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(Waters et al., 2009).  This finding was in agreement with that of Kirkin et al. who 
also demonstrated that through its ability to bind polyubiquitinated chains, and its 
interaction with LC3, Nbr1 is an autophagic receptor that targets polyubiquitinated 
proteins for autophagosomal degradation (Kirkin et al., 2009; Waters et al., 2009).  A 
number of other proteins including p62 (Pankiv et al., 2007a), Nix (Novak et al., 
2010) and NDP52 (Thurston et al., 2009) contain LIR domains.  There is now a 
major drive to identify additional proteins containing an LC3 interacting region as 
this mechanism is thought to be the major route by which proteins can be selectively 
targeted for autophagic degradation (Johansen and Lamark, 2011).  The ubiquitinated 
protein targets that are specific to Nbr1 are still unknown, therefore identifying these 
has become of paramount importance to the further understanding of Nbr1 function.  
Evolutionary analysis has shown that the yeast homologue of Nbr1 is Atg19, a cargo 
receptor in the yeast Cvt selective autophagy pathway (Xie and Klionsky, 2007).  
The degradation of proteins via the Cvt pathway does not involve ubiquitin however, 
the similarity between Nbr1 and Atg19 suggests that the Cvt pathway is 
evolutionarily related to the Nbr1-mediated ‗ubiquitinophagy‘ system (Kraft et al., 
2010). It is also plausible that in higher organisms a non-UBA region of Nbr1 is 
required for recognising and targeting specific cargo for autophagic degradation 
(Kraft et al., 2010).  In this respect, p62 has been identified as binding to and 
facilitating the autophagic degradation of STAT5A_ΔE18 through a ubiquitin 
independent mechanism (Watanabe and Tanaka, 2011).   
 
The light chain of the microtubule associated protein MAP1B was identified as an 
interacting partner of the highly conserved novel region of Nbr1 and subsequent in 
vitro binding assays confirmed this interaction.  Microtubules are known to facilitate 
autophagosome formation (Fass et al., 2006; Köchl et al., 2006).  The binding of 
adaptor proteins such as FYCO1 to both LC3 and microtubule motor proteins has 
been suggested as a mechanism by which preautophagosomal membranes are 
targeted to sites of autophagosomal formation (Pankiv et al., 2010).  The interaction 
between Nbr1 and MAP1B-LC1 provides evidence of a further mechanism by which 
proteins targeted for degradation via autophagic receptors are directed to sites of 
autophagosomal degradation via microtubule binding proteins.  
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In addition to the interaction between Nbr1 and MAP1B being involved in 
autophagy, it could be facilitating other processes.  MAP1B-LC1 is also involved in 
the endocytosis of the AMPA receptor which regulates synaptic transmission 
(Davidkova and Carroll, 2007).  It is proposed that through its interaction with the 
glutamate-receptor interacting protein (GRIP1), MAP1B-LC1 is able to mediate 
receptor endocytosis in neurons (Davidkova and Carroll, 2007; Seog, 2004).  Nbr1 
has also been implicated in the lysosomal degradation of cell surface receptors via its 
interaction with SPRED2 (Mardakheh et al., 2009).  This suggests that the interaction 
between MAP1B-LC1 and Nbr1 could mediate receptor internalisation and therefore 
regulate intracellular signalling pathways.  Additionally, Nbr1 interacts with 
monoubiquitin.  Monoubiquitin is required for the process of receptor internalisation 
and degradation. Ligand binding to the epidermal growth factor receptor (EGFR) 
induces receptor activation and recruitment of ubiquitin ligases that mediate 
ubiquitination of the EGFR at the plasma membrane leading to receptor 
internalisation (Haglund et al., 2003).  Proteins such as Eps15 bind to the 
monoubiquitin modifications on receptors and function as adaptors between 
ubiquitinated membrane cargo and the endocytic machinery (Polo et al., 2002).  
Therefore, similar to Esp15, through its interactions with MAP1B-LC1, SPRED2, 
monoubiquitin and the deubiquitinating enzyme USP8, all of which have been 
implicated in receptor degradation, Nbr1 could be acting as a scaffold to regulate 
receptor internalisation at the plasma membrane. 
 
Abnormal accumulation of MAP1B-LC1 results in neuronal death in giant axonal 
neuropathy (GAN) due to the inhibition of its degradation via it interaction with 
gigaxonin (Allen et al., 2005). Additionally, the aggregation of MAP1B-LC1 is 
prevented by its interaction with DJ-1.  This has been implicated in 
neurodegenerative disorders such as Parkinson‘s disease that are characterised by the 
presence of large protein aggregates (Wang et al., 2011).  The leucine-rich acidic 
nuclear protein (LANP) interacts with MAP1B-LC1 and modulates the effects of 
MAP1B-LC1 on neurite extension (Opal et al., 2003).  Therefore, it is clear that 
through specific interactions, MAP1B-LC1 function can be modulated and 
misregulation can contribute to the pathogenesis of aggregate prone neurological 
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diseases.  Collectively, these data suggest that through specific protein-protein 
interactions, Nbr1 could also be modulating MAP1B-LC1 function. 
 
Several components of the ubiquitination machinery were identified as putative 
interactors of Nbr1 in this thesis.  This suggests that Nbr1 could be acting as a 
scaffold to target such proteins to their sites of action and affect ubiquitination and 
subsequently protein degradation via the UPS.  Additionally, the identification of the 
eukaryotic elongation factor 1A (eEF1A) as a putative interacting partner of Nbr1 
may also suggest an involvement for Nbr1 in the cotranslational degradation of 
proteins.  Further work is required to confirm these putative interactions however, 
this study has been important in proposing new and exciting roles for Nbr1 in the 
control of protein degradation.  
 
7.2. Nbr1 and the regulation of bone   
This study has revealed that the interaction between Nbr1 and p62 is important in the 
early maintenance of normal bone volume, cortical thickness and bone mineral 
density.  Mice that are homozygous for the Nbr1
D50R
 mutation which inhibits the 
Nbr1-p62 interaction, display an early onset mild osteoporotic phenotype, probably 
due to a decrease in osteoblast differentiation and activity as well as an increase in 
osteoclast size and nucleation.  This phenotype is very different to the trNbr1 mouse 
model which maintains a functional p62, PB1 domain mediated interaction and 
displays an age dependent increase in bone mass and mineral density (Whitehouse et 
al., 2010).  Together, these mutant mouse models show that distinct regions of the 
Nbr1 protein are likely to be important for different functions within bone tissue.  
The C-terminus of Nbr1 may be more important for the regulation of bone mass as 
the trNbr1 mouse has a more severe phenotype than the Nbr1
D50R
 mouse model.  
Mice deficient in p62 also develop an age dependent increase in bone density 
(Rodriguez et al., 2006). Recent data has demonstrated that additional deletion of 
Nbr1 reverted this phenotype (Sengupta et al., 2011).  This could suggest that Nbr1 
and p62 could have opposing functions in relation to controlling bone mass. 
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The Nbr1-p62 interaction is important for the formation of signalling complexes in 
muscle (Lange et al., 2005).  Although not yet investigated, it is therefore likely that 
the abrogation of this interaction could affect signalling pathways in a range of other 
tissues including bone.  The trNbr1 mouse model identified Nbr1 to be involved in 
the activation of downstream signalling molecules.  TrNbr1 osteoblasts treated with 
the p38 MAPK activator anisomycin, displayed enhanced p38 MAPK activation 
whilst trNbr1 osteoclasts treated with RANKL displayed enhanced ERK and p38 
MAPK activation (Whitehouse et al., 2010).  This suggests that Nbr1 normally acts 
to inhibit these signalling pathways.  p62 inhibits ERK signalling (Rodriguez et al., 
2006) and is required for TNFα induced p38 MAPK activation but not for 
anisomycin induced p38 MAPK activation (Kawai et al., 2008).  This again suggests 
that as well as acting in unison to affect intracellular signalling (Lange et al., 2005), 
Nbr1 and p62 also act separately in response to different stimuli to coordinate 
distinct downstream signalling pathways.  
 
The trNbr1 protein is unable to bind a number of known Nbr1 interacting partners 
including FEZ1, CIB (Whitehouse et al., 2002) and SPRED2 (Mardakheh et al., 
2009).  The interaction between Nbr1 and SPRED2 inhibits FGF signalling, a 
pathway that activates ERK, JNK and p38 MAPK (Keren-Politansky et al., 2009; 
Makino et al., 2010).  FGF signalling is important in the regulation of bone formation 
and osteoblast differentiation (Ornitz and Marie, 2002).  Therefore, via its interaction 
with SPRED2, Nbr1 could be involved in the regulation of FGF signalling and 
subsequently bone formation.  Additionally, the Nbr1
D50R
 mouse model displayed 
slight changes in bone length.  SPRED2 deficient mice have a dwarfism phenotype 
due to earlier and augmented ERK phosphorylation in response to FGF (Bundschu et 
al., 2005).  It is therefore interesting to speculate that Nbr1, through its interactions 
with p62 and SPRED2 could be regulating FGF signalling in bone. 
 
Nbr1 has been implicated in the control of receptor tyrosine kinase degradation.  
Ectopic expression of Nbr1 can inhibit the ligand-mediated degradation of EGFR by 
trapping it at the cell surface, resulting in enhanced ERK 1/2 signalling (Mardakheh 
et al., 2010).  As the trNbr1 mouse model has lost the UBA domain (Whitehouse et 
al., 2010) which is vital for the inhibition of receptor degradation, this could be a 
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possible mechanism by which Nbr1 is regulating downstream signalling in 
osteoblasts and osteoclasts and therefore affecting bone remodelling.   
 
Due to the known involvement of Nbr1 in the maintenance of bone, it was 
considered possible that genetic mutations in the NBR1 gene that affect protein 
structure and function could be causing the idiopathic high bone mass phenotype 
identified in a number of individuals.  Genetic screening of NBR1 in these 
individuals did not identify any mutations suggesting that altered NBR1 function was 
not the cause of the high bone mass phenotype.  As the trNbr1 protein may act in a 
dominant negative manner, it would be interesting to examine NBR1 genetic 
variation in osteoporotic individuals to assess if NBR1 is involved in this disease. 
 
7.3. Vesicular trafficking, protein degradation, Nbr1 and 
bone   
Osteoclasts rely on intricate vesicular trafficking pathways including 
endocytic/lysosomal transport of acidic vesicles containing proteases for bone 
resorption and transcytosis of the digested bone matrix.  These pathways are 
mediated by a multitude of Rab GTPases (Coxon and Taylor, 2008).  Mutations in 
the gene encoding the Plekhm1 protein which is involved in the Rab-7 dependent 
endosomal lysosomal transport of proteins to the osteoclast ruffled border causes 
osteopetrosis due to the absence of the osteoclast ruffled border  (Van Wesenbeeck et 
al., 2007).  As Nbr1 is now known to play a role in autophagy and vesicular 
transport, it is possible that Nbr1 may be playing a role in these processes in bone 
cells.  FEZ1, an interacting partner of Nbr1 interacts with the Rab3 GTPase 
activating protein (Assmann et al., 2006) suggesting a link between Nbr1, Rab 
proteins and vesicular trafficking.  Nbr1 also interacts weakly with osteocalcin 
suggesting that Nbr1 could mediate the cotranslational degradation of osteocalcin 
and therefore inhibit osteoblast matrix secretion.  Indeed, the trNbr1 mouse model 
lacks the osteocalcin interacting region of Nbr1 and has elevated serum levels of 
osteocalcin (Whitehouse et al., 2010) which supports the possibility of Nbr1 acting to 
degrade osteocalcin prior to its secretion.  
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Recently, there has been increased research into the role of autophagy in bone.  The 
upregulation of autophagy in response to stress stimuli such as hypoxia has been 
identified in osteocytes (Zahm et al., 2011).  Additionally, the autophagy protein 
ALFY was shown to interact with p62 in the nucleus of osteoclasts and their 
precursors.  Under autophagic induction p62 and ALFY translocate to the cytoplasm 
where they form large cytoplasmic aggregates.  This relocalisation was more rapid in 
mature osteoclasts compared with their precursors suggesting a cell specific function 
for this interaction (Hocking et al., 2010).  Along with p62, Nbr1 is also known to be 
involved in the autophagy pathway, therefore through similar cell specific protein-
protein interactions Nbr1 could be regulating protein degradation and cellular 
activity in bone cells.  Furthermore, several studies have shown that proteasomal 
degradation is important for the regulation of osteoblast differentiation (Yang and 
Karsenty, 2004; Zhao et al., 2003).  This study has identified Nbr1 as a possible 
scaffold for the localisation of ubiquitination machinery therefore Nbr1 could be 
involved in the regulation of protein ubiquitination and degradation in osteoblasts 
and osteoclasts.  
 
7.4. Implications for NBR1 in other diseases 
NBR1 has been identified in ubiquitin- and p62-positive aggregates in the liver of 
patients with alcoholic steatohepatitis (Kirkin et al., 2009) suggesting the tissue 
specific accumulation of protein aggregates.  p62 has also been identified in protein 
aggregation diseases such as Parkinson‘s and  Alzheimer‘s disease (Wooten et al., 
2006).  Due to the known function of Nbr1 in the removal of protein aggregates, it 
would be interesting to investigate its role in the pathogenesis of these and other 
aggregation diseases such as inclusion body myopathy associated with Paget‘s 
disease of bone and frontotemporal dementia.   
 
Nbr1 could also be linked to a number of chronic inflammatory diseases through its 
known protein interactors and downstream signalling effects.  A recent GWAS study 
has identified genetic association between SPRED2 and rheumatoid arthritis (Stahl et 
al., 2010). As Nbr1 interacts with SPRED2, this could link Nbr1 with the 
pathogenesis of the disease.  Nbr1 could be further implicated in arthritis due to its 
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involvement in p38 MAPK activation (Whitehouse et al., 2010).  P38 MAPK is 
activated by proinflammatory cytokines such as IL-1 and TNFα which are elevated 
in rheumatoid arthritis and stimulate bone resorption by osteoclasts (Jean-Michel, 
2002; Jimi et al., 1999b; Kumar et al., 2001).  Nbr1 could therefore be involved in 
regulating p38 MAPK in rheumatoid arthritis individuals.  Inhibition of p38 MAPK 
activation could therefore represent an effective therapeutic target for the treatment 
of rheumatoid arthritis (Kumar et al., 2001).  Additionally, the generation of an 
activated T-cell specific Nbr1-deficient mouse model identified a role for Nbr1 in 
promoting lung inflammation and Th2 differentiation (Yang et al., 2010) again 
suggesting that through the control of intracellular signalling pathways, Nbr1 
modulates tissue inflammation. (Kumar et al., 2001).   
 
7.5. Concluding remarks 
Nbr1 was first cloned over 15 years ago by expression screening with an antibody 
raised against the ovarian tumour antigen CA125 (Campbell et al., 1994).  In the 
following years progress was slow in identifying the biological functions of this 
protein.  Prior to the commencement of the work presented here, it was known that 
Nbr1 contained a number of conserved protein domains and interacting partners 
(Whitehouse et al., 2002), and was involved in muscle signalling (Lange et al., 2005) 
and bone remodelling (Whitehouse et al., 2010).  The studies presented in this thesis 
have furthered current knowledge of Nbr1 function. 
 
In chapters three and four, yeast-2-hybrid screens identified a number of novel Nbr1 
protein-protein interactions.  These were instrumental in contributing to the 
discovery of Nbr1 as an autophagic receptor, targeting ubiquitinated proteins to sites 
of autophagosomal degradation via the microtubule network.  Additionally, putative 
interactors have alluded to a role for Nbr1 in targeting components of the 
ubiquitination machinery to their sites of action and in facilitating the cotranslational 
degradation of proteins by the proteasome. 
 
In chapters five and six, the involvement of Nbr1 in bone formation and remodelling 
was further investigated and demonstrated the importance of the Nbr1-p62 
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interaction in the regulation of postnatal bone volume and bone mineral density.  
Analysis of genetic variation in NBR1 in patients with idiopathic HBM also 
demonstrated that mutations in NBR1 are unlikely to be the cause of the observed 
phenotype. 
 
Interest in Nbr1 biology has dramatically increased in the past few years and much 
work has focused on its role as an autophagic receptor.  Further studies building on 
the data presented in this thesis will be instrumental in providing additional 
knowledge of Nbr1 function and may contribute to the identification of therapeutic 





A.1. Positive clones from yeast-2-hybrid screen 1 
Table A.1. illustrates additional positive clones identified in the yeast-2-hybrid 
screen carried out with amino acids 495-924 of Nbr1 as bait against a pretransformed 
7 day old mouse calvaria cDNA library.  These putative interactors include possible 
candidates that were not followed up in this study and likely false positives that are 
often identified in yeast-2-hybrid screens (Hengen, 1997).  A number of muscle 
specific proteins were alos pulled out of this library screen suggesting that the 
calvarial library was contaminated with muscle. 
 
Accession No. Gene ID No. of Colonies 
NM_007507.2 
ATPase, Ca++ transporting, cardiac 
muscle 
1 
NM_013593.2 Myoglobin 1 
NM_00771.02 Creatine kinase, muscle 1 
NM_009394.2 Troponin 3 
NM_026775.4 Transmembrane enp24-like trafficking 
protein 10 (Tmp21) 
1 
NM_010227.2 Filamin α 1 
NM_008509.2 Lipoprotein lipase 1 
NM_181582 Eukaryotic translation initiation factor 5A 2 





NM_011305.3 Retinoid X receptor α 3 
NM_025552.4 RNA polymerase II 1 
NM_019704.2 Transmembrane protein 115 1 
NM_001081654.1 Testis expression gene 264 variant 2 1 
NM_012015.1 H2A histone family, member Y 3 
NM_008218.1¥ Hemoglobin α, adult chain 1 8 
NM_011184.3¥ Proteasome subunit, α type 3 3 
NM_010240.2¥ Ferritin 2 










NM_009606.2¥ Actin 8 
NM_011756.4¥ Zinc finger protein 36 1 
NM_009943.2¥ Cytochrome C oxidase 2 
NM_008188.2 
Procollagen C-endopeptidase enhancer 
protein 
2 
NM_007743.2¥ Procollagen, type 1, α2 6 
NM_017476.2¥ Procollagen type 1, α1 8 
Table A.1.  Additional positive clones identified from the yeast-2-hybrid screen 
carried out in chapter 3. ¥ indicates likely false positives 
 
A.2. Positive clones from yeast-2-hybrid screen 2 
Table A.2. illustrates additional positive clones identified in the yeast-2-hybrid 
screen carried out with amino acids 346-498 of Nbr1(novel region) as bait against a 
pretransformed 7 day old mouse calvaria cDNA library.  These putative interactors 
include possible candidates that were not followed up in this study and likely false 
positives that are often identified in yeast-2-hybrid screens (Hengen, 1997). 
 
Accession No. Gene ID No. of Colonies 
NM_182993.2 Solute carrier family 17 1 
NT_039460 Solute carrier protein 25 1 
NM_146259.3 Zinc Finger protein 668 3 
NM_011747.2 Zinc finger protein 13 2 
NM_007563.3 2, 3-bisphosphoglycerate mutase 1 
NM_146169.2 
Poly (A) binding protein interacting 
protein 2B 
1 
NM_011865.3 Poly (rC) binding protein 1 1 
NM_010729.2 Lysyl oxidase-like 1 1 
NM_010227.2 Filamin α 8 
NM_009606.2¥ Actin α 1 (skeletal muscle) 5 
NM_007742.3¥ Procollagen type 1 α 1 1 
NM_007743.2¥ Procollagen type 1 α 2 3 
NM_199008.2¥ 
Cox11 Homolog, cytochrome C oxidase 
assembly protein 
11 
NM_007743.2¥ Procollagen type 1 α 2 3 
Table A.2.  Additional positive clones identified from the yeast-2-hybrid screen 
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